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FUNCTIONAL EFFECTS OF BOTULINUM TOXIN-A INTRAMUSCULAR 
INJECTIONS IN A PATIENT WITH TRAUMATIC BRAIN INJURY:
A SINGLE SUBJECT CASE DESIGN
ABSTRACT
Cristina M. Higel 
Molly L. Arndt
This single subject case design sought to evaluated the long-term and short-term 
effectiveness of Botulinum Toxin-A (BTXA) treatment in conjunction with directed physical 
therapy on spasticity, active range of motion (AROM), passive range of motion (PROM), 
Functional Independence Measurement (FIM) scores, and motor performance in a patient with 
TBI. Researchers hyopothesized that directed physical therapy in conjunction with BTXA would 
maximize a subject’s motor control and performance. An ^Ai-BC-B-Az” single subject design, 
scheduled to last six months and three weeks, was proposed. Clinically significant changes were 
defined as: a decrease by one point for the Modified Ashworth Scale score, an increase by one 
point for the FIM, an improvement of a minimum of eight degrees for AROM and PROM 
measurements, and an improvement in overall function on either of the two performance tests. 
Due to time constraints, this study was not completed and results were not obtained.
TEST-RETEST RELIABILITY OF THE MODIFIED ASHWORTH SCALE, 
ACTIVE AND PASSIVE RANGE OF MOTION, AND THE NINE HOLE PEG TEST 
IN THE UPPER EXTREMITY OF SUBJECTS WITH TRAUMATIC BRAIN INJURY
ABSTRACT
Seven subjects with traumatic brain injury (TBI) were evaluated for test-retest reliability 
of the Modified Ashworth Scale, active range of motion (AROM), passive range of motion 
(PROM), and the Nine Hole Peg test. Researchers evaluated muscle tone and range of motion 
(ROM) for the involved shoulder, elbow and wrisL Results were analyzed using Spearman’s rho 
(rg) statistical test and showed varying levels of reliability for each measurement tool and for 
each joint motion. In general, high test-retest reliability (rg = 0.75 - 1.00) was found for the 
Modified Ashworth Scale, PROM and the Nine Hole Peg test, making these measurement tools 
beneficial for clinical assessments. AROM, however, demonstrated variability between test days 
and between joints and may only be of limited benefit for the assessment in individuals with 
TBI. Due to the small sample size and limited generlizability in this study, further research on 
reliability of these measurements is needed.
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DEFINITION OF TERMS
Active range of motion: the amount of degrees a joint can be moved during unassisted 
voluntary motion (Noridn & White, 1985).
BTXA treatment: intramuscular injections o f the pharmacological agent Botulinum 
Toxin-A into spastic target muscles. The specific dosage o f this pharmaceutical product 
is determined by the attending physiatrist
Directed physical therapy: treatment that may consist of: facilitation techniques, 
stretching o f spastic agonist muscle group(s), strengthening o f weak antagonist to spastic 
muscle group(s), inhibition techniques, neuromuscular re-education and/or functional 
training and/or home exercise program. Specific intervention(s) will be determined by 
the subject’s attending physical therapist
Fixed contracture: a joint deformity that is unresponsive to active or passive ROM 
within a specific range.
Functional independence measurement (FIM ): an assessment instrument of functional 
status that consists of twenty-three items in seven areas of function: self care, sphincter 
control, mobility, locomotion, communication, social adjustment/cooperation, and 
cognition/problem solving (Guide for the Uniform Data Set, 1996; Hamilton et al.,
1994).
Involved group: a pilot-study group consisting of individuals with spasticity related to 
either cerebral vascular accident (CVA) or traumatic brain injury (TBI)
Long-term effects: any changes lasting longer than three montiis o f implementation of 
BTXA.
vm
DC
Modified Ashworth score: an assessment o f muscle spasticity utilizing a five point 
ordinal scale ranging from no increased muscle tone to rigid flexion or extension o f an 
affected joint (Bohannon & Smith, 1987; Hass et al^ 1996).
M otor control: the performance o f a purposeful action with a specific expected outcome 
(Carr et al., 1995).
O ther pharmacological o r physical treatm ent options for spasticity: may include: 
Baclofen, Diazepem, Dantrolene, Phenol, serial casting, thermal agents and/or electrical 
stimulation.
Passive range of motion: the degree of joint motion attained by the examiner without 
the patient’s assistance (Norkin & White, 1985).
Performance tests: standardized measurements that evaluate a subject’s motor control. 
The specific test will be determined according to subjects’ clinical presentation and 
targeted extremity (i.e. Nine Hole Peg test for an involved upper extremity (Appendix C) 
(Mathiowetz et al., 1985) or Footprint Analysis for an involved lower extremity 
(Appendix D) (Holden et al., 1984; Shores, 1980).
Short-term effects: any changes that occur within the first three months of 
implementation of BTXA treatment and directed physical therapy.
Spasticity: a motor disorder characterized by an increase in muscle tone due to velocity 
dependent hyperactive stretch reflexes (Allison et al., 1996).
Target muscle gronp(s): determined by a local participating physiatrist specializing in 
neurologic rehabilitation medicine via functional and postural presentation and 
palpation.
Traum atic Brain Injury (TBI): inclusive of both closed and open head injuries. Our 
patient incurred this status through gun shot wound, motor vehicle accident, falls, etc. 
Uninvolved Group: a pilot-study group consisting o f normal adults.
CH APTERl
INTRODUCTION
Spasticity, a motor disorder characterized by an increase in muscle tone due to velocity 
dependent hyperactive tonic stretch reflexes (Allison, Abraham & Petersen, 1996), is among the 
most highly prevalent impairments resulting from Traumatic Brain Injuries (TBI) (Bohannon & 
Smith, 1987). Decreases in range of motion and joint contractures are potential secondary 
impairments that commonly result when a muscle is limited by spasticity. Functional disabilities 
associated with TBI can often be associated with one or both of these impairments. Therefore, 
management of spasticity in these patients is an important rehabilitative goal in order to prevent 
secondary impairments and maximize functional outcomes.
The complexities and limited results o f conservative spasticity interventions such as 
muscle cooling and splinting have lead researchers to explore other forms of treatment for 
spasticity. In 1980 Dr. Alan Scott from the Smith Kettlewell Eye Institute (San Francisco, 
California) and Professor Edward Schantz at the Food Research Institute at the University of 
Wisconsin introduced a new pharmacological treatment for spasticity: Botulinum Toxin-A 
(BTXA). Utilizing a serologically distinct protein derived from Clostridium botulinum. Dr. Scott 
and Professor Schantz were able to prevent the presynaptic terminal release of Acetylcholine 
(ACh) into the neuromuscular junction, thus yielding muscle paresis. With the objective o f 
finding a treatment for essential blespharospasm, researchers injected the BTXA protein into the 
periocular and focial muscles o f monkeys. Injections yielded paresis-like effects in the target 
muscles and alleviated the spastic symptoms of the condition, therefore producing enhanced eye 
convergence (Tsui, 1996; American Academy of Neurology, 1990). The success of this drug 
unearthed a new treatment possibility for other disease processes characterized by involuntary
spasms of specific muscle groups. Consequently, since it’s discovery clinical studies have 
investigated the use o f BTXA for other conditions characterized by muscle hyperactivity, 
including spasticity related to TBI.
The success o f this new treatment option has prompted researchers to investigate the 
specific effects of BTXA, the clinical conditions for which it is most effective, its mechanism of 
action, and its possible side effects. Histologically, BTXA acts on specific muscles by causing a 
local chemical denervation, resulting in local muscular paralysis (Das & Pailc, 1989). Unlike 
other injectable treatments for spasticity, BTXA works at the target muscle’s motor end plate 
without compromising local sensation. Because “preserved sensation is an integral part o f 
maximizing motor recovery,” (Bhakta, Cozens, Bamford & Camberlain, 1996, p. 30) the use of 
BTXA injections is recommended over phenol injections when a patient’s sensation is intact 
(Bhakta et al., 1996).
BTXA injections appear to be a relatively safe therapeutic option for patient’s with 
hemifacial spasm, cervical dystonia, oromandibular dystonia, and focal and segmental limb 
dystonias (National Institute of Health, 1990). The occurrence o f side effects has been 
documented in a  relatively small number of cases and is limited to reports of a flu-like 
syndrome, self-limiting fatigue, nausea, and headaches (National Institute of Health, 1990). 
Moreover, there is indication that patients may develop BTXA antibodies in response to repeated 
BTXA injections (American Academy of Neurology, 1990).
Most recently, the use of BTXA as a pharmacological treatment for spasticity has been 
investigated with patients who have sustained central nervous system (CNS) damage of either 
cerebral or spinal origin. In addition to the drug’s potential to improve agonist-antagonist 
balance, BTXA injections have also been indicated for pain reduction, improved positioning of
limbs, better fit or tolerance o f braces, improved hygiene, and prevention of skin breakdown in 
patients with CNS damage (Pierson, Katz & Tarsy, 1996; Pullman, Greene, Gahn, & Pedersen, 
1996). The effectiveness of BTXA has been examined in many conditions involving the CNS: 
cerebral vascular accidents (CVA), spinal cord injuries (SCI), multiple sclerosis (MS), cerebral 
palsy (CP), and traumatic brain injury (TBI) (Pierson et al., 1996; Snow, Tsui, Bhatt, Varelas, 
Hashimoto & Caine, 1990; Giazko, Polo, Jabbari, 1995). In studies that have investigated the 
effects o f BTXA on cerebral forms of spasticity, researchers have either 1) reported on 
heterogeneous subject groups inclusive of a varied of diagnoses (Burbaud et al., 1996; Dunne, 
Heye & Dunne, 1995; Grazko et al., 1995) or 2) focused only on patients with lesions caused by 
CVA (Bhakta et al.,1996; Hesse et al., 1994). Following BTXA injections, researchers 
repeatedly report significant decreases in spasticity short-term, but the duration of spasticity 
relief ranges from six to 47 weeks post-injection (Simpson et al., 1996; Bhakta et al., 1996).
Randomized, double-blind, placebo controlled trials o f BTXA, demonstrate that 
although BTXA treatments decrease spasticity, the mjections do not produce measurable changes 
in function when administered to patients with spasticity (Simpson et al., 1996; Grazko et al.,
1995). However, no studies have specifically examined the short-term and long-term effects of 
BTXA when used as an adjunct to directed physical therapy intervention in subjects with TBI.
In a study by Bhakta et al. (1996), physical therapy intervention was not controlled for during the 
duration of the study and consequently one subject, post-CVA, implemented a vigorous self­
exercise program following BTXA injections. This particular subject reported significant long­
term (47 weeks) improvements following BTXA treatment. Therefore, Bhakta suggests that 
BTXA may offer a “window of opportunity” for physical therapists to help promote functional 
gains in patients with spasticity related to CNS damage. Yet further studies are needed to 
support this claim.
Therefore, the purpose o f this single subject case design will be to evaluate the long-term 
and short-term effectiveness of BTXA treatment in conjunction with directed physical ther^y  
on spasticiQr, active range of motion (AROM), passive range o f motion (PROM), Functional 
Independence Measurement (FIM) scores, and motor performance in a patient with TBI.
Directed physical therapy is included in order to maximize the subject’s motor control and 
performance following the temporary reduction of cerebral spasticity. The advantage o f a single 
subject case design is that researchers will be able to control for the heterogeneous nature o f the 
spasticity and functional disabilities in the TBI population. Instead o f measuring several 
subjects, researchers will be evaluating the results of an individualized physical therapy 
treatment program. It is expected that spasticity in the target muscle(s), measured by Modified 
Ashworth Scores, will decrease for three months following BTXA injections and directed 
physical therapy. Once directed physical therapy has ceased, researchers anticipate Modified 
Ashworth Scores will slowly return to near-baseline values. Researchers also expect to see long 
and short-term improvements in AROM, PROM, FIM scores and the Nine Hole Peg or temporal 
distance gait variables, depending on upper or lower extremity involvement o f die subject 
Effectiveness of BTXA plus directed physical therapy will be determined by examining 
Modified Ashworth Scale scores (Appendix A), FIM (Appendix B), AROM, PROM, and either 
the Footprint Analysis or the Nine Hole Peg test (Appendix C & D). By evaluating these 
measures, the researchers hope to determine whether or not BTXA treatment with directed 
physical therapy is a worthwhile intervention that can generate short-term and/or long-term 
functional changes in a patient with TBI.
CH APTER!
REVIEW OF LITERATURE AND CONCEPTUAL FRAMEWORK
Spasticity is a common clinical manifestation of an Upper Motor Neuron (UMN) 
syndrome characterized by ‘Velocity-dependent increase in tonic stretch reflexes (‘muscle tone’) 
with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex” (Lance, 
1980, p. 485). Spasticity is a primary impairment that alters the length-tension relationship of 
agonist and antagonist muscle groups. As a definitive physical sign of UMN syndrome, 
spasticity is often a primary concern in the rehabilitation process, treatment planning, and limb 
function o f many patients with traumatic brain injury. Secondary impairments resulting from 
spasticity, such as joint contractures and decreased range of motion, may lead to functional 
limitations that restrict the performance o f activities o f daily living (ADLs) and ambulation 
(Pierson et al., 1996; Yablon, Agana, Ivanhoe & Boake, 1996). Therefore, effective 
management o f spasticity has the potential to enhance mobility and performance of ADL’s, aid 
in the prevention of the above mentioned secondary impairments, and promote patient comfort 
(Haley & Inacio, 1990).
Although there remains much controversy regarding the neurophysiological background 
of spasticity, for the purpose o f this study, authors will adopt the following assumption. 
Spasticity results frx>m the hyperexcitability of the stretch reflex as commonly observed in CVA, 
TBI, anoxia, SCI, CP and MS UMN lesions. A normal stretch reflex receives input from muscle 
receptors that are modulated by velocity of muscle movement, amount of muscle movement, and 
length of the muscle when movement occurs (Carr et al., 1995). Under normal circumstances, an 
individual can inhibit this reflex to some degree. For example, the biceps muscle normally 
demonstrates little resistance to slow, passive stretching. With spasticity, however, the inhibition
signais fix>m higher centers in the CNS are altered and as a result, muscle receptors become 
hypersensitive to muscle movement, length, and tension. This abnormal muscular state 
manifests as an increase in tone, or resistance to movement making an attempt to passively 
stretch the biceps laborious or impossible.
One may felsely conclude that spasticity alone is responsible for alterations in motor 
nerve recruitment and motor control in patient’s status post TBI. However, there exists further 
rationale behind neuromuscular changes seen with TBI. Haley & Inacio (1990) advise that with 
UMN lesions, spasticity often coexists with other primary impairments including poor force 
production, abnormal timing of muscle synergists, delayed initiation of movement, and 
fatiguability. These later impairments are considered more detrimental to a patient’s movement 
ability than the presence o f spasticity alone (Carr et al., 1995). A muscle that is weakened or 
fatigued, secondary to an UMN lesion, will become shortened and mechanical changes in the 
musculo-tendinous unit will begin to take place. Evidence shows that shortened muscles lose 
sarcomeres, thus yielding increase resistance to passive stretch and eventual soft tissue 
contractures (Carr et al., 1995). All of these adaptations adversely effect motor control and 
passive and active motion. Therefore, spasticity should only be considered one of many possible 
factors contributing to abnormal motor control in a patient with TBI. In order to maximize 
motor control and functional outcomes in a patient with TBI, a comprehensive physical therapy 
program should include interventions that address all present primary impairments of the UMN 
sequelae.
Once a therapist or physician concludes that a patient exhibiting spasticity also has 
underlying muscular weakness and poor muscular control, treatment planning can begin. 
Treatments are initiated based on the assumption that spasticity is the chief obstacle to 1) 
addressing the other primary muscular impairments (weakness, motor control), 2) preventing 
secondary impairments, and 3) eventually regaining patient function (Carr et al., 1995; Haley &
Inacio, 1990). In essence, the early focus of rehabilitation of a patient with TBI is to discover die 
“therapeutic window” of spasticity management Once this opportunistic window has been 
identified, the rehabilitation team, with the patient’s active participation, can begin task-specific 
training. Task-specific training, muscle re-education, and hands-on neuromuscular facilitation 
techniques are just some of the physical therapy interventions clinicians may use to promote 
function and motor performance in patients with TBI.
In order to maximize a patient’s potential for improved function, rehabilitation 
professionals may need to apply a variety of spasticity management techniques during the 
“therapeutic window.” Conservative techniques utilized by physical therapists such as 
antagonist facilitation or serial casting, are initially attempted and are associated with the fewest 
side effects. If these techniques prove to be ineffective, management of spasticity will progress 
to invasive medical techniques such as: neuromuscular blocks, rhizotomy and orthopedic surgery 
which involve side effects that may be detrimental or permanent. Therefore, rehabilitation 
specialists must take into accoimt a patient’s recovery potential and the extent to which spasticity 
is limiting function when deciding which treatment approach will provide the greatest benefîts.
Physical therapy interventions that address TBI-related spasticity include topical 
cooling, neutral warmth, vibration, electrical stimulation, biofeedback, prolonged stretch, 
weight-bearing, slow rocking, massage, and serial casting or splinting (Giebler, 1990; Katz,
1988). Except for serial casting and splinting, spasticity management techniques used by 
physical therapists are, for the most part, short-term strategies (Katz, 1988). Muscle cooling is 
thought to increase the motor neuron’s action potential threshold, leading to decreased nerve 
conduction velocity and direct inhibition of a spastic muscle (Giebler, 1990). Neutral warmth, 
applied by means of hot pack, parafRn, or whirlpool, works to increase blood flow to a muscle, 
thus increasing musculo-tendinous extensibility and decreasing efferent muscle receptor activity 
of the stretch reflex (Giebler, 1990). Vibration, depending on the frequency, can either facilitate
or inhibit muscle contraction. Therefore, vibration can be applied to either the spastic agonist or 
the lengthened antagonist muscle group. Likewise, electrical current can also be used on 
antagonist and agonist muscle groups. Dependent upon the fiequency, electrical stimulation can 
be used to contract, inhibit, relax, or fatigue a muscle. When applied to a spastic muscle (the 
agonist), electrical stimulation yields a temporary fatigue of the target muscle fibers, thus 
suppressing hypertonus. When applied to the antagonist muscle, electrical stimulation and 
vibration produce reciprocal inhibition of the agonist muscle to decrease the firing of the stretch 
reflex (Giebler, 1990).
Biofeedback, although difficult to use effectively in patients with TBI secondary to 
deficits o f cognition and voluntary movement, has been used as a conservative spasticity 
management technique (Little & Massagli, 1993). Visual or audio feedback promotes relaxation 
by allowing the patient to monitor and control the degree of firing in a spastic muscle. The 
inhibitory effects of weight bearing may be attributed to afferent signals fiom joint receptors and 
the inhibitory effects of muscle stretch (Giebler, 1990). Both slow rocking and massage of the 
patient with spasticity produce generalized relaxation, but are very time consuming and the 
effects are short-lived (Giebler, 1990). Prolonged stretching of a musculo-tendinous unit, as 
occur with serial casting and splinting, is also used to decrease spasticity. By placing a joint in a 
lengthened position that inhibits tonic activity, rehabilitation specialists anticipate a reduction in 
muscle hyperactivity (Little and Massagli, 1993). However, these physical therapy techniques 
produce mostly transient changes and therefore results are best when they are utilized for 
patients exhibiting mild to moderate spastici^ (Simpson et al., 1996).
Rhizotomies and tenotomies are surgical interventions used to treat severe and 
deforming spasticity (Wheeler, 1997). Orthopedic surgeons use tenotomies, tendon transfers, 
and tendon lengthening to alter the biomechanics of ambulation or grasp deformities resulting 
from increased muscle tone. Rhizotomy, which includes the sectioning of posterior spinal nerve
roots (Little & Massagli, 1993) and peripheral neurectomy are two common neurosurgical 
^proacbes to spasticity management Despite medical sophistication, rhizotomy is associated 
with unpredictable spasticity recurrence and reappearance of the original deformity (Glenn, 
1990). Regardless of the severity o f spasticity or the compelling need for the drastic spasticity 
intervention, definitive surgery, such as tendon lengthening or rhizotomy, is contraindicated 
during the one year following CVA and the one and one-half years following head trauma due to 
the potential for motor recovery (Burbard et al, 1996; Garland & Keenan, 1983). Therefore, 
these invasive procedures are often a last resort and are reserved for extreme cases o f severe, 
disabling spasticity.
Less invasive and more typical approaches to treat chronic spasticity involve 
pharmacological interventions such as Baclofen, Diazepam, and Dantrolene. Working 
systemically, these oral medications provide temporary relief o f spasticity. Based upon a review 
by Young and Delwaide (1981a), Diazepam is most effective in managing spasticity related to 
spinal lesions. However, spasticity of cerebral origins is better managed with Baclofen or 
Dantrolene (Dali, Harmon, & Quinn, 1996).
Baclofen acts pre-synapdcally on motor end plate terminals to inhibit the influx of 
calcium, thus restricting the release of excitatory neurotransmitters. This drug can be 
administered both orally and via interthecal pump at the spinal cord level. In 1981, Baclofen, a 
powerful neuronal depressant, was considered “the most effective agent for the management of 
spasticity and the drug with the fewest side effects” (Young & Delwaide, 1981b, p. 98). Since 
then. Baclofen has been used therapeutically by physiatrists for the management of painful and 
disabling flexor or extensor spasms. By acting centrally via the CNS, presently, researchers feel 
that Baclofen’s numerous systemic side effects outweigh its therapeutic effects (Katz, 1996). 
Hallucinations, confusion, sedation, hypotonia, ataxia and generalized muscular weakness (Katz, 
1988) are rare side effects, but occur at a higher frequency in patients with cerebral lesions as
1 0
compared to patients with spinal lesions. The presence o f systemic muscular weakness is 
especially detrimental to a physical therapist’s ability to address the patient’s other primary 
impairments during the “therapeutic window” of opportunity. In addition, the required 
therapeutic dosage of Baclofen is higher in patients with cerebral lesions than those with spinal 
lesions.
Dantrolene, or Dantrhm, works by interfering with the excitation and contraction of 
Type n  muscle fibers. By reducing the release of calcium 6om the sarcroplasmic reticulum. 
Dantrolene decreases the force of muscle contraction (Katz, 1988). Preferred over Baclofen for 
cerebral forms of spasticity (Dali et al., 1996), Dantrolene is also useful to treat spinal spasticity 
(Katz, 1988). However, Dantrolene is mildly sedative and potential side effects include malaise, 
nausea, dizziness, diarrhea, hepatotoxicity, generalized weakness, and in patients with cerebral 
palsy, increased seizure episodes (Katz, 1988).
The inherent disadvantage of the above pharmacological interventions is that 
Dantrolene, Baclofen and Diazepam all work systemically to obviate spasticity. Although their 
therapeutic effectiveness is supported by research and their ease of administration makes them a 
popular choice for spasticity management. Baclofen, Diazepam and Dantrolene are each 
associated with generalized muscle weakness (Young & Delwaide, 1981a; Young & Delwaide, 
1981b). As earlier reported, the side effects of generalized muscle weakness can be considered 
more disabling to overall motor function than the primary impairment of spasticity in patients 
with UMN syndrome. Alternative management techniques, which involve injections into 
specific nerves, allow rehabilitation specialists to decrease focal spasticity without generating 
systemic side effects typical of oral medications (Glenn, 1986).
Phenol injection, a peripheral nerve block, is an example of an inexpensive spasticity 
management technique that allows for accurate isolation of a target muscle or nerve distribution. 
When injected directly into a nerve, phenol denatures proteins and causes necrosis of all axons or
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terminal nerve fibers with which it comes in contact. Phenol injections can be performed via 
both percutaneous and open methods. Percutaneous injections do not involve an incision and are 
indicated if the target nerve carries only motor fibers, or if sensation within the nerve distribution 
has been lost. Open injections, require an incision approximately three centimeters in length 
(Garland & Keenan, 1982) and allow physicians to isolate the motor branch of a mixed nerve 
and leave sensory nerve fibers undisturbed. Both methods result in transient muscle paralysis 
lasting three to six months (Katz, 1988; Garland & Keenan, 1982). However, a study conducted 
by Khalili et al. (1964) using the percutaneous injection method, showed that although phenol 
does not produce the cognitive side effects associated with many oral medications, it may cause 
an increased sensitivity to pain and touch known as "dysthesia." In addition, because phenol 
injections are known to elicit protein coagulation when administered in greater than S% 
solutions, the injections should be administered with great caution in patients who are at 
increased risk of blood coagulation. In a 1983 report featured in The Journal o f the American 
Medical Association, Macek suggested that phenol injections may contribute to the formation of 
deep vein thromboses in some patients.
Botulinum Toxin-A
A less invasive and longer-lasting spasticity intervention, called ‘*Botox,” has emerged in 
the last decade. Botulinum Toxin-A (BTXA), trade named BOTOX® (Allergan 
Pharmaceuticals, Irvine, CA) and Dysport® (Sperwood Pharmaceuticals, England), is a 
pharmacological agent that utilizes a serologically distinct protein derived fiom the anaerobic 
bacterium Clostridium botulinum. Following injection into the neuromuscular endplate, this 
protein becomes internalized via receptor-mediated endocytosis in the muscle cell, thus 
preventing the presynaptic terminal release of Acetylcholine (ACh) into the neuromuscular 
junction. The blockade of ACh induces paralysis in the target muscle (Borg-Stein & Stein, 1993;
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Grazko et al., 1995; Yablon et al., 1996; Hassan, Jennekens & Veldman, 1995; Dunne et al.,
1995; Das & Park, 1989).
In 1989, the United States Food and Drug Administration accepted the drug botulinum 
toxin as a safe and effective therapeutic intervention for strabismus, essential blepharospasm, 
and hemifacial spasm (National Institute of Health, 1990; Wheeler, 1987). In addition to these 
diagnoses, the usefulness o f BTXA is also being studied for the relief o f muscle spasms 
associated with torticollis, oromandibular dystonia, spasmodic dysphonia, and spasticity 
associated with cerebral and spinal cord lesions (National Institute of Health, 1990). However, 
BTXA is not a cure for spasticity and the long-term effects of BTXA treatment in adults or 
children with CNS disorders remain unknown.
Many different studies have evaluated the effectiveness of BTXA on spasticity in 
patients with upper motor neuron syndrome caused by CP, MS, TBI, SCI, and CVA (Burbaud et 
al., 1996; Bhakta et al., 1996; Dunne et al., 1995; Pierson et al., 1996; Simpson et al., 1996; 
Wilson, Childers, Cooke & Smith, 1997). These same studies have examined the efficacy of 
BTXA on spasticity by evaluating changes in a wide range of outcome measures, including range 
of motion (ROM), spasm frequency, ECO recordings, freedom from pain, grip strength, 
positioning, caregiver dependency scale, modified Fugl-Meyer, Modified Ashworth Scale scores, 
ambulation score, brace wear scale score, Barthel Index, and FIM scores.
A randomized, double-blind, placebo-controlled study conducted by Simpson et al.
(1996) examined the use o f BTXA in 39 subjects who had upper extremity spasticity related to 
CVA. Measurements of the Ashworth scale, FIM, Rand 36-Item Health Survey 1.0, Fugl-Meyer 
Scale, caregiver dependency scale, function and pain assessment, motor task/function rating 
scale, grip strength, and arm and forearm circumference were taken at baseline, two, four, six, 
ten, and sixteen weeks post BTXA injections. Subjects participated in physical therapy 
throughout the sbcteen weeks o f the study, but neither therapy activities nor frequency of
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participation was reported. Initial results at six weeks post-injection, indicated a significant (p < 
0.05) decrease in tone (Ashworth Scale) and a significant (p =  0.016) increase in grip strength. 
However, at sixteen weeks post-injection, muscle tone had returned to near baseline values, 
indicating a lack of long-term benefit. In addition, no significant differences were detected 
between placebo and treatment groups for the FIM. The subjects used for this study were 
relatively high functioning and therefore the FIM may not have been sensitive enough to 
measure any changes.
Another study conducted by Reiter, Danni, Cervolo and Provinciali (1996), examined 
disability changes following BTXA injections in seventeen patients with moderate to severe 
upper extremity spasticity related to either TBI or CVA. The goal of this study was to examine 
the cost/benefit ratio associated with this new trend of spasticity management. Participation in 
physical and occupational therapy was not controlled for in this study. One week following 
injection. Modified Ashworth scores decreased and ROM measurements increased in all 
subjects. Modified Ashworth scores remained steady for an average o f 3.58 months with peak 
changes occurring thirty days post BTXA treatment However, FIM scores were not affected by 
BTXA treatment; only four subjects increased by more than three points fiom pre- to post-tests.
Dunne, Heye, and Dunne (1995) examined the effects of BTXA injections combined 
with formal physical therapy in 40 subjects with moderate to severe spasticity in upper or lower 
extremities related to varying neurological diagnoses. Effectiveness was determined by by the 
following outcome measurements: the Modified Ashworth scale for spasticity, pain score, joint 
angles, Lindmark’s modified motor assessment system, and the Barthel Index for functional 
independence. Each subject initially underwent two baseline measurements performed three to 
four weeks apart. Two subsequent measurements were taken: the first between four and six 
weeks following injection, the second between four and six months following injection. Authors 
reported that the nature and intensity o f physical therapy remained unaltered throughout the
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study’s timetable and that all subjects participated in physical therapy at least once per week. 
However, no description of therapeutic procedures or duration o f treatment sessions was 
included in the study’s methodology.
The authors did not report significant changes in the Modified Ashworth scores 
following BTXA treatment. However, results o f mobility subscores fix>m Lindmark’s modified 
motor assessment system taken pre- and post-injection indicated that five subjects returned to 
walking and ten subjects showed improvements in their gait patterns following BTXA treatment. 
Joint angles, measured both by goniometer and videotape, showed improvement post-BTXA 
treatment in 75% of the subjects. In addition, 90% of the subjects with pain pre-injection 
reported pain reduction following treatment On average, the changes that were experienced 
were most significant at three weeks post-injection and endured for five months. The results of 
this study support the combination o f BTXA and directed physical therapy. However, without a 
control group, which this study did not incorporate, it is difficult to deduce whether the noted 
changes can be attributed to BTXA treatments alone or the combination of BTXA and physical 
therapy. In order to determine the source of the changes, either BTXA or directed physical 
therapy intervention must be manipulated.
In a study conducted by Bhakta et al. (1996), seventeen subjects status-post CVA 
received BTXA injections for severe upper extremity spasticity. Physical therapy was 
uncontrolled for and as a result, one subject, who implemented her own self exercise program, 
reported benefits lasting forty-seven weeks. The lasting benefits reported by this subject far 
exceed both the measurements o f the remaining sixteen subjects, whose benefits lasted fiom four 
to sixteen weeks, and the duration of BTXA treatment effects typically reported within the 
literature. The exceptional results observed in one subject raised the authors’ curiosity regarding 
the “window of opportunity” associated with BTXA injections.
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A single case design that investigated the effect of BTXA on function of a patient with 
poststroke quadriplegia (Cromwell & Paquette, 1996) reported specifically on physical therapy 
interventions administered. While the pharmacological effects of BTXA injections were taking 
place, the single subject was participating in 30 to 45 minutes of directed physical therapy, twice 
daily. Directed physical therapy included bed mobility and transfer and gait training. As a 
result, the patient exhibited improvements in FIM scores for the bed, toilet, and wheelchair 
transfers as well as the walking score. Measurements were taken three times: before injection, 
two weeks post injection and six months post injection. However, authors did not collect three 
data points during the pre-injection period, as required to show a stable baseline (Fortney & 
Watkins, 1993). From the data collected, Cromwell and Paquette concluded that improvements 
in function could be directly attributed to the patient’s participation in physical therapy while the 
effects of BTXA injections were present
Despite these promising results, few BTXA studies have focused strictly on the 
population of patients with TBI. To date, most studies have examined the effects of BTXA 
spasticity treatment on heterogeneous subject groups inclusive of a variety of patient diagnoses. 
Isolating the results gained from patients with TBI is significant due to the different potentials 
for motor recovery and the distinct pattern of spasticity. For example, patients post CVA 
demonstrate a majority of recovery in the first six months to one year after insult; whereas 
patients with TBI display a more prolonged recovery period from one to one and one-half years 
(Garland, Lucie & Waters, 1982). Furthermore, the pattern o f increased resistance to passive 
stretch in patients with TBI is more diffuse and segmental than seen in patients status-post CVA 
(St George, 1993). Finally, due to advances in medical technology and treatment, there are 
more survivors of TBI who are seeking management techniques for spasticity. Despite the 
strong argument for a specific investigation of spasticity management in patients with TBI, only 
two studies exclusively involving patients with TBI treated with BTXA were found in the
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literature. One was reported in Brain btjwry ^ i ls o n  et al., 1997) and another in Neurology 
(Yablon et al., 1996).
‘‘Kinematic changes following botulinum toxin injection after traumatic brain injury” 
(Wilson et al., 1997) is a single-subject case sturfy that used computerized, three-dimensional 
gait analysis to measure the functional effects o f BTXA management techniques in the 
gastrocnemious muscle of a patient with TBI. Gait parameters were measured at pre, one week 
post, and four weeks post BTXA injection. The report included no mention of participation in 
physical therapy. Results included increases in walking speed, stride length, percent swing time 
and decreases in stride length, stance time, and percent single-leg stance time. In addition, 
researchers reported a decrease on the Modified Ashworth Scale from a three at pre-injection to a 
two at four weeks post- BTXA injection. However, PROM measurements taken pre- and post 
management techniques failed to detect any differences. Results from this study suggest that 
BTXA injections alone may positively affect a patient’s gait pattern on a short-term basis 
although long-term benefits remain to be reported.
In the study conducted by Yablon et al. (1996), twenty-two subjects with severe 
spasticity in wrist and finger flexors secondary to TBI, underwent a BTXA spasticity 
management program. Following BTXA injections, patients received physical therapy 
described as, “ROM therapy, therapeutic modalities, splinting, and casting as indicated” (Yablon 
et al., 1996, p. 940). No mention was made of the duration or intensities of these interventions. 
Subjects were followed for twelve weeks. A significant {p = 0.01) improvement in Modified 
Ashworth Scores persisted for an average of three months. ROM also improved significantly {p 
=0.001). However, it was unclear whether these improvements persisted through out the twelve 
weeks of the study. This study did not report any functional outcomes related to BTXA 
intervention.
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Although there exists separate support for BTXA as a spasticity management technique, 
to date, no studies have examined the effects of BTXA in conjunction with directed physical 
therapy in a subject with TBI, while evaluating function, the musculo-tendenous unit, and the 
long and short-term duration o f effects. Therefore, this study is designed to meet this need.
Outcome Measurements
Several methods exist to objectively and subjectively measure spasticity in a muscle. 
Complex laboratory tools involving needles and computers offer the most quantifiable data. 
However, they tend to be costly and compromise patient comfort (Haas & Crow, 1995). 
Therefore, a six-point ordinal scale, known as the Modified Ashworth Scale (Appendix A), is the 
most often used tool by physical therapists to measure spasticity. Developed by Ashworth in 
1964, the original Ashworth scale created a standardized description of the amount of resistance 
felt by the examiner when moving the spastic limb passively through its full range of motion.
This five-point ordinal scale was slightly modified by Bohannon and Smith in 1987 (Allison et 
al., 1996). By adding an intermediate grade to the original Ashworth scale, Bohannon and Smith 
reduced the clustering that occurred around the middle grades. Using the new scale, researchers 
also assessed inter-tester reliability and found an 86.7% agreement for elbow flexors in patients 
with CVA and TBI (1987). Other means of evaluating spasticity such as: the Wartenberg 
(Pendulum) test, electromyography studies, hand-held myometers, grading of deep tendon 
reflexes, self-evaluation, H-reflex testing and performance measurements may also be used by 
clinicians. However, the Modified Ashworth Scale’s ease of use makes it the preferred clinical 
tool to evaluate spasticity in a variety of patient populations and muscle groups.
The inter-tester reliability of the Modified Ashworth Scale is variable depending on the 
muscles evaluated. Results, using Cohen’s k  and Spearman’s p  Coefficients, have ranged from: 
0397 - 0.727 for plantarflexors (Allison et al., 1996), 034 - 0.62 for hip adductors, 032 - 034
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for hip extensors, 028 for hip floors (Haas, BergstrOm, famous & Bennie, 1996), and 0.847 for 
elbow flexors (Bohannon & Smith, 1987). Allison et al. (1996) conducted a study to measure 
the intra-tester reliability o f this scale. Results showed only mild to moderate intra-tester 
reliability of the Modified Ashworth when performed on plantarflexors.
The authors of this intra-tester reliability suggest that the variability in raw data scores 
was due to both internal and external factors not controlled in the study. Specifically, the length 
of the lever arm available to the tester and the quantity of angular excursion of the joint being 
tested are both internal testing factors that limited the tester’s ability to detect subtle changes in 
resistance. Ambuiguous terminology used in the criteria for each score, (e.g., grade 1+ is 
described as a “slight increase” in muscle tone) also created a potential for varied interpretations 
of the measurements. Although the authors were unable to measure the occurance of this 
variation, the ambiguous terminology was proposed as a limiting internal factor of the Modified 
Ashworth Scale. The researchers reported suspicions that external influences, such as subject’s 
level of arousal or activity, affected the repeat scoring of the Modified Ashworth Scale (Allison 
et al., 1996). The report by Allison et al. has significant implications on the strength of test- 
retest results to be reported on in this study.
Studies conducted to correlate the Modified Ashworth Scores with H-reflex testing were 
inconclusive. Therefore, the validity of the Modified Ashworth scale is still undetermined 
(Allison & Abraham, 1995). Although experimental support is limited and it is difficult to 
control for external factors that may influence scores, the Modified Ashworth Scale is still the 
most commonly utilized clinical tool to assess spasticity.
To assess an individual’s need for assistance while performing ADL’s, the Functional 
Independence Measurement (FIM) is used by clinicians (Appendix B). Developed by a joint 
task force of the American Congress of Rehabilitation Medicine and the American Academy of 
Physical Medicine and Rehabilitation in 1987, the FIM is used “...to assess the degree of
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disability that a patient has and the outcome of rehabilitation” (Guide for the Uniform Data Set 
for Medical.Rehabilhation, 1996, p. II-J-2). Compared to another measurement o f function, the 
Barthel Index, the FIM affords rehabilitation professionals greater choices in grades of function 
and level of needed assistance. The scores available with the FIM are also more useful to 
evaluate change in a patient whose level of assistance falls in a “middle” range (Roth et al.,
1990). The FIM is used by clinicians and researchers to document the quality of a patient’s 
performance and determine the appropriate level o f assistance for the patient.
The FIM’s flexibility also allows professionals to compute either a total score or any 
combination of subscores. These subscores consist o f two domain scores (motor and cognition), 
six subscale scores (self-care, sphincter control, transfers, locomotion, communication and social 
cognition) or eighteen individual item scores. Each functional task is scored based on the 
clinician’s observation. Research performed on hospital inpatients has demonstrated high inter- 
tester reliability using the intraclass correlation coefficient (ICC) for the FIM’s total score (0.96), 
domain scores (motor = 0.96, cognitive = 0.91) and subscale scores (range: 0.89 for social 
cognition to 0.94 for self-care) (Hamilton, Laughlin, Fiedler & Granger, 1994). Using a fit 
Analysis to determine validity, the Uniform Data System for Medical Rehabilitation found that 
eight o f the FIM’s thirteen motor items lack internal consistency (1996). E. Roth, G. DavidofT,
J. Haughton & M. Ardner found that the FIM’s concurrent validity ranged from r^ = 0.64 to 0.76 
for the mobility subscale (1990). Although concurrent validity is weak, “the FIM was found to 
be the most useful tool in predicting burden of care ... [and] the subject’s level o f satisfaction 
with life” (Cole, Finch, Gowland & Mayo, 1995, p. 55). Although more research is needed to 
support the FIM, it is commonly used among clinicians to report a patient’s quality of 
performance and appropriate level of assistance.
Monitoring changes in passive and active range of motion, with goniometry, is a more 
quantitative tool used by health care professionals to determine the effectiveness of spasticity
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interventions. As stated earlier, spasticity can be described as a hyperactivity of a muscle’s 
stretch reflex. According to a report by Haley & Inacio (1990), increased muscle tone can be 
affected by the mechanical and elastic characteristics of a muscle. With chronic spasticity a 
muscle’s length usually becomes shortened. BTXA affects target muscles by producing a 
localized paralysis o f muscle fibers. Therefore, by measuring joint active and passive ROM after 
BTXA injections, rehabilitation professionals can hypothesize that changes in a muscle’s length 
across a joint may be due to changes in a muscle’s spasticity. Although an increase in ROM 
does not necessarily reflect an increase or potential for gain in the subject’s function, ROM can 
help rehabilitation professionals assess the need for further interventions or equipment.
As the most commonly used evaluation procedure by practicing physical therapists, 
goniometry’s reliability and validity have been well examined. Studies show that the reliability 
of goniometry can be effected by diagnosis, time intervals between repeat testing, complexity of 
the action to be measured, and the functional differences of the action (Gajdosik, & Bohannon, 
1987). According to a study by Fish and Wingate (1985), most variation in range of motion is 
due to misidentification of bony landmarks, variations in manual force, and improper alignment 
of the goniometer. Therefore, they suggest that through the use of standardized procedures even 
inexperienced examiners can accurately assess ROM.
Using the ICC, Elveru, Rothstein and Lamb determined intra- and inter-tester reliability 
for the subtalar joint to be .74 and 32  for inversion and .75 and .17 for eversion respectively 
(1988). Dorsiflexion and plantar flexion intra-tester reliability were each found to be 0.90 and 
0.86, respectively. Inter-tester reliability for the above mentioned joint motions were each found 
to be 0.50 and 0.72.
Rothstein, Miller and Roettger determined that intra-tester reliability for the knee and 
elbow joints was high using ICC (1983). Results ranged from 0.91 to 0.99 for knee flexion, 0.86 
to 0.99 for elbow extension, and 0.94 to 0.97 for elbow flexion, depending on the devices used.
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Inter-tester reliability was also high for elbow extension (0.93 to 0.96), elbow flexion (0.89 to 
0.96), and knee flexion (0.91 to 0.99). Knee «ctension was found to be poor (0.64 to 0.71). 
Researchers discovered that inter-tester reliability improved when clinicians used the same 
patient positions for each evaluation. However, inter-tester reliability never reached the same 
level as intra-tester reliability.
Monitoring changes in impairments is crucial to objectiiy research, but in order for 
researchers to assess an intervention’s effect on motor control, measurements using performance 
tools should be conducted. Velocity and cadence, taken from a Footprint Analysis for lower 
extremity function or the results of the Nine Hole Peg test for upper extremity function are 
examples of performance tools that may be used. Footprint Analysis is an inexpensive and quick 
way to obtain quantitative data regarding a patient’s gait parameters (Shores, 1980; Holden, Gill, 
Magliozzi, Nathan & Piehl-Baker, 1984). Temporal distance measurements that reflect 
impairments, such as velocity, cadence, foot angle, base of support, stride and step length, and 
step and stride-time differential can be computed from the ink footprint record. Later, this same 
information can be used for pre- and post-treatment comparison as well as for patient motivation.
Footprint Analysis has been found to have high intra-tester reliability for unimpaired 
women (r -  0.69 to r = 0.97) (Boeing, 1977) and subjects with hip disorders (r -  0.96 to r = 0.99) 
(Wadsworth, Smidt, & Johnston, 1972). Maureen K. Holden et al. found high inter- and intra- 
tester reliability (r = 0.90 to r = 1.00) for subjects with MS or post-CVA hemiparesis in all 
temporal distance measurements except stride-time differential (1984). Using thirty normal 
females, the validity of the Footprint Analysis was determined by Darlene D. Boenig in 1977. In 
her study, ‘^ Evaluation of a Clinical Method of Gait Analysis,” she indicated that this tool is 
sensitive enough to be used clinically to measure improvements in gait patterns as the result of 
medical interventions and objective enough to measure patients with neuromuscular disorders.
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Several different hand function tests exist to evaluate fine motor skills. A sensitive test 
is one that incorporates a desired patient skill targeted by rehabilitation professionals. For this 
proposed study, the Nine Hole Peg test was selected as a tool for performance evaluation because 
it requires the patient to be able to reach, grasp, and release with a relative amount of precision. 
These hand skills are essential for both ADLs, including oral and hair care, cosmetic application, 
cooking tasks; and also industrial labor skills such as parts manipulation. In addition, the Nine 
Hole Peg test can be administered in a relatively short amount of time with ease and is 
inexpensive. Although, no published literature exists to specifically support the sensitivity of the 
Nine Hole Peg test or its relation to patient function, this test has been moderately correlated 
with the Purdue Pegboard (Mathiowetz, Weber, Kashman & VoUand, 1985). The Purdue 
Pegboard test is a standardized tool for a large variety of industrial jobs.
The Nine Hole Peg test is a standardized unilateral evaluation of an individual’s aptitude 
to grasp, release, and manipulate small wooden pegs (Mathiowetz et al., 1985). This inexpensive 
test requires less than ten minutes to administer. Standard procediues for administration of the 
Nine Hole Peg test were outlined by Mathiowetz et al. (1985). Using a Pearson correlation 
coefficient, Mathiowetz et al. reported a very high inter-tester reliability among normal subjects 
(right r  = 0.97, left r  = 0.99). Right hand test-retest reliability was high (r= 0.69), but the left 
hand test-retest reliability was moderate (r=0.43). Practice effect was also determined in this 
study using a two-tailed, paired data t test Results indicated a significant difference in the right 
(p< 0.001) and left hands (p<0.05) (Mathiowetz et al., 1985).
Validity of the Nine Hole Peg test was evaluated against results of the Purdue Pegboard 
test using factory workers as subjects. A significant inverse relationship between the Nine Hole 
Peg and Purdue Pegboard test was found for die right (r= -0.61) and left (r= -0.53) hands. It 
should be noted that a high score on the Purdue Pegboard test indicates a better performance, 
whereas a low score on the Nine Hole Peg test indicates a better performance (Mathiowetz et al..
23
1985). These results, gathered fmm normal subjects, suggest that Nine Hole Peg test results may 
indicate the level o f performance on industrial tasks. The application of these results for patients 
with TBI, however, is unreported at this time.
Spasticity, a primary impairment found in patients with TBI, often leads to functional 
disabilities. In order to appropriately evaluate and guide management for this impairment, 
clinicians can rely on Modified Ashworth scores, AROM and PROM measurements, FIM scores 
and motor performance measures, such as Footprint Analysis and the Nine Hole Peg test 
Supporting studies have been conducted to evaluate the effectiveness and sensitivity o f each tool. 
BTXA, a new management technique for UMN syndrome-related spasticity, is considered an 
effective pharmacological intervention for spasticity (Grazko et al., 1995). In addition, the 
effectiveness of this drug has been investigated with many different UMN syndrome diagnoses. 
In light of BTXA’s determined ability to temporarily decrease spasticity, the question arises 
whether or not BTXA provides a window of opportunity for the physical therapy intervention of 
a patient with TBI. The purpose of this study is to determine whether directed physical therapy 
applied during the peak effectiveness of BTXA injections, can produce short and/or long-term 
changes in spasticity, AROM, PROM, FIM scores, and motor performance measurements in a 
patient with TBI. If the presence of a “therapeutic window” becomes evident through this study, 
physical therapists will be more capable o f addressing spasticity and it’s associated secondary 
impairments. By emphasizing soft-tissue lengthening and muscle re-education techniques during 
this opportunistic window, physical therapists may be able to maximize the functional outcomes 
o f a patient with spasticity caused by traumatic brain injury.
If results of this study indicate significant functional improvement due to a “BTXA plus 
directed physical therapy” treatment regime versus “BTXA alone” there are several clinical 
implications. First, in order for patients to capitalize on the reduction in spasticity, BTXA 
injections should be used in conjunction with physical therapy. This would support the inclusion
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of a physical therapy referral in a  BTXA treatment regime. Second, physical therapy treatments 
directed at both producing functional changes and preventing secondary impairments should be 
included in BTXA spasticity interventions.
Finally, this study will provide a detailed methodology to be utilized for future single­
subject investigations into the functional changes resulting fiom BTXA plus directed physical 
therapy. Replication of this study will strengthen die current literature available to support the 
use of BTXA as an adjunct to physical therapy interventions.
CHAPTERS
METHODOLOGY
Original Stiirfy 
Study Design
A single subject case design allows researchers to monitor an individual’s improvement 
in specific outcome measurements over time. Through the collection of repeated measurements 
on one or more variables and the systematic application or withdrawal of treatment(s), 
relationships between intervention and outcome measurements can be determined. Testing and 
instrumentation may threaten internal validity of this design unless measurements are taken on a 
regular basis in standardized format With these safeguards, a single subject case design prevents 
biased sample selection and allows direct observation of other threats, making this design a useful 
tool for demonstrating changes that occur over time.
There are several advant%es of a single subject case design. This design allows 
researchers to identify specific subject characteristics relevant to the subject’s performance while 
factors as gender, age, diagnosis, level of disability and intelligence are kept constant. Data 
collection occurs fiequently in a single subject case design and allows any observed variability to 
be related to specific environmental or physical characteristics. Frequent data collection also 
enables clinicians to develop measurement procedures unique to the subject’s presentation. 
Therefore, the results obtained in a single subject case design are suitably relevant to the specific 
research questions and therapeutic concerns of practitioners. Through the use o f accumulative 
single subject case studies, practitioners can develop a knowledge base and gain  an understanding 
of general relationships that occur with a specific individual (Ottenbacher, 1997).
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This single subject case design will evaluate the long-term and short-term effectiveness 
of BTXA injections in conjunction with directed physical therapy on spasticity, AROM, PROM, 
and
performance in a patient with TBI. Effectiveness will be determined by examining both 
impairment and disability outcome measures including Modified Ashworth Scale scores, AROM, 
PROM, FIM, and performance tests.
Data will be collected in an "A,- BC- B- A2” single subject design (Figure 1). This 
specific design format was selected based on the typical BTXA treatment regime. A stable 
baseline must be established during baseline phase A, to enable comparison of subsequent 
changes that occur throughout the study. Phases “BC” and “B” both evaluate the role directed 
physical therapy will have on improving function after BTXA injection. Clinically it is typical to 
see a 24 to 72 hour delay between administration of BTXA injection(s) and the onset of clinical 
effects (Borg-Stein & Stein, 1993; Polo & Jabbari, 1994). This fact may account for the lack of 
statistically significant changes that may occur at the beginning o f phase “BC.” Phase “BC” 
demonstrates the effects of BTXA treatment and directed physical therapy intervention, while 
phase “B” depicts the solitary effects of BTXA treatment and any prolonged effects of directed 
physical ther^y. Both of these phases are constructed to last six weeks to account for learning 
curves, neuromuscular re-education, and the typical progression of treatment The final baseline 
phase (A2) will continue for three months to document any changes in function that may occur 
long-term. Research has shown BTXA’s effects to wean on average between three to six months 
(Yablon et al., 1996; Pierson et al, 1996; Hermanowicz & Troung, 1995; Snow et al., 1990;
Agana & Yablon, 1994). This study’s duration is a total of six months and three weeks. During 
this time it is anticipated that the duration of BTXA’s effects on a single subject with TBI will be 
documented.
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Figure 1
Ai -^BC-B -A, Single Subject Design
Phase Baseline A, Intervention BC Intervention B Baseline Az
Treatment
Intervention
Pre BTXA BTXA + PT BTXA only Post BTXA
Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 2022 2426
Study she and subjects 
Data collection will involve one subject with a primary diagnosis of TBI. This subject 
will be selected by a local physiatrist specialized in treating neurological patients and is 
considered to be a good candidate for BTXA treatment. Furthermore, the subject must meet the 
following inclusion criteria to be considered for the study; 1) under the care of Dr. Kuldanek 
M.D. Physiatry of Rehabilitation Medicine Associates, PC in Grand Rapids, Michigan for muscle 
spasticity related to TBI, 2) at least twelve years of age, 3) spasticity is unresponsive to or 
unmanageable with other pharmacological or physical treatment options, 4) available for data 
collection according to research design, 5) able to comprehend simple one-step directions, 6) able 
to demonstrate selective shoulder and elbow control with limhed active wrist extension if the 
upper extremity is affected, 7) able to ambulate with or without an assistive device if the lower 
extremity is affected, and 8) not currently participating in regularly scheduled physical or 
occupational therapy at the time of the initial evaluation. In addition, any subject exhibiting fixed 
contractures of a joint crossed by the target muscle will be excluded from this study. The subject 
will sign a patient consent form (Appendix F). Data collection will take place in the subject’s 
home and will continue for a total of six months and three weeks. The Internal Review Boards at 
Grand Valley State University of Allendale, Michigan and Mary Free Bed Hospital of Grand 
Rapids, Michigan will approve this study.
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Instruments
Dependent measures used to describe changes resulting firom BTXA treatment will 
include the Modified Ashworth Scale for determining spasticity in all planes of movement of the 
affected joint as well as the joints directly proximal and distal; the Functional Independence 
Measure (FIM) for ambulation, stairs, and bed and toilet transfers; AROM and PROM of the 
affected extremity at, above, and below the affected joint(s); and performance tests specific to the 
affected extremity. Researchers will use standardized evaluation procedures to ensure the 
consistency and accuracy of results between data testers and collection dates (Appendix A-E).
All measurements will occur in the following order Modified Ashworth Scale, AROM, PROM, 
the FIM, and then either the Nine Hole Peg test or the Footprint Analysis, depending on the 
subject’s presentation. This order was chosen to enable researchers to assess the subject’s actual 
level of tone without any confounding external factors that may influence results.
The Modified Ashworth Scale is a six point ordinal scale used to assess the level of 
spasticity. In order to assure that changes observed in the Modified Ashworth Scale scores 
following BTXA treatment and directed physical therapy are a result of the treatment protocol, 
researchers will attempt to control for such confounding factors as: body position, time of day, 
day of the week, order of data collection measurements, and data collection she. The Modified 
Ashworth Scale will be the first performed measurement Researchers will test all joints fiom 
proximal to distal, one joint at a time, with the subject lying supine on a hard surface. The 
subject’s available range of motion will be assessed using PROM a total of three times and then 
the limb will be moved quickly through % range of motion four times to assess the level of 
spasticity. Grading will be based on Bohannon and Smith’s scale (1987) (Appendix A).
Although the Modified Ashworth Scale is highly variable, hs ease of use makes h the most 
commonly used tool for assessing muscle hypertonicity (Allison & Abraham, 1995; Bohannon & 
Smith, 1987). Concurrent validity o f die Modified Ashworth Scale currendy is lacking and still 
needs fiirdier research.
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In addition to measuring spasticity, goniometry will be used to assess the subject’s ROM. 
AROM and PROM are among the most elementary evaluation tools known to physical therapists. 
In patients with neurological diagnoses, AROM and PROM can be used to assess a muscle’s 
length/tension relationship. Goniometric reliability and validity using adult norms, have been 
well examined. Inter- and intra-tester reliability have been found to be variable depending on the 
joint being examined (Elveru et al., 1988; Rothstein et al., 1983). Fish and Wingate (1985) 
suggest that the use of a standardized procedure enables even inexperienced examiners to 
accurately assess ROM, making this tool valid.
AROM of the affected joint(s) plus one joint proximal and distal to each targeted 
muscle(s) will be evaluated directly following the Modified Ashworth Scale. AROM will be 
assessed for each joint from proximal to distal and in every available plane of motion.
Researchers will demonstrate the desired action by passively moving the subject’s joint and then 
ask the subject to replicate that motion. Once the subject performs active movement, the 
researchers will document the degrees of motion using a standard goniometer. Directly following 
measurements of AROM, all planes of PROM will be assessed in the affected extremity. While 
the researcher performs PROM, the subject will be instructed to offer no assistance. Researchers 
will follow standardized procedures describing patient positioning and how to perform ROM 
movements (Appendix E). Standardization pertaining to the use of either gravity eliminated or 
antigravity positioning will be determined based on the subject’s presentation during baseline 
phase “Ai”.
The FIM, a standardized tool used to assess level of function (Guide for the Uniform 
Data Set, 1996), will be employed after goniometry to monitor the effects of BTXA treatment and 
directed physical therapy on the subject’s ability to walk, climb stairs, and perform bed and toilet 
transfers. Researchers will score the subject’s performance and level of assistance needed at 
home based on FIM grades established by the Uniform Data System for Medical Rehabilitation 
(1996). Subjects will be asked to first perform a bed to chair transfer and then a chair to toilet
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transfer. After performing both transfers, the subject will walk 150 feet or as far as possible and 
then ambulate up and down twelve stairs with the appropriate level of assistance. Specific verbal 
commands for the performance of all tests are described in Appendbc B. High inter-tester 
reliability using Interclass Correlation CoefHcient (ICC) for the FIM’s total score (r = .96), 
domain scores (motor = .96, cognitive = .91) and subscale scores (r = .89 - .94) (Hamilton et al., 
1994) make the FIM a useful clinical tool for monitoring functional changes.
Lastly, a performance test will be performed to enable researchers to determine how 
BTXA treatment and directed physical therapy affect a subject’s level of function. If the 
subject’s target muscle is in the lower extremity, a Footprint Analysis will be utilized to calculate 
temporal distance parameters of gait (Shores, 1980; Holden et al., 1984). For a single trial, the 
subject will ambulate barefoot, a total of 30 feet on a continuous roll of paper at a self-determined 
speed. The use of orthotics or assistive devices will be used according to the subject’s functional 
needs. In order to create an inkblot record, paint is applied to the bottom of the feet before the 
subject walks across the paper. Each record will then be individually calculated by either one of 
the two researchers for velocity (cm/ sec.), cadence (steps/sec.), and stride and step length (cm).
Velocity will be measured for 20 feet using a digital stopwatch. The first and last five 
feet of the 30-foot total walk, are discarded to account for changes in velocity that occur with 
starting and stopping ambulation. Cadence is calculated by determining the number o f steps per 
second that occur within the remaining twenty feet Stride and step length are calculated 
according to the procedure outlined by Shores (1980). The average score for stride and step 
length is then calculated and used for data analysis. Each data collection session will follow 
standardized procedures to ensure reliable results between testers and data collection sessions 
(Appendix D).
Reliability of the Footprint Analysis has not been specifically examined for subjects with 
TBI. However, clinical trials using unimpaired women, subjects with hip disorders, subjects with 
MS, and subjects with post-CVA hemiparesis indicated high intra-tester reliability for all
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temporal distance measurements (Boenig, 1977; Wadsworth et al., 1972; Holden et al., 1984). 
Boenig (1977) suggests that Footprint Analysis is sensitive enough to be used clinically and 
objective enough to measure subjects with neuromuscular disorders.
If the target muscle is in the subject’s upper octremity, the Nine-Hole Peg test will be 
used to assess the patient’s ability to reach, grasp, and release small objects with precision 
(Mathiowetz et al., 1985). These hand skills are required for both ADLs and industrial labor 
skills and may be affected by spasticity. Using normal subjects, Mathiowetz et al. found a high 
inter- and intra-tester reliability for the Nine Hole Peg test (1985). The study also found a 
significant relationship between the Nine Hole Peg test and the Purdue Pegboard test suggesting 
that results may indicate performance in industrial tasks.
Standardized procedures for the administration of a single measurement trial of this test 
will be followed according to those outlined by Mathiowetz (1985) (Appendix C). Scores 
documented represent the length of time subjects required to place all pegs in the pegboard and 
return them to the holding container.
The selected performance test, either the Fooqirint Analysis or the Nine Hole Peg test, 
and all other outcome measurements (FIM, Modified Ashworth Scale score, AROM, and PROM) 
will be recorded based on a single measurement trial at each data collection session. Each data 
collection will be completed within a single day. Researchers will then return for a re-evaluation 
of all measurements based on the data collection schedule described under the following 
“procedures” section. All data collected will be documented on either an upper or a lower 
extremity data collection form (Appendix H & I), depending on the patient’s clinical presentation. 
Descriptive data obtained from subject and family interview, taken during the initial evaluation 
(baseline phase A|), will be recorded on the form located in Appendix J. This information will be 
used to document the subject’s baseline functional capabilities, past medical history, past 
spasticity treatment(s), and clinical presentation. Any changes in medications, subject’s health, or 
physical therapy intervention are also documented on a descriptive data collection form
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(Appendix K) throughout the duration of the staufy.
Procedures
Data collection will take on an “A|- BC- B- A%" single subject design. Two entry level 
Masters of Physical Therapy students, researcher *^ MA” and “CH”, will conduct all 
measurements. A pilot study will be performed to insure inter- and intra-tester reliability for all 
dependent measurement tools. A subject that meets all inclusion criteria will be recruited from 
the local physiatrist’s patient caseload. A data collection schedule will be determined by the 
subject and the researchers to enable the subject to be seen at approximately the same time every 
week. Researchers hope this will help control for fluctuations in tone that may occur over the 
course of a typical day.
To clinically assess which muscle(s) will be targeted for BTXA treatment, the local 
physiatrist uses functional presentation, postural presentation and palpation. In order to guarantee 
accuracy of injection into the targeted muscle(s), the physiatrist uses a dual-purpose needle to 
simultaneously measure EMG activity while injecting BTXA. According to the physiatrist, the 
maximum amount of BTXA administered to the subject will be determined by a general dose 
guideline: 10 units of BTXA for every one-kilogram of body weight (personal communication, 
July 16, 1998). The actual amount of BTXA injected into each muscle(s) will be based on the 
degree of spasticity and the muscle(s) being considered for treatment.
Baseline measurements for the dependent variables (A, phase) are taken prior to injection 
in the subject’s home for three weeks at five to seven day intervals. Researchers must determine 
a stable baseline for each dependent measurement tool before proceeding to phase BC. In order 
for a baseline to be considered stable, a majority o f scores must meet the following: 1) scores 
must be the same for the Modified Ashworth Scale score and FIM, 2) scores must not be greater 
than + five degrees for AROM and PROM, 3) scores must not be greater than + one second for 
the Nine Hole Peg test, 4) scores must not be greater than + 1 second for gait velocity, S) scores
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must not be greater than + one step for cadence, 6) scores must not be greater than ±  three 
centimeters for step length, and 7) scores must not be greater than + six centimeters for stride 
length. If a stable baseline does not occur during the designated three weeks, phase Ai will be 
lengthened until data stabilizes or time constraints limit the study.
Data collection for die ‘3 C  phase” will take place while the subject is both under the 
effects of BTXA injections and participating in directed physical therapy. “BC phase” 
commences three days post-injection to take into consideration the documented delay (24 — 72 
hours) in onset of clinical effects (Borg-Stein & Stein, 1993; Polo & Jabbari, 1994). Data 
collection will continue for six weeks at five to seven day intervals to determine the short-term 
effects of BTXA treatment and directed physical therapy. A local physician will write a physical 
therapy prescription for “strengthening” or to address a specific functional goal and directed 
physical therapy will then be administered accordingly. Duration, intensity and focus of physical 
therapy will be determined by the assigned physical therapist and should be based on the 
therapeutic needs of the subject. Although not under the researchers’ direct control, directed 
physical therapy treatments may include: facilitation techniques, stretching of the spastic agonist 
muscle group(s), strengthening of the antagonist muscle group(s), inhibition techniques, 
neuromuscular re-education, functional training, and any combination of exercises for a home 
exercise program. An ongoing description of the subject’s physical therapy treatment will be 
recorded throughout the study on a descriptive data collection form (Appendix K).
The third phase (B phase) of data collection examines the isolated effects of BTXA 
treatment without directed physical therapy. Dependent measurements in this phase are collected 
for six weeks at five to seven day intervals. “B phase” commences six weeks and three days post 
BTXA injection, and continues for six weeks to determine the retention of directed physical 
therapy. Many studies have demonstrated that the effects of BTXA injections wear off between 
three and six months (Yablon et al., 1996; Pierson et al., 1996; Hermanowicz & Troung 199S; 
Snow et al., 1990; Agana & Yablon, 1994). Therefore, the end o f phase B should coincide with
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the therapeutic duration of the BTXA treatment For this reason, the second “A phase,” or 
baseline measurement (A2), collection will begin twelve weeks and three days post-injection. 
Dependent measurements will be collected at two week intervals for three months to determine 
the duration and long-term effects o f BTXA treatment
For each data collection session, data will be collected in the subject’s home in the 
following order 1) Modified Ashworth Scale score, 2) AROM, 3) PROM, 4) FIM and 5) either 
Footprint Analysis or the Nine Hole Peg test This sequence was selected in order to control for 
changes in tone that may occur secondary to activity level. Standardized evaluation procedures 
and positioning for each dependent measurement as described in the “instruments” section will be 
used to ensure comparable results between researchers. Both researchers will be blinded for 
goniometric measurements by utilizing an independent recorder.
Data Analysis
Descriptive analysis will be used to examine the effects of BTXA treatment in 
conjunction with directed physical therapy on spasticity, AROM, PROM, FIM score, and 
performance in a patient with TBI. Researchers consider a clinical significant change to be: a 
decrease by one point for the Modified Ashworth Scale score, an increase by one point for the 
FIM, an improvement of a minimum of eight degrees for AROM and PROM measurements, and 
an improvement in overall function on either of the two performance tests. For example.
Footprint Analysis scores for velocity (cm/sec), cadence (steps/min), stride and step length (cm) 
must show an increase in measurement scores. The effectiveness of BTXA injections will be 
illustrated by a decrease in score on the Nine Hole Peg test (sec), indicating an increase in speed 
and improvements in dexterity.
Statistical analysis will consist of autocorrelating data to determine the degree o f serial 
dependency. A high value of autocorrelation represents a strong serial dependency. Serial 
dependency occurs when “successive observations in a series o f data points are related or
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correlated” (Poitney & Watkins, 1993, p. 223). Therefore, a strong serial dependency enables 
researchers to predict the value of subsequent points within the series. When researchers are able 
to predict data points, the method of determining significance using visual analysis of a two 
standard deviation band width becomes invalid.
All data will be analyzed using the two standard deviation band method. Variability is 
determined by calculating the mean and standard deviation of data points. Once the mean level 
of baseline performance is determined, lines are drawn two standard deviations above and below 
the mean and extended into the intervention phase. Data points are then plotted to determine if at 
least two successive points in the intervention phase fall outside the two standard deviation band. 
If two or more points do lie outside the standard deviation band width, the results are considered 
significant (Portney & Watkins, 1993). As stated above, however, if there is a strong level of 
serial dependency, this analysis is ineffective. This same analysis will then be carried out for 
each of the remaining phases to determine when significant changes occur between phases BC 
and B and then between phases B and Az.
Visual analysis will also be used to determine within-phase and between-phase 
characteristics. Within-phase characteristics enable researchers to determine the stability and 
trends of data points in that phase. A stable baseline and accelerating and decelerating treatment 
responses are desirable in order for researchers to accurately describe trends. Between-phase 
analysis (e.g. A vs. BC) allows researchers to evaluate the research hypothesis. However, 
comparisons based on three data characteristics: level, trend and slope, can only be made across 
adjacent phases (Portney & Watkins, 1993). Level represents the value of the dependent variable, 
or magnitude of performance. A change in level can be either positive or negative and represents 
changes that occur at the point o f intervention. Trends represent the direction of change within a 
phase and are described as accelerating or decelerating, stable or variable. Finally, slope refers to 
the angle of a trend, or the rate of change and can only be determined for linear trends. With this
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analysis, researchers are able to analyze data to determine whether treatment interventions appear 
to be effective and what outcomes may be predicted.
Researchers predict short-term results (up to three months) for the Modified Ashworth 
Scale score, to show a rapid decline from baseline phase A, to phase BC. This prediction is based 
on the immediate effects of BTXA on muscle tone, reported in the literature (Borg-Stein & Stein, 
1993, Polo & Jabbari, 1994). After three months, spasticity scores are then expected to stabilize 
until mid phase Az, at which time the effects of BTXA are expected to wear off. From mid phase 
Az to the end o f data collection (week 26), researchers expect spasticity scores to return to a 
stable, near-baseline value.
Researchers predict long-term results (greater than three months) to show an increase in 
both the AROM and PROM measurements for both an upper and lower extremity subject and an 
increased score on the FIM for a lower extremity subject. These increases are believed to be the 
result of directed physical therapy, consisting of functional retraining and muscle re-education of 
the antagonist muscle to the spastic agonist muscle, while the subject is under the effects of 
BTXA. Decreased Nine Hole Peg test times and cadence are also predicted to occur as a result of 
directed physical therapy.
Through these descriptive analyses of the dependent measures across phases, the 
researchers will then be able to determine; 1) if BTXA and directed physical therapy generated 
short-term and/or long-term functional changes in a patient with TBI, 2) when the most 
significant changes in spasticity occurred, 3) when BTXA injections in combination with directed 
physical therapy began to show an effect on spasticity and other outcome measurements, 4) when 
BTXA and directed physical therapy effects began to dissipate, S) what functional outcome 
measurements showed the greatest improvements after BTXA injections and directed physical 
therapy, and 6) what trends in spasticity scores occurred over time with BTXA injections and 
directed physical thenq)y.
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Limitations
The single subject case design of this study is both a limitation and a strength of this 
study. By examining only one patient with TBI, die response to the treatment intervention can 
only be applied to that particular subject Therefore, any significant findings of this study, as 
related to BTXA treatment in conjunction with directed physical therapy are of limited 
application and should be interpreted with extreme caution when relating to other patients with 
TBI. There is also a limited abiliQr to generalize the results of this study to groups of patients 
with similar neurologic diagnoses. However, the advantage of a single subject case design is that 
researchers can control for the heterogeneous nature of the TBI population and the individual’s 
clinical presentation. Researchers are also able to individualize the BTXA treatment and directed 
physical therapy to the subject’s precise impairments and target disability.
Another limitation of this study is attributed to the nature of the selected performance 
measurements. Although, both the Footprint Analysis and the Nine Hole Peg test have 
documented high intra- and inter-tester reliability (Mathiowetz et al., 1995; Holden et al., 1984), 
these studies were not conducted on patients with TBI. Furthermore, validity studies on these 
two tools using patients with TBI remains uiureported. Researchers therefore, will only be able to 
draw limited conclusions regarding findings and the clinical significance.
The inherent weakness of the Modified Ashworth Scale is that it is an ordinal scale used 
to describe spasticity. Ordinal scales are the second lowest level of measurement and require 
categories to be rank-ordered on the basis of an operationally defined characteristic or property. 
Because ranks are assigned, an ordinal value does not represent quantity, only a relative position 
within a distribution. Therefore, ordinal scores are only appropriate for descriptive analysis. 
Although it can be used with arithmetic operations, results can only be interpreted in the context 
of the terminology of the ranks and can not be used to imply quantities (Portney & Watkins,
1993). The Modified Ashworth Scale’s terminology may generate a problem if a clinician is 
unable to match what they feel to an operationally defined characteristic. Also, tiiere is a
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potential that ambiguous terminology may allow researchers to vary in their interpretation of the 
measurements. However, the Modified Ashworth Scale is still one of the most commonly used 
clinical tools to quantify this subjective measurement With practice, clinicians can become very 
reliable and the Modified Ashworth Scale can be used as a dependable way to document changes 
in spasticity.
The FIM’s weakness is that it evaluates a patient’s level of independence for a specific 
task but does not evaluate how that task is actually performed. Therefore, subjects are able to use 
substitutions for movements they are unable to perform. However, the FIM is one of the most 
commonly utilized clinical global assessment tools. The FIM’s standardized procediues enables 
clinicians to document a patient’s current level of independence and accurately reproduce results 
at a later date. Because the FIM is widely used and there is little variation in interpretation of 
scores, clinicians should be able to accurately interpret another clinician’s FIM scores and 
develop an individualized treatment that will address the patient’s specific disabilities.
Goniometry is another tool of evaluation that has documented limitations (Rothstein, 
Miller & Roettger, 1983; Gajdosik & Bohannon, 1987; Elveru, Rothstein & Lamb, 1988).
Physical therapists’ reliability in goniometric measurements may vary depending on the 
diagnosis, the time interval between repeat testing, the complexity of the action to be measured 
and whether the action is incorporated in typical functional tasks (Gajdosik & Bohannon, 1987). 
Clinicians accept goniometry as a valid tool assuming that; 1) measurement of joint ROM is 
limited to degree units of a circle and 2) goniometry only measures ROM, not the factors that 
affect ROM (Gajdosik & Bohannon, 1987). The advantage of PROM is that subjects are not 
required to actively participate in the measurement process. AROM is also advantageous as it 
incorporates movements that are natural to the subject. However, because AROM requires an 
adequate amount of motor control to be performed in the appropriate planes as designated by 
Nortkin and White (1985), subjects with TBI who demonstrate poor motor control may not 
successfully complete these motions. Furthermore, validity studies for ROM measurements that
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specifically examine patients with TBI are unavailable. This limits the researchers' abilities to 
draw conclusions and suggest clinical implications regarding AROM and PROM results.
A third limitation of this study design is the lack of control for a number of intrinsic and 
extrinsic factors that may affect dependent measures. Diet, emotional level, illness, arousal level, 
medications, level of motivation or activity level may either positively or negatively effect a 
subject’s degree of spasticity and motor control. Researchers will attempt to develop a pre­
determined schedule with the subject that will enable the subject to be evaluated on the same day 
of the week at the subject’s home. Researchers will also work co-operatively with the subject to 
determine the most appropriate time of day to conduct all data collection sessions. With these 
two controls, researchers will hopefully minimize some possible external factors that may 
negatively affect the subject’s level of spasticity. All other internal and external factors will not 
be controlled for and the researchers accept this as a possible limitation to this study.
In addition, researchers are not blinded to the study’s purpose or phase, as they are also 
the authors of the study. With this knowledge, researchers’ measurements may be biased. 
Researchers will attempt to limit this bias by recording each session’s findings on separate data 
collection forms and utilizing an independent recorder for data collection sessions. At the end of 
the study, researchers will then transcribe all findings onto one collective form for data analysis. 
Researchers will also follow standardized procedures for each dependent measurement to help 
minimize the occurrence of testing error.
Previous researchers have suggested that BTXA injections produce the best functional 
outcomes when injected within one and a half years following traumatic brain injury (Garland & 
Keenan, 1983). Although some studies have reported changes in subjects injected well past one 
and one-half years post-injury, Garland & Keenan (1983) speculate that the amount of change in 
functional outcomes may be limited in subjects with long-term spasticity. However, due to 
patient availability, the researchers are unable to control for the subject’s duration of spasticity 
and accepted it as another limitation.
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A final limitation of this study is die inexperience of the researchers. Because both data 
collectors are student physical therapists thqr have limited knowledge and experience regarding 
research procedures, the application and grading of tone using the Modified Ashworth Scale, the 
measurement of ROM in subjects with TBI, the application of functional tests, and the use of the 
FIM. These factors may influence the researchers’ ability to accurately measure results. 
Therefore, a pilot study will be conducted to enable researchers to standardize measurement 
procedures for each dependent measurement tool. The pilot study will also provide the 
researchers with further experience with the measurement tools and will enable researchers to 
determine inter- and intra-tester reliability of each tool. A Board Certiried Neurological Clinical 
Specialist (NCS) will supervise the pilot study and provide suggestions for improved application 
of the measurement tools. Through the use of the pilot study researchers hope to minimize the 
effects of researchers’ inexperience.
However, in order to proceed with this single subject case design, researchers need to 
first determine inter- and intra-tester reliability for all dependent measurements. Therefore, 
researchers plan to perform a pilot study to examine the reliability of these measurements using 
both involved and uninvolved subjects.
Pilot Studv 
Study she and subjects
Two sets of subjects were utilized for the pilot study to determine inter- and intra-tester 
reliability; one group denoted as “uninvolved” and the other as “involved.” Ten healthy, graduate 
students fiom Grand Valley State University were recruited for measurements of the Footprint 
Analysis (velocity, cadence, right and left step and stride length) and the Nine Hole Peg test.
Adult normals were utilized for this portion of the pilot study because the procedures o f both the 
Nine Hold Peg test and the Foo^rint Analysis should not vary between normal individuals and 
individuals with UMN syndrome. All data collection occurred at Grand Valley State University
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and took approximately two hours. Each subject performed a single measurement trial o f both 
the Nine Hole Peg test and die Footprint Analysis.
Eight subjects with UMN syndrome agreed to participate in the second portion of 
the pilot study. Due to time constraints and subject availability, researchers were unable to limit 
the subject population to include only subjects with TBI, therefore, subjects with UMN syndrome 
of either TBI or CVA origin were utilized. This group was considered the “involved” group and 
signed an informed consent (Appendix F). Involved subjects were chosen for this portion of the 
pilot study because of the researchers’ inexperience with neurologically impaired individuals. 
Because the “hands on” measurement procedures of AROM and PROM can be greatly affected 
by a subject’s neurological state and presence of neuromuscular impairments, researchers needed 
to practice their goniometric skills with this specific population. Also, researchers had little 
exposure to assessing a subject’s level of tone using the Modified Ashworth Scale. Because of 
this lack of experience and because both the Modified Ashworth Scale and the FIM are tools 
created to help clinicians describe and classify patient impairments or disabilities, these 
measurements would have been meaningless if applied to adult normals.
Inclusion criteria for this group consisted of: 1) an upper motor neuron diagnosis or 
involvement, 2) spasticity present in at least one upper or lower extremity, 3) at least twelve years 
of age, 4) not currently involved in formal physical or occupational therapy, and 5) able to 
comprehend simple one-step conunands. Any subjects exhibiting fixed contractures of either the 
upper or lower extremity were excluded from this pilot study. Subjects were recruited fiom 
Grand Valley Foster Care, Kent Community Hospital, and various professional relationships of 
the researchers.
All subjects were evaluated using the Modified Ashworth Scale, AROM, PROM and the 
FIM. Both researchers saw each subject twice within the same day and all results were recorded 
on an upper and lower extremity data collection form (Appendices H & I). The FIM, however, 
was only applied to six of the eight subjects secondary to subject fatigue and time constraints.
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Each data coUectioii session took approximately two hours to complete and the duration of this 
portion of the pilot study lasted a total of five weeks.
Instruments
Dependent measures used in the pilot study to determine inter- and intra-tester reliability 
included the Modified Ashworth Scale, the Functional Independence Measure (FIM) for 
ambulation, stairs, and bed and toilet transfers; AROM and PROM of the affected extremity at, 
above, and below the affected joint(s); and performance tests. All measurements were performed 
on involved subjects except the performance tests, for which the researchers utilized uninvolved 
subjects.
The Modified Ashworth Scale, is a six point ordinal scale used to describe the levels of 
spasticity. Because it requires no equipment, it is considered a basic physical therapy evaluation 
tool of impairment. Researchers utilized this tool to evaluate spasticity in all planes of movement 
for both the upper and lower extremities of our involved subjects.
The FIM, a standardized tool used to assess level of function (Guide for the Uniform 
Data Set, 1996), was used to evaluate the subject’s ability to walk, climb stairs, and perform bed 
and toilet transfers. Researchers observed the subject’s performance and assistance needed at 
home and then graded the FIM based on the scale by the Uniform Data System for Medical 
Rehabilitation (1996). Reports of high inter-tester reliability, with hospital bound patients, using 
Interclass Correlation Coefiicient (ICC) for the FIM’s total score (r = .96), domain scores (motor 
= .96, cognitive = .91) and subscale scores (r = .889 - .94) (Hamilton et al., 1994) make the FIM a 
useful clinical tool for monitoring functional changes.
AROM and PROM, both evaluated by goniometry, are among the most elementary 
evaluation tools known to physical therapists. In patients with neurological diagnoses, AROM 
and PROM can be used to assess a muscle’s length/tension relationship. Goniometric reliability 
and validity have been well examined on adult norms, but not TBI. Inter- and intra-tester
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reliability have been found to be variable depending on the joint being examined (Elveru et al^ 
1988; Rothstein et al^ 1983). Fish and Wingate (1985) suggest that the use of a standardized 
procedure enable even inexperienced examiners to accurately assess ROM, making this tool 
valid.
The Footprint Analysis was utilized to calculate temporal distance parameters of gait in 
the uninvolved subjects (Shores, 1980; Holden et al., 1984). Subjects ambulated barefoot, for a 
single measurement trial, a total of 30 feet at a self-determined speed on a continuous roll of 
paper. A videotape was made for each subject’s single trial in order to assist with repeat scoring. 
Paint was applied to the bottom of the feet in order to create an inkblot record. Each record was 
then individually calculated by either one of the two researchers for velocity (cm/ sec.), cadence 
(steps/sec.), and stride and step length (cm).
Velocity was measured for 20 feet using a digital stopwatch. The first and last five feet 
of the 30-foot total walk, were discarded to account for changes in velocity that occur with 
starting and stopping ambulation. Cadence was calculated by determining the number of steps 
per second that occurred within twenty feet. Stride and step length were calculated using the 
middle 20 feet according to Shores’ definitions (1980). The average scores for stride and step 
length were then calculated and used for data analysis.
The Nine Hole Peg test was used to assess the uninvolved subject’s ability to reach, 
grasp, and release small objects with precision (Mathiowetz et al., 1985). Standardized 
procedures for the administration of a single trial of this test were followed according to those 
outlined by Mathiowetz (1985) (Appendix C). A score, in seconds, represents the length of time 
subjects required to place all pegs in the pegboard and then return them to the holding container.
Procedures
Two entry level Masters of Physical Therapy students, researcher “MA” and “CH”, 
conducted all measurements to determine inter- and intra-tester reliability. As stated under the
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"subjects” section, a total of ten uninvolved and eight involved subjects were evaluated. The 
uninvolved subjects were seen for a single trial for both the Nine Hole Peg test and the Footprint 
Analysis. Each subject’s trial for both measurement tools was videotaped to avoid tester bias and 
assist with multiple scoring. A tripod was used to standardize videotaping of the Nine Hole Peg 
test The tripod was set at a distance that only showed the subjects’ hands, the peg board, and 
their random identification number. Researcher MA and CH independently examined the 
videotape of each subject’s Nine Hole Peg test Using visual and auditory determination for 
start/stop timing, both researchers recorded the time in seconds it took for each subject to 
complete the task.
Videotaping of the Footprint Analysis, however, was performed by an independent 
student recorder. No standardized procedures were followed pertaining to the recorder’s distance 
from each subject the camera’s position in relationship to each subject or the camera angle in 
relationship to the start/stop lines. The videotape of the Footprint Analysis was used to determine 
each subject’s velocity. A stopwatch was used to measure the time in seconds between the 
moment the subject initially crossed the first line and when the subject crossed the second line. 
Both lines were pre-marked at five feet from the beginning or the end of the paper. Before 
performing the videotape of the Footprint Analysis, paint was applied to the bottom of subjects’ 
feet. This marking enabled subjects to create a footprint record while they were being 
videotaped. Following the procedures outlined by Holden et al. (1984) for calculation of 
cadence, step length and step width, both researchers examined the footprint record obtained 
during videotaping independently. The actual measurement process was performed later using 
transparency film pre-marked with cross hairs. This control allowed researchers to measure 
sections of the original footprint record without marking the original. Both researchers performed 
a single trial measurement for each of the ten subjects for the Nine Hole Peg test, velocity, 
cadence, step length, and step width. This enabled researchers to compare their results, thereby 
determining inter-tester reliability. To determine intra-tester reliability for both tests, the
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perfonnance of one randomly chosen subject (#5) was reviewed by each researcher independently 
a total of ten times. Two weeks later, each researcher reviewed the original footprint record and 
the videotape of both the Footprint Analysis and the Nine Hole Peg test again and repeated all 
measurements.
Using the involved subjects, researchers determined inter- and intra-tester reliability for 
the Modified Ashworth Scale score, FIM, AROM and PROM. Researchers MA and CH 
evaluated eight subjects that presented with spasticity secondary to UMN syndrome. All subjects 
were seen by both researchers and all dependent measurements were taken on the same day. The 
above dependent variables were evaluated for each subject a total of four times: twice for each 
researcher inorder to determine inter- and intra-tester reliability. The order of measurements 
consisted of Modified Ashworth, AROM, PROM and then the FIM.
Using the Modified Ashworth Scale, researchers determined each subject’s level of tone 
for both the upper and lower extremity. To determine the subject’s available range of motion, 
researchers assessed PROM. Researchers then quickly moved the subject’s limb through the 
available range of motion to assess the level of tone. Grading was based on Bohaimon and 
Smith’s scale (1987) (Appendix A). All joints were measured from proximal to distal and in all 
planes. Researchers did not use the standardized number of repetitions as described in the 
original study to assess PROM or the level of tone. Researchers had hoped to utilize this study to 
practice grading tone, using the Modified Ashworth Scale and were not as concerned about 
utilizing specific numbers of repetitions. Due to patient fatigue and the long duration of data 
collection sessions, not all joints were assessed for each subject.
In addition to measuring spasticity, researchers also measured AROM of the affected 
upper and lower extremity in the involved group. AROM for each joint was assessed in every 
available plane of motion by each researcher a total of two times. Researchers demonstrated the 
desired action by passively moving the subject’s joint and then asked the subject to replicate that 
motion. Once the subject performed the active movement, an independent recorder documented
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the degrees of motion using a standard goniometer. Directly following measurements of AROM, 
PROM was assessed in all planes in the affected extremity. While the researcher performed 
PROM, the subject was instructed to offer no assistance. Researchers followed Nortkin and 
White’s description for patient positioning (1985) and standardized procedures describing how to 
perform the range of motion movements (Appendix E). Researchers were blinded to goniometric 
results by utilizing either a physical therapist or a student physical therapist to read and record all 
measurements for both trials. Once again, due to patient fatigue and the long duration of the data 
collection session, researchers were not always able to obtain all measurements for both the upper 
and lower extremity.
The FIM, a standardized tool used to assess the level of function of oiu* involved subjects 
(Guide for the Uniform Data Set, 1996), was employed to assess the subject’s ability to perform 
walking, stair climbing, and bed and toilet transfers. The researchers observed the subject’s 
performance and level of assistance needed at home, then graded function according to the scale 
defined by the Uniform Data Set (1996). Subjects were asked to first perform a bed to chair 
transfer and then a chair to toilet transfer. After performing both transfers, the subject attempted 
to walk 150 feet or as far as possible and then ambulated up and down twelve stairs as 
independently as possible. Specific verbal commands for the performance of all tests were 
followed (Appendix B). Because of patient characteristics, patient fatigue, and the length of time 
required for data collection, not all subjects were able to perform the FIM (six out of eight).
Data Analysis
Intraclass Correlation Coefficient ^ CC) was used to determine inter and intra-tester 
reliability for the Nine Hole Peg test (sec.), velocity (cm/sec.), cadence (steps/sec.), step and 
stride length (cm), AROM and PROM (degrees). The level of significance was set at a  = 0.05 for 
all data analysis. ICC is a reliabili^ coefficient that is primarily designed to be used with 
interval/ratio data that possesses rank-order characteristics with known and equal distances
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between units of measurements (Portney & Watkins, 1993). The advantages of using ICC are 
four fold: I) it has broad clinical applicability by being used to assess reliability among two or 
more raters, 2) it does not require the same number o f raters for each subject, giving it clinical 
flexibility, 3) it may be used with ordinal data when intervals are assumed to be equivalent, and 
4) it supports the generalizability model proposed by Cronback. This model states “...that 
differences between observed scores are due to a variety o f factors, not Just true score variance 
and random error” (Portney & Watkins, 1993, p. 509). The ICC reflects both the degrees of 
correspondence and agreement among ratings. Because both the Footprint Analysis and the Nine 
Hole Peg tests produce ratio data, researchers determined ICC to be the most appropriate test for 
inter- and intra-tester reliability.
Spearman’s rho ( r j was used to determine inter- and intra-tester reliability for the 
Modified Ashworth Scale and FIM. The Spearman’s rho (r,) is a nonparametric analog of the 
Pearson r and is used with ordinal data. Ordinal data places categories in rank-order based on an 
operationally defined characteristic or property. These categories do no have equal distances or 
intervals between units of measurements (Portney & Watkins, 1993). Because both the Modified 
Ashworth Scale and the FIM are ordinal scales, the ICC, which is best for ratio data, would not be 
the appropriate statistical tool.
After completing this pilot study, researchers had hoped to apply the results to the 
original proposed single subject case design. However, after a statistical consultant analyzed the 
data from the involved and uninvolved subjects in the pilot study, researchers decided that 
inadequate data had been collected on the Modified Ashworth Scale score, AROM and PROM 
for the lower extremity. This problem lead to an inability to determine inter and intra-tester 
reliability for lower extremity measurements. The researchers suspect that their inexperience and 
numerous measurements may have prolonged the duration of each data collection session, 
yielding patient fatigue and subsequent missing data points. Therefore, researchers had to repeate 
their pilot study. Considering the prolonged duration o f data collection, the lack of available
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subjects, the lack of data obtained for the lower extremity, and the occurrence of subject Atigue, 
the methodology o f the pilot stucty was modified and applied to a preliminary study. Researchers 
also realized that in order for results fiom this preliminary study to be applied to the original 
single subject case design, test-retest reliability needed to be determined. Therefore, researchers 
eliminated intra-tester reliability and focused on determining inter-tester and test-retest reliability 
o f upper extremity measurements for both impairment and function.
Preliminary Studv 
Study site and subjects 
The purpose of the preliminary study was to determine inter-tester and test-retest 
reliability for the Modified Ashworth Scale, AROM, PROM and the Nine Hole Peg test in the 
upper extremity of subjects with spasticity secondary to TBI.
Ten subjects’ upper extremities were evaluated using the Modified Ashworth Scale, 
AROM, PROM and the Nine Hole Peg test. All subjects met the following inclusion criteria: 1) 
spasticity present in at least one upper extremity, 2) at least twelve years of age, 3) signed a newly 
designed informed patient consent form (Appendix G), and 4) available for two forty minute 
evaluation sessions within a seven day period. Subjects were excluded if they had: 1) cognitive 
involvement that affected data collection (e.g. inability to understand “relax,” “stop,” and “go”),
2) demonstrated aggressive behavior that may result in harm to the researcher, and 3) 
demonstrated any permanent joint contractures in either the shoulder, elbow or wrist. Subjects 
were recruited primarily fiom the Grand Rapids Brain Injury Support Group and Grand Valley 
Foster Care. The level of independence for subjects ranged fix)m community ambulation to 
wheelchair bound and fiom independent with all ADLs to total dependency. Subjects also had 
varying levels of spasticity and motor control. Motor control was severe enough in some subjects 
to limit active motion to synergistic movement patterns.
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Instruments
Due to the lack of lower «ctremhy data, the length of data collection sessions, and patient 
fatigue encountered by the researchers during the pilot study, all measurements pertaining to the 
lower extremity were eliminated for the preliminary study. All subjects were evaluated using the 
Modified Ashworth Scale for all planes of motion in the involved shoulder, elbow and wrist; 
AROM and PROM measurements for all planes of motion in the involved upper extremity; and 
the Nine Hole Peg test.
Because testing variability occurred when assessing the Modified Ashworth Scale in the 
pilot study, researchers developed detailed standardized procedures (Appendix A). Researchers 
hoped this would decrease variability in testing procedures and would eliminate any confounding 
variables that may affect the level of inter-tester and test-retest reliability. For the preliminary 
study, researchers controlled for the number of repetitions for determining the subject’s available 
range of motion and the level of tone. All subjects were evaluated in supine and joints were 
measured fiom proximal to distal. Also, all results were recorded on an upper extremity data 
collection form (Appendix H).
AROM, PROM, and the Nine Hole Peg test still followed the same standardized 
procedures as described in the pilot study (Appendices C & E). For range of motion 
measurements, the description of testing positioning presented by Nortkin and White were 
utilized. Although data was missing for many measurements for AROM and PROM in the pilot 
study, especially for the lower extremity, researchers felt that the standardized procedures were 
sound and should be useful for this preliminary study. Researchers decided to eliminate 
videotaping of the Nine Hole Peg test from the pilot study in order to determine test-retest 
reliability for the preliminary study. Although videotaping was eliminated, researchers followed 
the testing procedures as described by Mathiowetz (1985) for the preliminary study.
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Procedures
A total of ten subjects were needed for this study in order to detemine inter-tester and 
test-retest reliability. Both researchers would independently evaluate four subjects twice, for a 
total o f eight subjects. The other two subjects would be seen by both researchers for the initial 
data collection session, in order to determine inter-tester reliability. Then, for the second data 
collection date, of these two subjects, either researcher CH or MA would re-evaluate the subject. 
This would enable both researchers to obtain a sample of five subjects and determine intra-tester 
reliability. The two data collection dates were separated by four to seven days to minimize tester 
bias and allow for accurate test-retest reliability. All data collection occurred in each subject’s 
home and dependent measurements were performed in the following order Modified Ashworth 
Scale, AROM, PROM and the Nine Hole Peg test. This order was chosen in order for researchers 
to accurately assess the subjects’ true level of tone without any confounding variables.
Researchers attempted to see all subjects the same time of day for each data collection session in 
order to minimize changes in tone due to these external variables Standardized procedures were 
followed for the implementation of all dependent measurements (Appendices A — E).
For the Modified Ashworth Scale, all subjects were tested in supine. Joints were tested 
one at a time moving from proximal to distal. Researchers first assessed the subject’s PROM 
three times in order to determine the subject’s available range of motion. Then researchers 
quickly moved the subject’s limb through % range of motion four times to determine the level of 
tone. Grading was based of Bohannon & Smith’s scale (1987) (Appendix A).
Next, ROM was assessed for the involved shoulder, elbow, and wrist in all available 
planes moving from proximal to distal. All standardized procedures described under the pilot 
study’s “procedures” section was followed for the preliminary study. Shoulder extension, 
however, was only tested to neurtral and researchers only utilized an independent recorder for the 
initial data collection sessions. For the preliminary study, researcher were also only able to 
employ student physical therapists as their independent recorders. All measurements were
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recorded on an upper extremity data collection form (Appendix H).
Finally, the Nine Hole Peg test was evaluated for each subject Researchers followed 
standardized procedures for the implementation of this test (Appendix C). Specific verbal 
directions were given to each subject for each trial. All subjects performed a practice trial before 
the actual testing occurred. This enabled them to practice the testing procedures and ask any 
questions.
Data Analysis
Inter-tester and test-retest reliability for the Modified Ashworth Scale, AROM, PROM, 
and the Nine Hole Peg test was determined using Spearman’s rho (r%). A statistical level of 
significance was set (a  = 0.05). Because of the occurrence of skewed data sets in the pilot study 
for AROM, PROM and the Nine Hole Peg test, researchers needed to utilize a nonparametric 
statistical test. Spearman’s rho is a nonparametric statistical tool that can be used for both ratio 
and ordinal data. The reader is referred to page 47 for details about Spearman’s rho.
CHAPTER4
RESULTS
Pilot Studv 
Involved Subjects
Eight subjects with spasticity of either TBI or CVA origin agreed to participate in the 
involved portion of the pilot study. These subjects were examined to evaluate the intra- and 
inter-tester reliability of the Modified Ashworth, FIM, AROM, and PROM measurements. 
Unfortunately, die researchers did not collect data regarding the involved subjects’ actual age, 
side of lesion, or time since onset of the spastic condition. However, this group was comprised 
of both males and females.
Unfortunately, the researchers did not properly account for the significant length of time 
necessary to obtain all measurements for the involved subjects. As a result, a high incidence of 
fatigue was observed among subjects in the involved group and a full set of lower and upper 
extremity measurements (Modified Ashworth, AROM, PROM, FIM) was often unattainable. 
Several missing data points in this portion of the pilot study produced multiple data sets 
comprised of scores from only one or two subjects. All statistical tests used to analyze the pilot 
study data require scores from at least three subjects to calculate reliability. Therefore, when the 
number of available data points, or the n, fell below three, researchers did not complete statistical 
analysis for that joint motion. All lower extremity measurements for AROM and PROM had 
two or fewer data points and thus are excluded from the succeeding reports o f reliability. For 
upper and lower extremity measurements of the Modified Ashworth Scale, AROM, PROM, and 
FIM, an asterisk (*) was entered into the tables to denote what measurements could not be 
computed due to missing data points.
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Ordinal data (Appendices T - W), including Modified Ashwordi Scale scores and FIM, 
were analyzed using Statistical Package for Social Science (SPSS) version 8.0. To determine 
inter- and intra-tester reliability of these measurements, a Kendall’s tau (t) test of covariance 
was applied. In chapter three of this study, researchers proposed Spearman’s riio (r$) to calculate 
inter- and intra-tester reliability for these measurements. However, due to the high occurrence of 
matched data sets within FIM and Modified Ashworth Scale measurements, the Kendall’s t  was 
selected. Kendall’s t  is preferred over the Spearman’s rho for matched data sets. Like 
Spearman’s rho, Kendall’s t  is used to determine the degree of agreement between two testers or 
between two variables obtained by one tester (Sheskin, 1997, p.627). Applied to the current 
study, Kendall x was used to calculate the agreement between researchers, or inter-tester 
reliability, and between the scores obtained by each researcher for trial one and trial two, or 
intra-tester reliability.
Kendall’s x is a descriptive measure of the discrepancy, “. ..between two sets of ranks 
with respect to the relative ordering of all possible pairs of subjects/objects” (Sheskin, 1997, p. 
627). For example, for intra-tester reliability of FIM scores for bed transfer (FIMB), one data set 
was comprised of all subjects’ ranked trial one scores. The other data set consisted of all 
subjects’ ranked scores from trial two. For the Kendall’s x, the number o f discordant and 
concordant pairs within the FIMB data set were calculated and divided by the total number of 
possible pairings. If the ordering of the concordant and discordant pairs is the same for each 
ranked data set, the agreement would produce a value o f x = 1.0, which represents perfect 
concordance and high reliability. Likewise, complete discordance of the ordering of the two 
ranked data sets will yield a x value equal to -1.0, or an inverse relationship (Sheskin, 1997). For 
specific levels or reliability, researchers used the following values of x: x > 0.76 for high 
reliability, x = 0.75 - 0.51 for moderate reliability, x = 0.50 - 0.26 for fair reliability, x = 0.25 -  
0.00 for little or no reliability (Colton, 1993).
54
It should be noted that statistical significance and level o f reliability are mutually 
exclusive characteristics of data analysis. Determining statistical significance of reliabili^ 
results allows researchers to draw conclusions fiom data analysis with greater confidence. 
However, the power o f statistical tests of reliability is dependent upon the sample size (Portney 
& Watkins, 1993). Therefore, although the authors o f this study originally set die level of 
statistical significance, or alpha level, to O.OS, the interpretation of significance was limited due 
to the small number of actual subjects available for our pilot study. For this reason, reliability, 
not statistical significance, will be discussed within the text. However, the author refers the 
reader to Appendices L through P for reports of statistical significance.
Functional Indeoedence Measurement (FIVP
Results of Kendall t for inter and intra-tester reliability for the FIM subscores (walking, 
toilet transfer, bed transfer, and stairs) are illustrated in Appendix L. Data analysis of the FIM 
subscore “stairs” was not possible due to the insufficient sample size for this item. In addition, 
the sample size available to calculate intra-tester reliability of researcher MA for the “toilet 
transfer,” as well as inter-tester reliability for this item, was insufficient However, reliability 
scores for the walking and bed transfer subscores indicated high inter- and intra-tester reliability 
(x=1.0).
Modified Ashworth Scale
Results of Kendall’s x for scores from the Modified Ashworth Scale, as applied to the 
involved subjects, are illustrated in Appendix M. Out of the twenty-four joint motions evaluated, 
intra-tester reliability for researcher CH could not be determined in eight o f the motions 
(shoulder flexion, pronation, hip flexion, hip extension, hip abduction, knee flexion, knee 
extension, and ankle dorsiflexion) due to tied ranks. However, for die remaining sixteen joint
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motions, high intra-tester reliability was found (x = 1.0). Likewise, for researcher MA four joint 
motions (supination, hip abduction, knee extension, and ankle eversion) could not be computed 
due to tied ranks. Intra-tester reliability for the remaining twenty joint motions was also high for 
researcher MA (x = 0.92-1.0).
When tied ranks, or equal scores, occurred for all data points within a set (Le., all scores 
for all subjects had the same value) no discrepancy was produced between scores. Kendall x 
gives a ratio of the occurrence of disagreement between sets of ranked data points. One of the 
assumptions of this test is that some degree o f discrepancy is expected within a sample of ratio 
or ordinal data. Therefore, if all pairs of data have discrepancy values o f zero, Kendall x cannot 
be used. As stated above, the occurrence of tied ranks prevented the calculation o f reliability for 
some variables. Items where tied ranks prevented statistical analysis are denoted within the 
tables by a double asterisk (**).
Although reliability could not be computed for some Modified Ashworth Scale items, 
careful examination of raw data (Appendices T-W) supports the researchers’ level of intra- and 
inter-tester reliability. For example, intra-tester reliability for shoulder extension Modified 
Ashworth Scores could not be computed for researcher CH due to the occurrence of tied ranks. 
Visual analysis of the raw data, however, illustrates that trial one and trial two scores for each of 
the sbc subjects matched exactly. Therefore, although scores fiom trial one and trial two were 
equal, thereby representing perfect agreement, Kendall’s tau was unable to compute reliability 
for this measurement.
The results of inter-tester reliability for Modified Ashworth Scale scores varied for each 
joint action measured. Reliability could not be analyzed for shoulder flexion, elbow extension, 
pronation, hip flexion, hip extension, knee flexion, dorsiflexion, and ankle eversion due to the 
occurrence of tied ranks. Also due to insufficient data points, inter-tester reliability for hip 
abduction could not be analyzed. For the remaining joint actions, a fidr level of inter-rater
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reliability was found for shoulder abduction (x = 0^70) and wrist extension (x = 03S9), and 
moderate reliability for shoulder extension (x = 0.707), shoulder internal rotation (x = 0.707), 
elbow extension (x = 0.740), and wrist flexion (x = 0.548). High inter-tester reliability was found 
in hip adduction and ankle inversion (both x = 1.0), whereas little or no reliability was indicated 
for shoulder adduction (x = 0.087), elbow flexion (x = 0.125), and ankle inversion (x = 0.00). 
Finally, negative levels of inter-tester reliability were found in shoulder external rotation (x = - 
0.408), and hip internal and external rotation (both x = -1.0).
Negative levels of reliability occur when the pattern of the ranked scores for day one is 
the inverse of the pattern of ranked scores for day two (e.g., the pattern for day one is ACBD and 
the pattern for day two is DBCA). Because Kendall’s tau compares the order of ranked pairs of 
data, and not the actual disparity between scores, an inverse relationship does not necessarily 
imply the individual scores were opposite, but that the order o f the disparity between the pairs of 
scores is opposite.
Due to the small sample size, inter-tester reliability for the Modified Ashworth Scale 
was misrepresented by statistical analysis. Visual analysis of shoulder abduction scores indicate 
that both researchers agreed perfectly in four of the five subjects analyzed. For the one subject 
on whom the researchers did not agree, they disagreed by two grade points. When the sample 
size is small, a large disparity in scores firom one subject can have a tremendous impact on the 
overall reliability and possibly change a high level of reliability to fair or little reliability. 
Researchers suspect that a small sample size may also have caused the misrepresentation of 
reliability for inter-tester Modified Ashworth Scale reliability for wrist flexion, wrist extension, 
and ankle plantar flexion.
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Range of Motion
AROM and PROM (Appendices N-O) were analyzed by calculating Spearman’s rho (r^) 
for correlation coefficient to determine intra-tester reliability. The Statistical Analysis System 
(SAS proper version) computer program was used to analyze diis data. In chapter three the 
researchers proposed to use Intraclass Correlation Coefficient (ICC) for data analysis of AROM 
and PROM, which are both ratio data. ICC is the preferred test for determination of inter- and 
intra-tester reliability for ratio data. However, due to time constraints, the statistical consultant 
of this study was unable to access a computer program that had capabilities to compute ICC for 
intra-tester reliability. Therefore, under the recommendation of the statistical consultant, the 
authors of this study determined Spearman’s rbo would be the appropriate test for the analysis of 
intra-tester reliability for AROM and PROM. The statistician’s recommendation was based on 
the skewed distribution of AROM and PROM data points. In order for researchers to apply a 
parametric test, such as Pearson’s r, the data points must follow a normal distribution. Like 
Kendall t, Spearman’s rho is a nonparametric test that requires data be assigned a rank order.
For this statistical test, the sum of the differences between the rank of the measurements for 
subject one, first trial, is compared against the measurements for subject one on the second trial. 
This process is repeated for each subject’s data set. The total disparity found between trial one 
and trial two scores for all subjects is calculated to produce a measurement of correlation. The 
researchers adopted a four-point scale of correlation strength as described by Colton (1993). The 
scale defines the following correlation measurements: r ,  > 0.76 is indicative of high reliability, 
rg = 0.75 - 0.51 for moderate reliability, r ,  = 0.50 - 026 for a fair reliability, r_j = 025 — 0.00 
for little to no reliability. A negative r ,  value indicates disassociation and an inverse relationship 
within the ranked pairs. Therefore, the degree of association is indicated by a numerical value, 
whereas a negative or positive sign only indicates the direction of the association (Portney & 
Watkins, 1993).
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Tied ranks also occurred within data sets for AROM and PROM, thereby limiting the 
results of inter- and intra-tester reliability. For «cample, MA recorded 0" of AROM for shoulder 
extension for all of the involved subjects that she measured. Likewise, researcher CH also 
recorded 0° of AROM for four of her five subjects, which were the same four subjects also 
measured by MA. So, although scores matched perfectly, inter- and intra-tester (MA) reliability 
could not be computed by the selected statistical tests. A similar data analysis problem was 
found for inter- and intra-tester reliability o f AROM and PROM for shoulder adduction.
The results of data analysis for AROM measurements can be found in Appendix N. For 
joint motions including shoulder adduction, shoulder internal rotation, supination, ulnar 
deviation, and radial deviation, researchers were unable to calculate intra-tester reliability for CH 
due to tied ranks. Likewise, MA’s intra-tester reliability for shoulder extension, shoulder 
adduction, and shoulder internal rotation could not be calculated. However, for the remaining 
joint motions for which intra-tester reliability could be calculated (shoulder flexion, shoulder 
abduction, shoulder external rotation, elbow flexion, pronation, and wrist extension), results 
indicated a high level of reliability (r^ = 0.80-1.0) for scores of both researchers. Researcher CH 
also demonstrated high intra-tester reliability for shoulder extension (r^= 1.0) and elbow 
extension (r^= 1.0). Furthermore, high intra-tester reliabilty was demonstrated by MA for 
AROM of supination (r$= 1.0), wrist flexion (r,=  0.949), ulnar deviation (r^= 1.0), and radial 
deviation (r_j= 1.0). A fair level of reliability was found for AROM measurements of wrist 
flexion by researcher CH (r^ = 0316), and for elbow extension for MA (r^ = 0.400).
Inter-tester reliability o f AROM, however, was calculated using Intraclass Correlation 
Coefficient (ICC) for mean scores. The author refers the reader back to data analysis in chapter 
three (p. 47) for a complete description of this test. ICC reflects both the degree of 
correspondence and the agreement between researchers. Reliability values for ICC (r) can range 
between 0.00 and 1.00, with scores falling closer to 1.00 representing a high level o f reliability.
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Levels of reliability are specifically defined as: r  > 0.76 for high reliability, r  = 0.75 - 0.51 for 
moderate reliability, r  = 0.50 - 026 for feir reliability, and r  = 025 -  0.00 for little to no 
reliability.
The occurrence of tied ranks, once again limited the researchers’ ability to calculate 
inter-tester reliability for AROM in six out o f the possible fourteen joint motions. Results of 
ICC analysis indicate a high level o f inter-tester reliability for AROM for five joint 
measurements: shoulder flexion (r = 0.968), shoulder external rotation (r= 0.87), elbow flexion (r 
= 0.97), elbow extension ( r = 0.90), and pronation (r= 0.986). The three remaining joint motions 
did not show high levels of inter-tester reliability: shoulder abduction (r = 0.653, moderate 
reliability), wrist flexion (r = 0.143, little  reliability), and wrist extension (r = 0216, fa ir 
reliability).
Researchers used the same statistical analysis tools for PROM as were used to calculate 
inter- and intra-tester reliability o f AROM. The rationale for deviating from the proposed 
statistical tools is stated under AROM (page 57). Results of inter- and intra-tester reliability for 
PROM can be found in Appendix O.
The intra-tester data sets for PROM measurements included tied ranks, thus limiting 
statistical analysis of both researchers’ scores for shoulder adduction, and for MA’s scores for 
shoulder extension. However, data analysis was possible for the remaining PROM joint motions. 
Both researchers were found to have a high level of intra-tester reliability fbr shoulder internal 
rotation (r^ = 1.0, for both researchers), shoulder external rotation (r, = 1.0 for both researchers), 
elbow flexion (r, = 1.0 for both researchers), elbow extension (MA’s = 1.0, CH’s = 0.821), 
supination (CH’s r ,  = 1.0, MA’s = 0.866), and wrist extension (CH’s = 1.0, MA’s r_j = 
0.800). Researcher CH also showed high intra-tester reliability for shoulder extension (r, =
1.0), shoulder abduction (r, = 0.943), ulnar deviation (r^ = 1.0), and radial deviation (r, = 1.0). 
MA showed high intra-tester reliability for shoulder flexion (r, = 0.975), pronation (r^ = 1.0),
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and wrist flexion (r^ = 0.949). Researcher CH demonstrated an inverse relationship for shoulder 
flexion (r, = -0.10), pronation (r^ = -1.0), and a moderate level of intra-tester reliability for wrist 
flexion (r^ = 0.6). Intra-tester reliability  ^results for researcher MA showed a moderate level o f 
reliability for shoulder abduction (r^ = 0.667), no reliability for ulnar deviation (r , = 0.00), and 
fair reliability for radial deviation (r^ = 0.621).
Due to the occurrence o f tied ranks, only eight of the fourteen inter-tester reliability 
scores for PROM could be statistically analyzed. Of the eight, four joint motions had high 
reliability: shoulder abduction (r = 0.82>, shoulder internal rotation (r=0.985), shoulder external 
rotation (r = 0.82), and elbow extension (r = 0.778). Three PROM measures had moderate levels 
of reliability: shoulder flexion (r = 0.669), ulnar deviation (r = 0.73), and radial deviation (r= 
0.62); and wrist flexion had little reliability (r = 0.06).
Furthermore, limitations o f the tests used for statistical analysis also affected reliability 
scores for PROM and AROM measurements. Fair intra-tester reliability for shoulder abduction 
PROM was found for MA (r^ = 0.667). However, visual analysis of the raw data illustrated that 
for the five data sets analyzed trial one and trial two scores never differed by more than 5°. As a 
rule of thumb, AROM and PROM repeat measurements can differ of up to 5° due to instrument 
error and still be considered accurate (Norkin & White, 1993). The statistical test, Spearman’s 
rho, could not factor in this accepted instrument error when calculating reliability of AROM and 
PROM measurements. This may also explain why researchers were unable to determine high 
levels of intra-tester reliability for researcher CH for wrist flexion PROM (r, = 0.6).
When data from the involved group in the pilot study could be statistically analyzed it 
was often distorted by the small sample size. The strength of the reliability of AROM, PROM, 
Modified Ashworth, and FIM scores depends on the size of the available sample. Furdiermore, 
when data &om AROM, PROM, the Modified Ashworth, and the FIM could not be analyzed due
61
to tied ranks, the tests of statistical analysis limited inter- and intrartester reliability results. 
Therefore, the researchers were unable to determine inter- and intra-tester reliability for many 
AROM, PROM, FIM, and Modified Ashwordi Scale measurements. The results of the involved 
portion of the pilot study provide rationale for further investigation of inter- and intra-tester 
reliability for Modified Ashwordi Scale, AROM, and PROM using a larger sample size and 
different tests for statistical analysis.
Uninvolved Subjects
For the second portion of the pilot study, the researchers utilized ten uninvolved subjects 
to measure the inter- and intra-tester reliability o f Footprint Analysis subscores (i.e., velocity, 
cadence, right step and stride length, left step and stride length) and the Nine Hole Peg test. The 
age of these subjects ranged fiom twenty-two to fifty years. Three males and seven females 
were used for this portion of the pilot study.
Scores for the Nine Hole Peg test and the Footprint Analysis measures (Appendices X -  
Z) were analyzed using a computer SAS program. Videotaped performances of the Nine Hole 
Peg test and the Footprint Analysis of ten normal adults, plus the paper records fiom each 
Footprint Analysis trial, were used to collect data for inter- and intra-tester. Intra-tester 
reliability for these two tests were analyzed using Spearman’s rho (r^). In chapter three, the 
researchers proposed to use ICC to calculate intra-tester reliability for these two performance 
test However, because the statistical consultant could not located a computer program to 
calculate intra-tester reliability using ICC, Spearman’s rho was used.
Reliability results for the Footprint Analysis subscores (velocity, cadence, stride and step 
length) and the Nine Hole Peg test are illustrated in Appendix P. For researcher CH, intra-tester 
reliability for left step length had fair reliability (r^ = 0384), and little reliability was determined 
for measurements of velocity ( r , = 0320) and cadence (r^ = 0320). For researcher MA, right
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Step length was also found to have little reliability (r , = 0238). All remaining intra-tester 
reliability scores for the Footprint Analysis and the Nine Hole Peg Test had inverse relationships 
between day one and day two. The author refers the reader back to page 56 for an explanation 
of inverse relationships.
Inter-tester reliability of these two performance tests was determined using single 
observations for ICC (Portney & Watkins, 1993). This statistical test was selected because 
researchers were not striving to generalize the results o f the pilot study to a larger population of 
physical therapists. A high level of inter-tester reliability was determined for the Nine Hole Peg 
(r = 0.959) and all subscores of the Footprint Analysis (r = 0.77 - 0.99).
Researchers had hoped to apply the results of this pilot study to the originally proposed 
single subject case design that would have investigated the use of Botulinum Toxin-A injections 
in conjunction with directed physical therapy in a subject with TBI. However, the researchers 
were unable to locate a subject for this study that met all inclusion and exclusion criteria within 
the established data collection schedule. The inability to find a subject, confounded by weak 
reliability findings in the pilot study, prompted researchers to repeat the pilot study with 
modifications to attempt to establish reliability prior to proceeding to the single subject design.
For the pilot study, researchers had sought to determine intra-tester reliability for the 
specific outcome measurements. The time between data collection points is generally less than a 
day for intra-tester reliability. However, for the originally proposed BTXA study the intervals 
between data collection points ranged fiom seven to fourteen days. Considering this data 
collection schedule, the researchers should have designed the pilot study to determine test-retest 
reliability of the outcome measurements. Therefore, in order to proceed with the single subject 
case design and eventually draw accurate conclusions fiom the data, researchers first need to 
establish test-retest reliability of the outcome measurement tools.
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Researchers also decided to modify testing procedures due to the high incidence of 
subject fatigue that occurred during the pilot study. Researchers hypothesized that if the data 
collection process could be abbreviated, by only focusing on either upper or lower extremity 
measurements, researchers would be able to minimize subject fatigue. Therefore, the researchers 
proposed a second pilot study, known as the “preliminary study.” The purpose of this 
preliminary study was to determine the inter-tester and test-retest reliability of the Modified 
Ashworth Scale, AROM, PROM, and the Nine Hole Peg test using the upper extremities of 
subjects with TBI.
Preliminary Study
A total o f seven subjects meeting the inclusion criteria proposed in chapter three were 
evaluated for the preliminary study. Due to subject availability, researcher CH was only able to 
obtain measurements from four subjects and researcher MA from three subjects. All subjects 
evaluated by researcher CH were recruited from the Grand Rapids Brain Injury Support Group. 
Three of the subjects were community ambulators (without any assistive device), with minimal 
physical impairments; the one remaining subject was a wheelchair user with physical 
impairments. Researcher MA evaluated two subjects, recruited from Grand Valley Foster Care, 
whom were wheelchair users and presented with significant physical limitations. The third 
subject was recruited through a professional relationship of the researcher; this subject was a 
community ambulator with minimal physical disability. Researcher MA was unable to include 
one potential subject, whom met all inclusion and exclusion criteria, because the subject lacked 
sufficient motor control needed to perform the Nine Hole Peg test This subject also fatigued 
quickly and therefore could not tolerate the data collection process.
All subjects were evaluated for the Modified Ashworth Scale for all planes of motion in 
the shoulder, elbow, and wrist; AROM and PROM for all planes of motion in the shoulder.
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elbow, and wrist; and the Nine Hole Peg test The interval between data points for each measure 
ranged fiom four to seven days, thus allowing test-retest reliabiliQ^ to be computed. Researchers 
failed to collect data regarding the subjects’ age, affected UE, or time since TBI onset However, 
all subjects were male. Difficulties with subject recruitment also prevented researchers fiom 
examining inter-tester reliability. Consequently, the results o f the preliminary study will only 
contain test-retest reliability for upper extremity Modified Ashworth, AROM, PROM, and the 
Nine Hole Peg test (Appendicies AA & BB).
The researchers analyzed all preliminary data using Spearman’s rho. This nonparametric 
test was selected over Kendall tau due to poor results found in the pilot study. Kendall’s tau and 
Spearman’s rho are both nonparametric tests that rank data and are used with both ordinal and 
ratio data. Both can also be used with a small sample size. Therefore, employing a 
recommendation offered by this study’s statistical consultant, the researchers applied 
Spearman’s rho to the preliminary data set. The researchers adopted prior definitions of level of 
reliability from the pilot study for the preliminary study. Despite changes in methodolo^ from 
the pilot study, data sets in the preliminary study also contained many tied ranks. When data 
analysis was not possible due to tied ranks, a double asterisk (**) was inserted into the chart.
Results of test-retest reliability for the Modified Ashworth Scale for the preliminary 
study can be found in Appendix Q. Due to the nature of ordinal scale data, the limited number of 
available subjects, and the similarities of the disability levels among the subjects, the statistical 
analysis of the preliminary study was limited by the occurrence o f tied ranks. This finding was 
consistent with the analysis of the pilot study data. Out of the twelve joint actions, only six 
measured by researcher CH (shoulder flexion, shoulder internal rotation, shoulder external 
rotation, elbow extension, supination, and wrist extension) and only eight measured by 
researcher MA (shoulder extension, shoulder abduction, shoulder external rotation, elbow 
flexion, elbow extension, supination, wrist flexion, and wrist extension) could be analyœd for
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test-retest reliability. High levels of reliability (r^ = 0.866 - 1.0) were found for each of these 
joint actions for both researchers. The only measure that did not reach a high level of reliability 
for the Modified Ashworth Scale was shoulder extension, measured by MA, which demonstrated 
feir reliability (r, = 0.50).
Test-retest reliability findings for AROM from researchers CH and MA are illustrated in 
Appendix R. Test-retest reliability for AROM measurements obtained by CH varied greatly. 
Shoulder extension, shoulder adduction, and elbow extension, could not be computed due to tied 
ranks. Of the nine remaining joint motions, three had high test-retest reliability: shoulder 
external rotation (r^ = 1.0), elbow flexion (r^ = 1.0), and wrist extension (r, = 0.80). Supination 
had moderate reliability (r^ = 0.63) and the remaining joint motions, shoulder flexion, shoulder 
abduction, shoulder internal rotation, pronation, and wrist flexion each had &ir (r^ = 027 - 0.50) 
test-retest reliability.
Test-retest reliability for AROM measurements taken by researcher MA also varied 
greatly. Test-retest reliability for shoulder extension and shoulder adduction could not be 
analyzed due to tied ranks. Shoulder flexion, shoulder abduction, and pronation each had high 
test-retest reliability with rg values equal to 1.0. Shoulder internal rotation, shoulder external 
rotation, elbow extension and supination all had moderate reliability and rg values equal to 0.50. 
However, for elbow flexion and wrist extension no reliability was found (rg = 0.00) and an 
inverse relationship was calculated for wrist flexion (rg= -0.50).
The analysis of test-retest reliability for PROM measurements is displayed in Appendix 
S. Tied ranks prevented statistical analysis of shoulder extension, shoulder adduction, elbow 
extension, and pronation scores obtained by researcher CH. Of the eight remaining scores, 
shoulder flexion (rg = 1.0), shoulder abduction (rg = 0.80), shoulder external rotation (rg =
0.775), elbow flexion (rg = 1.0), and wrist extension (rg = 1.0) all have high test-retest 
reliability. Moderate test-retest reliability was found for shoulder internal rotation (rg = 0.60)
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and supination (r, = 0.632), while only a  feir level of test-retest reliability for CH’s PROM wrist 
fledon (r_5 = 0333) was found.
For PROM measurements obtained by researcher MA, calculations o f test-retest 
reliability were not possible for shoulder extension and shoulder adduction. The remaining 
shoulder motions plus supination, had high test-retest reliability with equal to 1.0. Moderate 
reliability was indicated for elbow extension (r, = 0.5), pronation (r^ = 0.50), and wrist extension 
( /j  = 0.50). However, negative values for test-retest reliability were calculated for MA’s PROM 
measurements of elbow flexion and wrist flexion (r^ = -0.866 and = -0.50, respectively).
Test-retest reliability for the Nine Hole Peg test showed high levels o f reliability for both 
testers. Reliability for this performance measurement was calculated at r$ = 0.800 (n=4) for 
researcher CH, and r ,=  1.0 (n=3) for MA.
Due to the occurrence of tied ranks, researchers were unable to calculate reliability for 
some AROM, PROM, and Modified Ashworth Scale items. Like Kendall’s tau, Spearman’s rho 
is a nonparametric test that gives a ratio of the occurrence of disagreement between sets of 
ranked data points. An assumption of this test is that some degree of discrepancy is expected 
within a sample of ratio or ordinal data. Therefore, when all pairs of data had discrepancy values 
o f zero, Spearman’s rho could not be used. Consistent with the pilot study, in data sets with tied 
ranks, visual analysis of the raw data illustrates that trial one and trial two scores for each of the 
subjects matched exactly. Therefore, although scores from trial one and trial two were equal, the 
researchers were unable to compute reliability for this measurement due to limitations of the 
statistical analysis.
Again, the small sample size also limited the accuracy of the reliability measures. For 
example, researcher MA showed moderate reliability (r^ = 0.50) in Modified Ashworth Scale 
scores for shoulder extension. However, of the three sets of data available, two had perfect 
matches. The remaining set of data had a difference of one grade, thereby altering test-retest
67
reliability fiem high to moderate. With a small sample size, any variation within one data set 
can adversely affect scores of reliability. This is clearly illustrated when one examines elbow 
flexion PROM scores obtained by MA; while two of the three sets of data showed little (I*) or 
no difference in scores, the remaining set varied by 109°. Therefore, no test-retest reliability was 
found for this measurement. In addition, pronation and wrist flexion AROM obtained by CH and 
wrist flexion PROM scores obtained by both researchers were also affected by the occurrence of 
a single deviating data set
For the preliminary study, researchers were unable to recruit a large sample size. As a 
result data sets for all measurement tools (AROM, PROM, Modified Ashworth Scale, and the 
Nine Hole Peg test) contained several tied ranks and little variability. Therefore, statistical 
analysis was weak. Despite the weakness of the statistical procedures, the results of the 
preliminary study can be compared to those obtained in the pilot study.
Summary
The researchers accept that test-retest reliability and intra-tester reliability are similar in 
nature, but do not represent the same measures. Therefore, the comparison of results from the 
pilot study to those from the preliminary sturfy should be interpreted with caution. The most 
significant difference between the results of the pilot and preliminary studies was found in 
reliability measurements for the Nine Hole Peg test In the pilot study, an inverse relationship 
was found for intra-tester reliability. However, in the preliminary study both researchers 
demonstrated high test-retest reliability for this performance test
Synthesizing results from both the pilot and preliminary study, the researchers regard the 
levels of test-retest, inter- and intra-tester reliability found for upper extremity measurements to 
be acceptable and would ^ p ly  the results to die proposed single subject case design. The single 
most influencing characteristic in the results of the pilot and preliminary studies was the small
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sample size. Therefore, this limitatioo would need to be stated when reporting the results o f 
AROM, PROM, Modified Ashworth, and the Nine Hole Peg test in die single subject case 
design.
CHAPTERS 
DISCUSSION AND IMPLICATIONS
Discussion of Findings 
Due to time constraints and the inability to obtain an appropriate subject, researchers 
were not able to complete the proposed research study: the functional effects of Botulinum Toxin- 
A intramuscular injections on a subject with traumatic brain injury: a single subject case design. 
The results o f the single subject design would have evaluated both the long- and short-term 
effects of BTXA injections in conjunction with directed physical therapy. Researchers did, 
however, complete both a pilot and preliminary study.
The purpose of the pilot study was to determine intra- and inter-tester reliability for each 
of the proposed outcome measurements. These measurements included the Modified Ashworth 
Scale, AROM, PROM, the FIM, the Nine Hole Peg test, and Footprint Analysis. Reliability was 
determined using involved subjects for the Modified Ashworth Scale, AROM, PROM, and the 
FIM. For the Nine Hole Peg test and Footprint Analysis, however, reliability was measured using 
normal adults. Due to patient fatigue, results of the pilot study had several missing data points, 
yielding sets of data that could not be statistically analyzed.
Considering the incomplete results o f the pilot study, researchers re-examined reliability 
via a preliminary study. The purpose of the preliminary study was to evaluate test-retest 
reliability for upper extremity measurements of the Modified Ashworth Scale score, AROM, 
PROM and the Nine Hole Peg test in subjects with traumatic brain injury. Another purpose of the 
preliminary study was to establish inter-tester reliability for these measurements. However, 
difhculty with subject recruitment prevented data collection for this reliability. Therefore, this 
discussion will highlight fire results of inter- and intrartester reliability obtained firom the pilot 
study, and test-retest reliability determined by the preliminary study.
69
70
Functional Peifonnance Measures
Although the results were limited by the availability of subjects for the pilot study, 
researchers found high inter- and intra-tester reliabiliQr for the FIM subscores: bed transfers and 
walking. Due to incomplete data sets, the subscores for stair and toilet transfers could not be 
analyzed using Kendall’s tau. In a study 1^ Hamilton et al. (1994), researchers examined 1,018 
hospital bound patients for all subscores of the FIM. Using ICC, researchers found moderate 
inter-tester reliability for bed transfers (r = .64 - .78) and walking (r = .59 -  76). The high inter- 
tester reliability results in this pilot study were stronger than the levels of reliability reported by 
Hamilton et al. (1994). Researchers postulate that this higher reliability can be accounted for by 
the small sample size (n = 6) and limited variability in the functional levels o f the subjects for foe 
pilot study. However, foe sample cohorts and statistical tests differed between the pilot study and 
foe Hamilton study; therefore, comparisons can only be made with caution.
Intra-tester reliability of foe Footprint Analysis subscores (velocity, cadence, stride and 
step length) was found to have an inverse relationship or little reliability (r = -.580 - 220) 
according to results from foe pilot study. This finding is not consistent with a previous study by 
Boeing (1977) and Wadsworth et al. (1972). In foe Boeing study, researchers examined normal 
adults for test-retest reliability of cadence, step and stride length, and found high reliability (r = 
.782 - .972). Examining patients with hip disease, Wadsworth and colleagues also found a high 
level of test-retest reliability for velocity, cadence and stride length (r = .96 - .99). Researchers 
hypothesize that foe discrepancy between foe results of foe pilot study and foe results reported by 
Boeing and Wadsworth et al. is due to foe use of different tests of statistical analysis. For foe 
pilot study, researchers used Kendall’s tau for statistical analysis; for foe other studies, a 
parametric test was used. Kendall’s tau, a nonparametric test, examines foe ordering of 
concordance and discordance between pairs of ranked data. This test does not compute foe actual 
disparity between scores. Therefore, foe inverse relationships in foe pilot study may be a result of 
foe limitations of foe statistical procedures utilized.
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Inter-tester reliability, however, was found to be high (r = .77 -  .99) for velocity, 
cadence, step, and stride length in the pilot study. This finding suppwts the results o f a study by 
Holden et al.(1984), who also reports high inter-tester reliability (r = .98 — 1.0) for Footyrint 
Analysis subscores. However, Holden and colleagues evaluated 61 subjects with MS or 
hemiparesis, while authors of the pilot study examined ten normal adults. Therefore, comparison 
of the two studies is limited.
Using ten normal subjects, researchers found an inverse association for intrartester 
reliability in the pilot study. However, using seven subjects with TBI for the preliminary study, 
researchers found a high level of test-retest reliability (r = 76—1.00). Researchers realize that 
intrartester reliability and test-retest reliability are similar in nature, but do not represent die same 
measures. Therefore, comparison of results between the pilot study and those of the preliminary 
study should be interpreted widi caution. Researchers hypothesize that the discrepancy between 
the two studies is due to the use of different statistical tools, methodologies, and subject cohorts. 
The author refers the reader back to chapter three for descriptions of statistical tools, 
methodologies and subject cohort for these two studies. However, when specifically examining 
the difference between the same day trials (pilot study) and repeat testing trials (preliminary 
study), the authors believe that the repeat testing procedures used for test-retest reliability are 
more appropriate for the proposed single subject case design. Researchers also realize that their 
abilities to score the Nine Hole Peg test improved from the pilot study to the preliminary study 
due to their increased exposure to testing procedures. Each of these confounding factors may 
have influenced the higher level of reliability found in the preliminary study.
In a study by Mathiowetz et al. (1985), 26 normal adults were evaluated using the Nine 
Hole Peg test Using Pearson’s correlation coefficient, researchers reported a high level o f test- 
retest reliability for the right hand (r = .69), a moderate level of reliability for the left hand (r = 
.43), and a high level o f inter-tester reliability (r = .97 - .99). Inter-tester reliability results fipom
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the pilot study and results o f test-retest reliability in the preliminary study support die reports by 
Mathiowetz and colleagues.
Modified Ashworth Measures
Reliability results on the Modified Ashworth Scale, were significantly weakened by the 
small sample size and the occurrence of tied ranks. When data analysis was possible, using 
Kendall’s tau, inter-tester reliability for the Modified Ashworth Scale scores was, at best, only 
moderately reliable. To date, no studies have reported inter-tester reliability for full upper or 
lower extremity joint motions in patients with TBI. However, using 30 subjects with TBI,
Allison et al. (1996) found a moderate level of inter-tester reliability (r, = .73) when examining 
plantarflexor spasticity. On the contrary, the results of the pilot study illustrated no inter-tester 
reliability for plantarflexors (x = 0). Furthermore, in a study by Bohannon and Smith (1987) that 
specifically evaluated Modified Ashworth Scale scores of the elbow flexors in 30 subjects with 
UMN syndrome (TBI, MS or CVA), the researchers found high inter-tester reliability (x = .847). 
This conclusion is not supported by results of the pilot study, in which the authors found little 
inter-tester reliability (x = .125) for elbow flexors. Although each study evaluated similar subject 
cohorts (i.e., subjects with upper motor neuron syndrome), the sample size in the pilot study (n = 
8) was significantly less than the sample evaluated by Allison et al. and Bohannon and Smith (n = 
30 for both).
The authors o f the pilot study suggest the lower inter-tester reliability scores can be 
attributed to researcher inexperience with the Modified Ashworth Scale and the limited sample 
size. The Modified Ashworth Scale uses ambiguous terminology in fire grading fisr each 
spasticity level (i.e., grade 1+ is described as a “slight increase” in muscle tone). Therefore, the 
researchers’ inexperience in evaluating and scoring muscle spasticity in neurologic patients may 
have led to misinterpretations of the grades. Researchers hypothesize that further training may
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have enhanced inter-tester reliability, as is evidenced in the preliminary study’s results. In the 
preliminary study, researchers were found to have high test-retest reliability (r, = .86 — 1.0)
Also, no studies to date that have reported intra-tester and test-retest reliability for all 
possible joint motions in patients with TBI using die Modified Ashworth Scale. However, in a 
study by Allison et al. (1996), researchers determined intra-tester and test-retest reliability of the 
Modified Ashworth Scale in the ankle plantarflexors o f 30 TBI subjects. Using Spearman’s rho 
(rj, Allison et al. found moderate intra-tester reliability (r, = .74 and .75) and high test-retest 
reliability (r, = .82). The authors of the pilot study found high level of intra-tester reliability (t =
1.0) for this lower extremity measurement. However, this specific joint motion was not examined 
for test-retest reliability in the preliminary study. Although the pilot study and the study by 
Allison et al. both examined similar subject cohorts (e.g., subjects with upper motor neuron 
syndrome), the pilot study contained a smaller sample size (n = 8 versus, n = 30). Furthermore, 
the studies used different statistical tests for data analysis. Therefore, comparison o f the two 
studies is limited.
In summary, researchers were not able to determine inter- and intrartester reliability of 
most o f the lower extremity Modified Ashworth scores due to the occurrence of tied ranks and 
missing data points. However, using pilot study data researchers were able to report on inter- and 
intra-tester reliability for the FIM, the Footprint Analysis, the Nine Hole Peg test and upper 
extremity measurements for AROM, PROM and the Modified Ashworth. Due to patient fatigue, 
all lower extremity measurements were therefore elim inated  fiom analysis fiom the pilot study, 
thereby leaving the Nine Hole Peg test, and upper extremity AROM, PROM, and the Modified 
Ashworth Scale measurements for evaluation in the preliminary study.
Range of Motion Measures 
The small sample size and the occurrence of tied ranks significantly weakened AROM 
data analysis for both the pilot and the preliminary studies. Despite the factors confounding data
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analysis, both researchers demonstrated high intra-tester reliability ( r= 0 .8 —1.0) and moderate to 
high inter-tester reliability (r = 0.65 — 0.97) for the pilot study’s AROM data in die joints that 
were able to be statistically analyzed. For test-retest reliability, results were variable based on the 
joint motion and the researcher. When comparing intrartester and test-retest reliability, those 
measurements found to have high test-retest reliability (preliminary study) for CH were also 
found to have high intra-tester reliability (pilot sturty). Specifically, these joints include shoulder 
external rotation, elbow flexion and wrist extension. For researcher MA, however, there was no 
consistency relative to specific joints when compairing intra-tester and test-retest reliability.
Researchers feel that the variability in intra-tester and test-retest reliability scores for 
AROM of the wrist is due to a number o f Actors. Researcher MA, and at times, researcher CH 
were both unable to follow standardized procedures for measuring AROM due to subject’s 
clinical presentation, severity of motor control deficits, and environmental factors. For example, 
researchers had difficulty finding a flat surface and an appropriate height to use to stabilize the 
subject’s elbow and forearm for wrist and forearm measurements. This predicament occurred for 
each subject in a wheelchair. Therefore, researchers had to improvise the data collection 
procedures, thus increasing the variability of testing procedures and ultimately affecting AROM 
and PROM scores for wrist flexion, wrist extension, supination, and pronation. This deviation 
fiom standardized procedures may also have changed the patient’s performance from one day to 
another. Testing variability also made identification of specific landmarks difficult which, in 
turn, could affect intra-tester and test-retest reliability. According to a validity study by Fish and 
Wingate (1985) most variation in range o f motion is due to misidentification of bony landmarks, 
variations in manual force, and improper alignment of the goniometer. Therefore, these testing 
procedure variables may have influenced our findings.
Researchers also believe that a number of other subject characteristics may have affected 
AROM results. When working with four of the subjects wifir TBI, researchers noted that there 
was variability in the levels of active motor control. Poor motor control may lead to synergistic
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patterns or substitutions when attempting AROM movements such as: shoulder flexion, shoulder 
abduction, elbow flexion and wrist extension. For example, in our preliminary study, subject six 
could not perform active shoulder flexion in a pure sagittal plane. Instead, subject six adducted, 
internally rotated, and flexed his shoulder. Researchers hypothesize that the movement 
selectivity variability seen between subjects may have been better controlled if a predetermined 
level of movement selectivity had been included in the inclusion criteria. Although, researchers 
attempted to minimize substitution by following standardized procedures, the differing levels of 
motor control, at times, prevented the use of our protocol. Therefore, researchers accept the 
variable levels of motor control as another limitation to the preliminary and pilot studies.
AROM measures may have also been affected by the subject’s Amiliarity with the testers 
and testing procedures. Unfamiliarity may have increased subjects’ anxiety levels, thereby 
affecting the subject’s central state. As stated in chapter two, intrinsic and extrinsic variables 
such as time of day, day of the week, arousal level, level of fatigue and emotional level may 
affect the level of spasticity in patients with TBI. Although spasticity and poor motor control are 
very separate clinical manifestations of TBI, one impairment may influence the other. Therefore, 
an increased level of anxiety may have changed the subject’s performance for AROM by 
affecting their levels of motor control and spasticity. For example, two subjects seen by 
researcher MA were fighting just prior to data collection on the second date. Researchers 
hypothesize that the changes in AROM scores for these two individuals may be partially 
attributed to their heightened state of arousal.
Furthermore, the subjects’ unfamiliarity with the testing procedures and directions at 
initial data collection, may have caused misunderstandings. Confusion was most apparent when 
subjects performed shoulder flexion, shoulder abduction, supination, pronation, wrist flexion and 
wrist extension. However, during the second data collection session o f the preliminary study, 
procedures were repeated and any m isunderstandings  should have been clarifled. This possible
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“practice efifecf' may account for some of Ae variability seen in AROM measurements between 
Ae two data collection days (preliminary study) and for intra-tester reliability for Ae pilot study.
AnoAer possAle explanation fear Ae variability in AROM is due to recorder error. In 
order for researchers to remain blinded to initial goniometric resiAs, student physical Aerapists 
read and recorded Ae position of Ae goniometer during Ae initial data collection period. 
Researchers Aen recorded results for Ae second data collection day. Due to time constraints and 
schedule conflicts. Afferent students were utilized for each data collection dates. AlAough Ae 
researchers assumed all recorders (i.e., student physical Aerapists) possessed a certain level of 
skill wiA goniometric reading, during data collection several recorders expressed concerns when 
reading Ae goniometer. This problem specifically occurred wiA wrist motion measurements.
The imcertainties expressed by Ae recorders and Ae use of multiple recorders increases Ae 
likelAood of recording errors and increases variability in test-retest results.
A final explanation for Ae varying levels of reliability for AROM measurements is due to 
Ae validity of goniometry. Nortkin and White stated that “mean gomometric measurements 
differed 0.5 to 5 degrees from Ae means o f measurement determined by still photogr^hy” (1993, 
p. 36). Given this reported error in goniometric measures, reliability results may have been 
underestimated in Ais study, as this level of error was not factored in Ae data analysis for Ae 
pilot and preliminary stuAes.
Data analysis for PROM scores was also limited due to tied ranks. However, when 
analysis was possible, results revealed Aat PROM measurements for boA researchers 
demonstrated a high level of intra-tester reliability (r = 0.80 - 1.0) for Ae upper extremities of 
subjects wiA upper motor neuron syndrome. Results varied for inter-tester and test-retest 
reliability varied depending on Ae joint motion and researcher. For example, researcher CH was 
found to have high test-retest reliability for five out o f eight upper extremity motions (r, = .775 -
1.0), while researcher MA was highly reliable for only five out of ten joint motions (r, = 1.0). 
Also, inter-tester reliability was found to be high for five out of eight upper extremity
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measurements: shoulder abduction (r = .821), shoulder internal rotation (r = .985), shoulckr 
external rotation (r = .824), and wrist flexion (r = .778). The remaining joint positions calculated 
had moderate inter-tester reliability (r = .621 — 731) accept for wrist flexion which had little 
reliability (r = .062).
A study conducted on adult norms which examined 22 joint positions in both the upper 
and lower extremity (Mayerson et al., 1984), reports high inter-tester (r = 0.97) and intra-tester (r 
= 0.98) reliability for PROM measurements. Intra-tester reliability results fiom the pilot study 
concur with these findings. However, it is difficult to compare inter-tester reliability results fiom 
the Mayerson study to this pilot study because Mayerson et al. does not specifically mention 
which joints in the upper extremity were tested. Furthermore, the Mayerson study examined 
normal adults, while our study examined patients with upper motor neuron syndrome.
As with AROM measurements, possible errors in PROM data collection may be due to 
difficulties following standardized procedures, recording inconsistencies, and the validity of 
goniometry. However, researchers attribute high PROM reliability to the nature of PROM 
measurement; PROM scores can be collected independent of the subject’s motor control 
impairments. Therefore, any variability in specific joint measurements is more likely due to the 
researcher’s technique then to subject variability. At the time of data collection, both researchers 
had considerable exposures to a variety of end-feels encountered during PROM measurements. 
Knowledge o f end feels allowed researches to properly identify the end point for PROM 
measurements and strengthen the reliability findings for this measure.
In summary, when data analysis was possible, researchers found acceptable high intra­
tester reliability for the FIM subscores (walking and bed transfer), upper extremity AROM, 
PROM, and the Modified Ashworth Scale; high inter-tester reliability for the Nine Hole Peg test. 
Footprint Analysis subscores (velocity, cadence, step and stride length), the above mentioned 
FIM subscores, and upper extremity AROM; and moderate to high inter-tester reliability for 
upper extremity PROM, and the Modified Ashwordi Scale. Researchers also demonstrated high
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test-retest reliability for the upper extremity using the Modified Ashworth Scale, upper extremity 
PROM, and the Nine Hole Peg test, but did not find high test-retest reliability for upper or lower 
extremity AROM. Because the dependent measurements showed either moderate to high or high 
levels of intra- or test-retest reliability, the researchers accept the levels of reliability and plan to 
apply the upper extremity reliability results to their originally proposed single subject case design. 
However, researchers need to first determine test-retest reliability for AROM before applying this 
measurement to our originally proposed single subject case design. By using these dependent 
measures with documented high reliability, the researchers will be able to confidently describe 
the effects of BTXA in conjunction with directed physical therapy.
In our original single subject case design, a decrease by one point for the Modified 
Ashworth Scale score, an increase by one point for the FIM, an improvement of a minimum of 
eight degrees for AROM and PROM measurements, and an improvement in overall function on 
either of the Nine Hole Peg test or the Footprint Analysis was designated as “clinically 
significant” After visually analyzing the data fix)m our pilot study, researchers feel more specific 
criteria is warranted for the performance tests. Specifically, researchers would now propose the 
following scores to reflect “clinically significant” improvements in overall function: for velocity, 
a change of four centimeters per second; for cadence, a change o f four steps per minute; for stride 
length, a change of two centimeters; for step length, a change o f one centimeter; and for the Nine 
Hole Peg test, a change of four tenths of a second. By adding these new criteria to die previously 
stated guidelines for PROM, AROM, and the Modified Ashworth Scale, researchers now believe 
that appropriate guidelines for determining clinical significance have been established.
Clinical Imolications
Currently, many clinicians use die Modified Ashworth Scale, AROM, PROM and the 
Nine Hole Peg test to document changes in a padent’s impairment and functional status. These 
tests are simple and inexpensive to perform. However, the disadvantage of these tests, is that
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most have not been specifically evaluated for inter- and test-retest reliability in patients with TBI. 
The results o f the preliminary sturfy indicate that the Modified Ashworth Scale, PROM, and the 
Nine Hole Peg test each have a high level o f test-retest reliability for the upper extremities of 
subjects with TBI. However, AROM measurements demonstrated a 6 ir  to moderate test-retest 
reliability when applied to this subject cohort Researchers feel that the &ir to moderate level of 
reliability in AROM measurements is due to numerous confounding variables as described in the 
discussion section. The major limitation of AROM is that it requires an adequate amount of 
active motor control in order to be performed according to descriptions offered by Nortkin and 
White (1985). Many subjects with TBI, however, do not have adequate motor control and may 
use substitution or synergistic patterns to complete AROM movements. Therefore, researchers 
suggest using a specific fimctional task (e.g., reaching) that incorporates the desired end range of 
motion in order to objectively measure AROM in subjects with TBI.
In general, researchers were able to follow procedures outlined by Nortkin and White 
(1985) in order to obtain measurements of AROM and PROM. For wrist measurements, 
however, researchers deviated fit>m the outlined procedures and subsequently, test-retest and 
inter-tester reliability were poor for these measurements. These findings suggest a stable surface 
at a consistent level should be used for repeat measurements of wrist AROM and PROM.
Through comparison o f both the pilot and preliminary studies, researchers surmised that 
more experience and exposure to the Nine Hole Peg test may account for the improvement in 
reliability. Researchers also suspect that the highly detailed standardized procedures for the Nine 
Hole Peg test minimize tester error, thereby enabling researchers to be highly reliable. These 
findings are clinically relevant for new graduates. In order for new graduates to be comfortable 
with the testing procedures of the Nine Hole Peg test, they should seek out opportunities to 
perform the test on a wide variety of patients.
Both the pilot and preliminary studies utilized a small sample size and only two student 
raters. Therefore, the results should not be generalized to physical therapists or die larger target
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population. However, the preliminary study does provide a methodology for future researchers to 
follow. The preliminary study outlines methods that would help determine inter-tester and test- 
retest reliability in individuals with TBI. The results of that study could then be ^ p lied  to the 
original single subject case design. However, in order to apply the results to the single subject 
case design to similar subjects with TBI, future researchers will need to use a larger sample that 
includes subjects with a wide range of motor and functional deficits. By establishing reliability in 
measurement tools, ther^ists can more accurately measure changes in a patient’s functional 
status and the effects o f treatment interventions.
Researchers encountered significant difficulties in finding subjects with TBI that met pre- 
established inclusion and exclusion criteria. Therefore, future studies that examine this specific 
subject cohort should have adequate time and resources in order to acquire an appropriate sample 
size (n > 30). Furthermore, considering the specific criteria of the originally proposed single 
subject case design, future researchers may want to modify the criteria in order to guarantee 
subject availability.
Finally, the Modified Ashworth Scale, the Nine Hole Peg test, and upper extremity 
PROM measurements can be used by student physical therapists at a high level of test-retest 
reliability to measure changes in a patient’s status. Also, the Modified Ashworth, FIM subscores 
(walking and bed transfer), and upper extremity AROM and PROM have a high level of intra- 
tester reliability when applied by student physical therapists. Because o f these findings, 
researchers believe that diese measurements can be applied in the examination o f subjects with 
TBI.
Limitations
The use o f a small sample size is a significant limitation of both the pilot (n = 8 involved 
subjects, n = 10 uninvolved subjects) and preliminary studies (n = 7). As stated by Sheskin, ‘*in 
order fw a sample to be useful in drawing inferences about the larger populatitm fix>m which it
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was drawn, it must be representative of the population” (1997, p. I). Although our pilot and 
preliminary studies had specific inclusion and exclusion criteria to define our target population, a 
convenience sample of less than ten subjects was obtained for both studies. This sample size is 
too small and inappropriate for reliability studies. With convenience sampling, subjects are 
chosen based on availability, not randomization. Therefore, researchers cannot assume that 
subjects in the pilot and preliminary studies represent the larger population of subjects with TBI.
Also with a small sample, the standard error of the mean tends to vary, thus creating a 
large amount o f variability within the sampling distribution curve. For example, the pilot and 
preliminary studies’ samples both contained less than twenty subjects. Therefore, any large 
variability found within one subject’s scores could have a significant impact on reliability results. 
As a sample size increases, the sample distribution curve becomes narrower, the sample becomes 
more representative of the population, and the sample error will be smaller (Portney & Watkins, 
1993). Furthermore, the data fiom the pilot study was not normally distributed, thereby 
preventing the use of a parametric statistical tool. Instead, researchers utilized a nonparametric 
tools in an attempt to analyze skewed data: Kendall’s tau (x) and Spearman’s rho (rj.
Spearman’s rho was also applied to the preliminary study because of the small sample size. 
Researchers accept the limitations associated with a small sample size and the sample’s effects on 
data distribution. Both limitations confounded the results o f the pilot and preliminary studies
Kendall’s tau (x) and Spearman’s rho (r,) are two nonparametric statistical tools used to 
measure the amount of variation between data points. Both tests place data in a ranked order and 
assume that there is some level of variability among data points. Because both the Modified 
Ashworth Scale and the FIM are ordinal scales with operationally defined scores, the number of 
possible scores is limited. This characteristic, confounded with the small sample sizes in both 
studies, led to little or no variability between data sets. Therefore, statistical analysis using 
nonparametric statistical tools was impossible for some items. The small sample size was also 
the major limiting factor for statistical analysis o f die Nine Hole Peg test, goniometry, and the
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Footprint Analysis subscores. Because o f the small sample size, a large variation in one subject’s 
scores may have an impact on the level of reliability reported for that measurement Due to 
difficulties with data analysis, researchers could only draw very limited conclusions pertaining to 
results and their clinical significance.
Another limitation for both the pilot and preliminary studies is attributed to examiner and 
recorder error. For both studies, researchers utilized an independent recorder to read and record 
initial goniometric measurements. Although this allowed researchers to remain blinded to 
goniometric results, thus decreasing tester bias, the use of different recorders was a limitation.
Also, because both researchers were entry level Masters of Physical Therapy students 
their lack of experience should be noted as a  significant limitation. At the start o f data collection, 
neither researcher had extensive experience working with individuals with TBI. Therefore, their 
exposure to examination procedures for this patient population was limited. To address this 
inexperience, researchers utilized the experience and guidance of a Board Certified Neurological 
Clinical Specialist (NCS). This allowed researchers to improve their goniometry skills and 
abilities to apply the Modified Ashworth Scale to subjects with TBI. Furthermore, throughout the 
pilot study data collection process, researchers needed to consult various testing and scoring 
criteria. Although this dependency decreased with time, initially it substantially lengthened the 
time required for data collection to approximately two hours. Researchers also had attempted to 
perform four complete sets of data collection scores for both the upper and lower extremity in the 
pilot study (the Modified Ashworth Scale, AROM, PROM, and the FIM). Due to the two hour 
data collection sessions, many subjects complained of fatigue and requested to be dismissed from 
the data collection early, thereby creating numerous missing data points.
However, when researchers performed the preliminary study, their exposure to the target 
population and the data collection process had broadened. Also, the researchers were no longer 
reliant on texts during the data collection process. These improvements in researcher efficiency 
considerably abbreviated the length o f data collection sessions fiom two hours to approximately
S3
forty minutes, thereby eliminating patient fatigue and missing data points. Furthermore, 
considering the difficulties encountered during the pilot study, researchers minimized testing 
variability in the subsequent preliminary study by applying more standardized procedures and 
limiting the number o f measures taken. Although the experience and skill of both researchers 
improved from the pilot study to the preliminary study, they were still only entry level physical 
therapists with limited competency in testing. The results o f the preliminary study should be 
interpreted considering this level of experience.
A fourth limitation of both the pilot and preliminary study was the lack of control for a 
number of intrinsic factors. Diet, time of day, day of the week, emotional level, illness, arousal 
level, level of motivation, and activity level may either positively or negatively effect the 
subject’s degree of spasticity and motor performance (O’Sullivan & Schmitz, 1988). Many of 
our subjects in both the pilot and preliminary studies had physical handicaps that required them to 
utilize assistive devices for mobility and activities of daily living (ADLs). Researchers suspect 
these subjects required a significant amount of energy expenditure to perform simple ADLs and 
joint movements. Increased energy expenditure, confounded by the length of the data collection 
sessions, caused many o f these subjects to quickly 6tigue during testing. Fatigue often affected 
the subjects’ ability to participate in AROM or the FIM tests. As stated earlier, these subjects 
usually requested to terminate the data collection session early, thus yielding missing data points, 
particularly in the lower extremity.
In order to minimize some of the intrinsic effects o f anxiety, researchers performed all 
preliminary study data collection in the subject’s home. However, researchers were unable to 
control for any anxiety the subject may have experienced during the first day of data collection. 
For instance, researchers suspect subjects experienced less anxiety on the second day of data 
collection as compared to the first day of data collection. Researchers suspect the decrease in 
anxiety is likely due to the use of standardized procedures for both data collection dates. On the 
second day of data collection, many subjects demonstrated an increased understanding of their
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participation in testing procedures. Improved understanding o f the testing procedures may have 
decreased their level of anxiety thereby altering the level of muscle tone. Although researchers 
did attempt to control for the before mentioned intrinsic variables, they were unable to control for 
anxiety, which may have altered a subject’s level of spasticity and motor control.
Researchers also attempted to minimize die possible extrinsic factors that could confound 
test-retest reliability results for the preliminary study. Researchers proposed the use of 
standardized procedures in order to minimize testing variability for each of the dependent 
measurement tools. However, because preliminary study data collection occurred in the subject’s 
home, researchers encountered variations in testing surfaces. For the goniometric measurements 
o f supination, pronadon, wrist flexion and wrist extension, it was difficult for researchers to find a 
hard surface at an appropriate height Researchers often had to deviate dom the procedures 
defined by Nortkin and White (1985). However, subjects were evaluated using the same surface 
for both data collection sessions; therefore, the effects of this variability on test-retest reliability is 
minimal.
Researchers also attempted to see patients at the same time of day for both data collection 
dates. Through consistency in data collection times, researchers hoped to control for extrinsic 
factors that may influence motor control and spasticity. However, because of subjects’ schedules, 
this control was not always possible.
Another limitation for both the pilot and preliminary studies is attributed to procedural 
errors. During videotaping of the Footprint Analysis for the pilot study researchers did not follow 
standardized procedures for video camera placement Researchers did not use standardized 
camera angles in relationship to the start/stop lines. This error may have lead to discrepancies in 
scoring, as researchers may have misinterpreted start and stop timing for velocity calculations. 
This lack of standardization in video camera placement also makes it difficult for future 
researchers to replicate our pilot study. Furthermore, researchers also failed to document specific 
information pertaining to subject characteristics (i.e. age, side of lesion, and duration of
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impairment). This lack of documentation also makes it difficult for clinicians to apply our results 
to any specific patient population.
Researchers used standardized procedures for the Modified Ashworth Scale in both 
studies. However, in the pilot study researchers failed to explicitly describe the number of 
repetitions to be used when determining the subject’s available range of motion or spasticity 
level. This omission lead to variability in testing procedures from one researcher to another, 
thereby affecting inter-tester reliability. Researchers did, however, correct for this error by 
implementing a more detailed Modified Ashworth Scale protocol for the preliminary study.
Researchers followed standard testing procedures to minimize tester bias. In order to 
remain blinded to initial results, researchers used an independent recorder for both the pilot and 
preliminary studies. However, researchers failed to educate the independent recorders on the 
interpretation of the goniometer. Furthermore, researchers were unable to utilize the same 
independent recorder for all subjects for both studies due to schedule conflicts. These sources of 
variability yield potential for inaccuracies in goniometric scores. Nevertheless, researchers 
accept them as study limitations.
A final limitation can be attributed to instrument error. The inherent weakness of the 
Modified Ashworth Scale is that it is an ordinal scale used to describe spasticity. Ordinal scales 
are the second lowest level of measurement and are used purely as labels for identification. The 
terminology of the Modified Ashworth Scale may generate a problem if a clinician is unable to 
match what they feel to an operationally defined characteristic. Researchers’ interpretations of 
the measurements may also vary. Both researchers had limited exposure to the Modified 
Ashworth Scale, especially for the pilot study. This inexperience lead to an increased reliance on 
operationally defined scoring criteria (Appendix A). For the preliminary study, however, both 
researchers had increased exposure to and practice with the Modified Ashworth Scale. Therefore, 
they were more confident in their abilities to accurately grade a subject’s level o f spasticity.
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Goniometry is another evaluative tool that has documented limitations (Rotbstein, Miller 
& Roettger, 1983; Gajdosüc & Bohannon, 1987; Elveru, Rothstein & Lamb, 1988). Physical 
therapists’ reliability in goniometric measurements is variable depending on the diagnosis, the 
time interval between repeat testing, the complexity o f the action to be measured, and the 
functional difference between actions (Gajdosik & Bohannon, 1987). For AROM, the subject 
must have a moderate level o f motor control in order to perform the desired actions in the planes 
of motion specified by Nortkin and White (1985). Many of our subjects, for both the pilot and 
preliminary stutty, demonstrated substitutions and synergistic movement patterns when 
performing AROM. Although researchers attempted to utilize standardized procedures to 
minimize testing variability, they were unable to strictly adhere to the procedures due to these 
abnormal movement patterns.
Suggestions for Further Research
Due to the lack o f current research on test-retest reliability for the Modified Ashworth 
Scale, AROM, PROM and the Nine Hole Peg test in the upper extremities of patients with TBI, 
future research should focus on replication of this preliminary study using a larger and more 
diverse sample size. In addition to having a primary diagnosis of TBI, subjects in this larger 
sample should also present with a wide range of motor and functional deficits. This diversity 
would help to normalize the distribution of data points so researchers can utilize strong statistical 
tests such as the parametric Pearson’s r or ICC. Replication and strengthening o f the preliminary 
study will help future researchers determine whether the Modified Ashworth Scale, AROM, 
PROM, and the Nine Hole Peg test should be used to document functional changes in patients 
with TBI. Researchers will also be able to evaluate the efficacy of treatment interventions such 
as BTXA and directed physical therapy.
Future researchers should remain blinded during data collection but should consider 
using the same recorder for all goniometric measurements. A consistent setting for data
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collection should also be used. Due to logistics, the researchers of this preliminary study could 
not control for these two sources o f measurement error. Furthermore, the data for this 
preliminary study was collected by student physical therapists. Their inexperience may have 
affected test-retest reliability results. Therefore, future research is needed to determine whether 
clinical experience and training affect levels of test-retest reliability for the Modified Ashworth 
Scale, AROM, PROM, and the Nine Hole Peg test.
Finally, to improve upon AROM reliability, future researchers may wish to develop a 
specific functional task diat incorporates a desired range of motion. Due to the possible 
movement substitution and synergistic patterns, researchers may be unable to reliably assess 
AROM in subjects with TBI using positions described by Nortkin & White (1985). Use of a 
functional task for data collection will enable researchers to obtain a more objective measurement 
o f AROM in subjects with TBI. With these changes in methodology, test-retest error could be 
significantly minimized.
Further research examining inter-tester reliability, using subjects with TBI, is also needed 
for the Nine Hole Peg test and upper extremity Modified Ashworth Scale, AROM, and PROM 
measurements. To date there is little, if any, inter-tester reliability studies that apply these 
dependent measurement tools and specifically examine individuals with TBI. The Modified 
Ashworth Scale, which evaluates spasticity, is supported by some inter-tester reliability research. 
However, many studies do not specifically evaluate subjects with TBI, nor do the studies include 
a comprehensive evaluation using the Modified Ashworth Scale on upper or lower «rtremity 
muscles. Also, studies that examine inter-tester reliability for the Nine Hole Peg test and upper 
extremity AROM and PROM report results using normal adults. However, these measurements 
are commonly used in physical therapy clinics for the evaluation and re-evaluation o f patients 
with TBI. Therefore, in order for clinicians to report that changes in outcome measurements are 
due to treatment interventions and not tester error or variability, inter-tester reliability first needs 
to be established for these tools using individuals with TBI.
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Future research should also apply the methodology proposed in the original single subject 
case design. Due to the current lack of research that specifically examines the use of BTXA 
treatment plus directed physical therapy in subjects with TBI, examination using the original 
study is warranted. The single subject design is preferred over an experimental design because of 
the heterogeneous nature o f the target population. Due to the fact that many patients with TBI 
have variable levels of motor control, researchers can only determine the appropriate dependent 
measurement tools after evaluating a specific patient’s functional capabilities. The strict 
procedures used with an experimental design, however, do not enable researchers to modify 
testing procedures from one subject to another. Thus, the use of predetermined measurement 
tools may not adequately measure changes in a subject’s function nor the effects of a treatment 
regime.
Future research should also examine the most effective techniques to use for muscle re­
education with patients with TBI who are experiencing the effects of BTXA injections. Research 
is needed to establish the most effective time period for implementation of physical therapy 
treatments. Although no two patients with TBI present with the same degree of spasticity or 
motor control deficits, descriptions of effective treatment techniques and the timing of 
implementation of these techniques will provide clinicians with a starting point for physical 
therapy intervention. This preliminary study provided support for Ae use of the Modified 
Ashworth Scale, AROM, PROM, and the Nine Hole Peg test for monitoring efRcacy of the 
BTXA and directed physical therapy treatment interventions.
Conclusions
The results of the pilot and preliminary study indicated high levels of test-retest and/or 
intra-tester reliability for the FIM subscores (walking and bed transfers), the Nine Hole Peg test, 
and the upper extremity measures of PROM and the Modified Ashworth Scale. High levels of 
inter-tester reliability for the Nine Hole Peg test and Footprint Analysis and moderate to high
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levels of inter-tester reliabiliQf for upper extremity AROM and PROM were found in the pilot 
study. Unfortunately, due to limited subject availability and fatigue with testing protocol, 
researchers were unable to determine the level of test-retest, inter- ot intra-tester reliability for 
lower extremity AROM, PROM, and the Modified Ashworth Scale measurements; intra-tester or 
test-retest reliability for the Footprint Analysis; and inter-tester reliability for the Modified 
Ashworth Scale. Further research is needed to support the reliability o f these tools in patients 
with TBI. However, the results of the pilot and preliminary studies support the use of the Nine 
Hole Peg test and upper extremity PROM and the Modified Ashwordi Scale as dependent 
measures to monitor the effects of BTXA and directed physical therapy, as proposed in the 
original single subject case design.
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THE MODIFIED ASHWORTH SCALE SCORE 
FOR ASSESSING MUSCLE SPASTICITY
Grade Description
0 No increase in muscle tone
1 Slight increase in muscle tone, manifested by a catch and release or by minimal 
resistance at the end o f range o f motion when the affected part is moved
1+ Slight increase in muscle tone, manifested by a catch, followed by minimal resistance
throughout the remainder (less than half) o f the ROM
2 More marked increase in muscle tone through most of the ROM, but affected part easily 
moved
3 Considerable increase in muscle tone, passive movement difGcult
4 Affected part rigid in flexion or extension
Boharmon, R.W. and Smith, M 3 . (1987). Interrater reliability of a Modified Ashworth scale of 
muscle spasticity. Physical Therapy, 67(2), 207.
Standardized Testing Procedures
1) position patient in supine
2) test joints proximal to distal
3) test one joint and one motion at a time
4) move the joint to be tested through gentle PROM three times
5) move the joint to be tested quickly through % ROM four times
6) determine score
APPENDIX B
THE FUNCTIONAL INDEPENDENCE MEASURE (FIM)
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THE FUNCTIONAL INDEPENDENCE MEASURE (FIM)
FOR ASSESSING LEVELS OF FUNCTION
FIM items Scores
Transfers
Bed
Toilet
Locomotion
Walking
Stairs
Independent: Another person is not required for the activity
7 Complete independence: All tasks are safely performed without 
modification, assistive devices, or aids, and within reasonable time.
6 Modified independence: Activity requires any one or more than one 
of the following: An assistive device more than reasonable time or 
with safety (risk) considerations.
Dependent: another person is required for either supervision or physical 
assistance for the tasks to be performed.
Modified dependence: The subject expends half (50%) or more o f the 
effort The levels o f assistance required:
5 Supervision or setup: The subject requires no more help than 
standby, cueing or coaxing, without physical contact, or, needs 
assistive devices.
4 Minimal contact assistance: with physical contact the subject
requires no more help than touching, and the subject expends 75% or 
more of the effort 
3 Moderate assistance: The subject requires more help than touching, 
or expends half (50%) or more (up to 75%) o f the effort.
Complete dependence: The subject expends less than 50% of the effort. 
Maximal or total assistance is required, for the activity. The levels of 
assistance required are:
2 Maximal assistance: The subject expends less than 50% of the effort 
but at least 25%.
1 Total assistance: the subject expends less than 25% of the effort.
Functional Independence Measure. Copyright © 1996. Uniform Data System for 
Medical Rehabilitation (UDSMR). All rights reserved. Used with permission of 
UDSMR, University at Buffalo, 232 Parker Hall, 3435 Main Street Buffalo, NY 14214.
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THE FUNCTIONAL DVDEPENDENCE MEASURE (FIM)
FOR ASSESSING LEVELS OF FUNCTION
Standardized Testing Procedures
1) Tell patient “We are about to perform a bed (chair) to chair (toilet) transfer. Try to do as 
much as possible without compromising your safety. I will be here to assist you as needed.”
2) Perform the bed to chair then chair to toilet transfer
3) Record score
4) Tell the patient “Next, I would like you to walk 150 feet or as far as you can. Try to do it as 
independently as possible without compromising your safety. I will be here to assist you if 
needed.”
5) Perform the locomotion test
6) Record score
7) Tell the patient “Finally, I would like you to walk up and down twelve stairs using as little 
assistance as possible without compromising your safety. I will be here to assist you if 
needed.”
8) Perform the stair assessment
9) Record score
APPENDK C
NINE-HOLE PEG TEST FOR ASSESSING 
UPPER EXTREMITY FUNCTIONAL PERFORMANCE
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NINE-HOLE PEG TEST FOR ASSESSING 
UPPER EXTREMITY FUNCTIONAL PERFORMANCE
Materials Required:
•  Hard surfaced table, at comfortable height
•  Nine-Hole Peg Test (available; North Coast Medical)
•  Stop watch
• Chair at comfortable height
Performing the Test
1. Place all nine pegs in test container.
2. Set up test sight according to subject comfort and the involved hand.
3. Read to subject standardized test instructions.
4. Time subject’s test performance.
5. Record Results.
Standardized Test Instructions
1. Center pegboard in fiont o f subject, 6.5 cm from the edge of the table.
2. Place pegs on the table to the same side as the hand being tested, 10 cm from the edge of the 
table and 6.5 cm from the nearest edge o f the pegboard.
3. Test only the involved hand.
4. Have the subject start with the tested hand resting at the edge o f the table.
5. Read the following instructions:
T ick  up the pegs one at a time, using your right (or left) hand only and put them into the 
holes in any order until all holes are filled. Then remove the pegs one at a time and 
return them to the container. Stabilize the pegboard with your left (or right) hand. This 
is a practice test See how fast you can put all the pegs in and then take them out again. 
Are you ready? Go!” (Mathiowetz et al., 1985, p. 29).
5. After one trial run, instruct the subject with:
“This will be the actual test The instructions are the same. Work as quickly as you can. 
Are you ready? Go! (During the test) FASTER (as soon as the last peg is in the board) 
OUT AGAIN....FASTER.” (Mathiowetz et al., 1985, p. 29).
Mathiowetz, V.; Weber, K.; Kashman, N. & Volland, G. (1985). Adult norms for the nine hole 
peg test o f finger dexterity. The Occupational Theraov Journal o f Research. 5( 1), 24-38.
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Footprint Analysis for Assessing Gait Deviations
Materials required:
Paint brush 
Tempera paint
Sheet of paper 9 ^  m (30 ft) to place on floor
One chair at each end of paper sheet
Water and towel for cleaning feet placed at far end
Stopwatch
Yardstick
Performing the test (Standardized procedures)
Preliminaries;
Have materials ready.
Mark a  line 1.5 m (5 ft.) from the begiiming and far end o f paper.
2. Have patient sit at one end of paper with shoes, socks and any ankle-foot orthoses off 
Instruct subject to walk at his regular speed across the paper looking straight ahead.
Start the timer on the stopwatch from the time one heel crosses over the first line drawn until they 
cross over the end line. This controls for the decreased velocity of ambulation that occurs at the 
beginning and the end of a  marked distance.
Record time in seconds
6. Clean subject’s feet
5 f t— e -Timed Sequence ■ ^ —  5 ft —
A
1.5 m (5 ft)
Fig. I : Diagram showing paper measurements and footprints prior to computaUon.
Shaded areas are to be ignored for calculation purposes.
Shores, M. (1980). Footprint analysis in gait documentation. Physical Therapy. 60(9 \ 1163-1167.
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Footprint Analysis for Assessing Gait Deviations
Data Calculations
Velocity = distance fcm l 
Time (seconds)
Cadence =  steps_______
Seconds X 60sec/minute
Stride length (cm)= distance between two consecutive ipsilateial heel strikes
Step length (cm)= distance between two consecutive contralateral heel strikes
APPENDIX E 
STANDARDIZED PROCEDURES FOR ROM
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STANDARDIZED PROCEDURES FOR ROM
AROM
1. Place patient in the proper position based on Noridn and White (198S)
• Except shoulder extension, which will be tested in supine firom available shoulder flexion 
ROM to neutral
2. Test joints proximal to distal
3. Test one joint at a time
4. Test one motion at a time
5. Demonstrate testing motion for the subject using PROM one time
6. Ask subject to reproduce the same movement one time
7. Record goniometric score
PROM
1. Place patient in the proper position based on Noridn and White (1985)
•  Except shoulder extension, which will be tested in supine from available shoulder flexion 
ROM to neutral
2. Test joints proximal to distal
3. Test one joint at a time
4. Test one motion at a time
5. Move tested joint through ROM to end of range
6. Record goniometric score
APPENDK F
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MARY FREE BED HOSPITAL INFORMED PATIENT CONSENT
i  itjlE; Functional Effects of Botulinum Toxin-A Intramuscular Injection
in a Patient with Traumatic Brain Injury: A Single Subject Case Design.
PRIMARY INVESTIGATORS: Molly L. Arndt. SPT; Cristina M. Higei, SPT
PURPOSE OF RESEARCH
I understand that the purpose of this study is to examine the effectiveness of Botulinum Toxin-A 
injections in decreasing muscle spasticity. Knowledge gained fix>m my participation in this study 
is expected to help rehabilitation specialists, including physical therapists and physiatrists. This 
study will provide a better understanding o f the therapeutic use of Botulinum Toxin-A injections 
for the management of muscle spasticity.
PROCEDURE
I also understand that
1) participation in this study will involve three pre-injection screenings and eighteen post­
injection screenings (total= twenty-one screenings) that entail measuring: passive and active 
joint movements, the amount of spasticity at a joint, and the quality of limb movement while 
performing a simple skilled task. The duration o f this study will be six months and three 
weeks.
2) I have been selected for participation because: a) I am not currently emolled in a formal 
physical therapy program for spasticity that has not responded to conventional treatments, b)
I have not previously undergone any neurotoxin treatments (including but not limited to 
phenol or baclofen injections), c) I do not have a fixed contracture of my affected joint, and 
d) I am currently under the care o f Dr. A. Kuldanek of Rehabilitation Medicine Associates.
3) It is anticipated that the screening procedures involved in this study will not cause any 
adverse effects. However, Botulinum Toxin-A injections may involve some side effects. This 
potential has been discussed with me by Dr. A.S. Kuldanek.
4) The data collected will be kept strictly confidential so that when results are recorded, my 
identity will remain anonymous.
5) A summary of the results will be made available to me upon my request.
I acknowledge that:
1) I have been given an opportunity to ask questions regarding this research study, and that these 
questions have been answered to my sadWaction.
2) In giving my consent, I understand fiiat my participation in this study is voluntary and that I 
may withdraw at any time without affecting the care I receive from Dr. A. Kuldanek or the 
staff at Mary Free Bed Hospital.
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M a r y  F r e e  Be d  H o s p it a l  F o r m e d  P a t ie n t  C o n se n t
TiTLE; Functional Effects of Botulinum Toxin-A Intramuscular Injections
in a Patient with Traumatic Brain Injury: A Single Subject Case Design
3) The investigators, Molly L. Arndt, SPT, and Cristina M. Higel, SPT have my permission to 
review the records of my Botulinum Toxin injections and any physical therapy treatments 
that may take place during the course o f this study, as deemed necessary.
4) I hereby authorize the investigators to release the information obtained in this study to 
scientific literature, I understand that I will not be identified by name.
5) I have been given the phone numbers o f Molly L. Arndt, SPT (616-669-6448); Cristina M. 
Higel, SPT (616-895-6037); Paul Huizenga, G.V.S.U. Chairperson Human Research Review 
Committee (616-895-2472); Mary Green, PT, Thesis Committee Chair (616-895-3356), and 
Ellen M. Ballard, PhD., Mary Free Bed Chairperson Human Subjects Review Committee 
(616-242-9201) so that I may contact any of these individuals if I have questions.
  Please send me a copy of the study’s results _______________________
f t itid pint's  Signatiâë DXTE
I acknowledge that I have read and understand the above information, and that 1 agree to 
participate in this study.
Witness Signature OL’IT
Investigator Signature UA'lï.’
Participant Signature DA'lk
Legal Guardian Signature (if under 18) UA'lb
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111 1  R: Functional Effects o f Botulinum Toxin-A Intramuscular Injection
in a Patient with Traumatic Brain Injury: A Single Subject Case Design.
PRIMARY INVESTIGATORS; Molly L. Arndt, SPT; Cristina M. Higel, SPT
PURPOSE OF RESEARCH
I understand that the purpose o f this pilot study is to assist researchers in determining inter- and
intra-rater reliability for the following upper extremity tools: Modified Ashworth Scale, active
and passive range of motion, and the Nine Hole Peg test
PROCEDURE
I also understand that
1) participation in this pilot stucty will involve two screenings of the involved upper extremity, 
separated by four to seven days, that entail measuring: passive and active joint movements, 
the amount of spasticity at a joint, and the quality o f limb movement while performing a 
simple skilled task. Each screening will take approximately 1 hour to complete.
2) I have been selected for participation because: a) I am not currently enrolled in a formal 
physical therapy program for spasticity, b) I do not have a fixed contracture of my upper 
extremity, c) I am status post traumatic brain injury, and d) I am at least twelve years of age.
3) It is anticipated that the screening procedures involved in this study will not cause any 
adverse effects.
4) The data collected will be kept strictly confidential so that when results are recorded, my 
identity will remain anonymous.
5) A summary of the results will be made available to me upon my request.
I acknowledge that:
1 ) I have been given an opportunity to ask questions regarding this research study, and that these 
questions have been answered to my satisfection.
2) In giving my consent, I understand that my participation in this study is voluntary and that I 
may withdraw at any time without consequence.
3) I hereby authorize the investigators to release the information obtained in this study to 
scientific literature, I understand that I will not be identified by name.
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in a Patient with Traumatic Brain Injury: A Single Subject Case Design
4) I have been given the phone numbers of; Molly L. Amdt, SPT (616-669-6448); Cristina M. 
Higel, SPT (616-895-6037); Paul Huizenga, G.V.S.U. Chairperson Human Research Review 
Committee (616-895-2472); Mary Green, PT, Thesis Committee Chair (616-895-3356), and 
Ellen M. Ballard, PhD., Mary Free Bed Chairperson Human Subjects Review Committee 
(616-242-9201) so that I may contact any o f these individuals if I have questions.
  Please send me a copy of the stiKfy’s results _______________________
PMicipm fs Signatme UA lb
I acknowledge that I have read and understand the above information, and that I agree to 
participate in this study.
Witnes Signatme DXTE
loveadgator Signature u À lk
Patddpant Signatme U A lb
Legal Gaandan Signatme (if under 18) U A tk
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UPPER EXTREMITY DATA COLLECTION FORM
DATE
TEST
Mod. Ash. 
Shldr. Flex
Shidr. Ext
Shldr. Abd.
Shldr. Add.
Shldr. IR
Shldr. ER
Elbow flex.
Elbow ext
Supination.
Pronation
Wrist flex
Wrist ext
Shoulder A 
Flexion P
Shoulder A 
Extension P
Shoulder A 
Abduction P
Shoulder A 
Adduction P
Shoulder A 
Internal Rot. P
Shoulder A 
External Rot P
Elbow A 
Flexion P
Elbow A 
Extension P
Supination A 
P
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Pronation A 
P
W rist A 
Flexion P
W rist A 
Extension P
FIM-bed
transfer
toilet transfer
W alking
Stairs
Nine Hole Peg 
Test (sec.)
APPENDIX I
LOWER EXTREMITY DATA COLLECTION FORM
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LOWER EXTREMITY DATA COLLECTION FORM
DATE
TEST
Mod. Ash. 
Hip flex.
Hip ext
Hip abd.
Hip add.
HipIR
HipER
Knee flex.
Knee ext
Ankle PF
Ankle DF
Ankle IV
Ankle EV
Hip A 
Flexion P
Hip A 
Extension P
Hip A 
Abduction P
Hip A 
Adduction P
Hip A 
Internal Rot P
Hip A 
External Rot. P
Knee A 
Flexion P
Knee A 
Extension P
lis
Ankle A 
Dorsiflexion P
Ankle A 
PlantaiflexionP
Ankle A 
Inversion P
Ankle A  
Eversion P
FIM-bed
transfer
toilet transfer
Walking
Stairs
Footprint-
velocity
(cm/sec)
Cadence
(steps/min)
Stride length R 
(cm) L
Step length R 
(cm) L
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DESCRIPTIVE DATA COLLECTION FORM 
FIRST DAY OF DATA COLLECTION
Past Medical History: 
Surgeries:
Medications:
Other current medical treatment: 
Previous treatments for spasticity:
Reason why target muscle(s) was/were chosen:
Objective Findings:
Activities o f Daily Living (ADL’s):
PT interventions:
• Frequency
• Duration
•  Treatment given:
APPENDIX K
DESCRIPTIVE DATA COLLECTION FORM
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DESCRIPTIVE DATA COLLECTION FORM
Objective Findings (since last data collection): 
Activities o f Daily Living (ADL’s):
PT interventions:
•  Frequency
•  Duration
•  Treatment given:
Other:
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Table 1
FIM Inter- and Intra-Tester Reiiabilitv 
Pilot Study
Inter-tester
Subscores Intra-tester reiiabilitv reliability
Kendall’s 
CH T=
T
n MAx= n
Kendall’s r  
r= n
Bed transfer 1.0 6 1.0 4 1.0 3
Stairs * I * 0 * 0
Walking 1.0 3 1.0 4 1.0 2
Toilet transfer 1.0 2 * 1 * 0
* small sample size prevented statistical analysis
** tied ranks prevented statistical analysis
Negative (-) represents inverse relationships between data sets
Bold represents statistically significant results (a  = 0.05)
APPENDIX M
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m o d ifie d  ASHWORTH SCALE 
INTER- AND INTRA-TESTER RELIABILITY 
PILOT STUDY
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Table 2
Modified Ashworth Scale Inter- and Intra-tester Reliability
126
Pilot Study
Joint action
Intra-tester reiiabilitv 
Kendall’s r
CHx= n MA x= n
Inter-tester 
reiiabilitv 
Kendall’s  r
r= n=
Shoulder Flexion ** 6 1.0 6 ** 5
Shoulder Extension 1.0 6 1.0 6 0.707 5
Shoulder Abduction 1.0 7 1.0 6 0270 6
Shoulder Adduction 1.0 7 1.0 6 0.087 6
Shoulder Internal Rotation 1.0 7 1.0 5 0.707 5
Shoulder External Rotation 1.0 7 1.0 5 -0.408 5
Elbow Flexion 1.0 7 1.0 7 0.125 7
Elbow Extension 1.0 7 0.920 6 0.740 6
Supination 1.0 3 ** 4 ** 2
Pronation $* 5 1.0 3 ** 3
Wrist Flexion 1.0 5 1.0 5 0.548 4
Wrist Extension 1.0 6 1.0 6 0.359 5
Hip Flexion ** 2 1.0 3 $* 2
Hip Extension ** 2 1.0 3 ** 2
Hip Abduction ** 2 ** 2 ♦ 1
Hip Adduction 1.0 2 1.0 3 1.0 2
Hip Internal Rotation 1.0 2 1.0 3 -1.0 2
Hip External Rotation 1.0 2 1.0 2 -1.0 2
Knee Flexion ** 2 1.0 3 ** 2
Knee Extension ** 2 $* 3 ** 2
Dorsifiexion ** 3 1.0 4 ** 3
Plantarflexion 1.0 3 1.0 4 0.00 3
Ankle Inversion 1.0 3 1.0 4 1.0 3
Ankle Eversion 1.0 3 ** 3 ** 2
* small sample size prevented statistical analysis
** tied ranks prevented statistical analysis
Negative (-) represents inverse relationships between data sets
Bold represents statistically significant results (a  = 0.05)
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Table 3
Active Range of Motion Measurements Inter- and Intra-tester Reiiabilitv
Pilot Study
Joint Motions Intra-tester reliability 
Spearman’s rho
Inter-tester 
reliability 
ICC (MEAN)
CH r= n= MA r= n= r= n=
Shoulder Flexion 1.0 4 1.0 4 0.96846 4
Shoulder Extension 1.0 5 ** 4 ** 4
Shoulder Abduction 0.900 5 0.800 4 0.65346 4
Shoulder Adduction ** 4 ** 3 ** 3
Shoulder Internal Rotation ** 4 ** 4 ** 4
Shoulder External Rotation 1.0 4 1.0 4 0.87199 3
Elbow Flexion 1.0 4 1.00 5 0.97465 4
Elbow Extension 1.0 4 0.400 4 0.90759 4
Supination $* 2 1.0 3 ** 2
Pronation 1.00 2 1.0 3 0.98688 2
Wrist Flexion 0J16 4 0.949 4 0.14324 4
Wrist Extension 0.8 4 1.0 4 0.27670 4
Ulnar deviation ** 2 1.00 3 ** 2
Radial deviation ** 2 1.0 3 ** 2
* small sample size prevented statistical analysis
** tied ranks prevented statistical analysis
Negative (-) represents inverse relationships between data sets
Bold represents statistically significant results (a  = 0.05)
APPENDK O  
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INTRA- AND INTER-TESTER RELIABILITY 
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Table 4
Passive Range of Motion Measurements Intra- and Inter-tester Reiiabilitv
Pilot Study
Joint Motions Intra-tester reiiabilitv
Spearman’s rho
CH p= n= MA r= n=
Inter-tester 
reliability 
ICC (MEAN) 
r= n=
Shoulder Flexion -0.100 5 0.975 5 0.66935 5
Shoulder Extension 1.0 6 * * 5 ** 5
Shoulder Abduction 0.943 6 0.667 5 0.82186 5
Shoulder Adduction * * 5 * * 5 ** 5
Shoulder Internal Rotation 1.0 5 1.0 5 0.98531 5
Shoulder External Rotation 1.0 5 1.0 5 0.82455 5
Elbow Flexion 1.0 5 1.0 5 ** 5
Elbow Extension 0.821 5 1.0 5 0.77816 5
Supination 1.0 2 0.866 3 * 2
Pronation -1.0 2 1.0 3 ** 2
Wrist Flexion 0.6 4 0.949 4 0.062730 4
Wrist Extension 1.0 4 0.800 4 ♦ 4
Ulnar deviation 1.0 2 0.000 3 0.73140 2
Radial deviation 1.0 2 0.500 3 0.62149 2
* small sample size prevented statistical analysis
** tied ranks prevented statistical analysis
Negative (-) represents inverse relationships between data sets
Bold represents statistically significant results (a  = 0.05)
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Tables
Footprint Analysis and Nine Hole Peg Test Inter- and Intra-tester Reiiabilitv
Pilot Study
Measurements
Intra-tester reiiabilitv 
Spearman’s  p
CH  p= n= M Ap=
Inter-tester 
reliability ICC
n= r= n==
Velocity 0220 10 -0.163 10 0.94464 10
Cadence 0220 10 -0301 10 0.77188 10
Right stride -0.570 10 0238 10 0.99840 10
Right step -0.063 10 -0394 10 0.99974 10
Left stride -0.118 10 -0340 10 0.99617 10
Left step 0384 10 -0.131 10 0.99655 10
Nine Hole Peg -0.162 10 -0.580 10 0.95941 10
* small sample size prevented statistical analysis
** tied ranks prevented statistical analysis
Negative (-) represents inverse relationships between data sets
Bold represents statistically significant results (a  = O.OS)
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Table 6
Modified Ashworth Score Test-retest Reliability 
Preliminary Study
Joint Action
Researcher CH 
r ,=  n=
Researcher MA 
r, = n=
Shoulder Flexion 1.00 4 ** 3
Shoulder Extension ** 4 0.500 3
Shoulder Abduction ** 4 0.866 3
Shoulder Adduction ** 4 ** 3
Shoulder Internal Rotation 1.00 4 ** 3
Shoulder External Rotation 1.00 4 0.866 3
Elbow Flexion ** 4 0.866 3
Elbow Extension 1.0 4 0.866 3
Supination 0.943 4 1.0 3
Pronation ** 4 $* 3
Wrist Flexion ** 4 0.866 3
Wrist Extension 1.00 4 1.00 3
* small sample size preyented statistical analysis
** tied ranks preyented statistical analysis
Negatiye (-) represents inyerse relationships between data sets
Bold represents statistically significant results (a  = O.OS)
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T able?
Active Range o f  Motion Measurements Test-retest Reliability 
Preliminary Study
Joint Motions
CH = r, 
n=
n= M Ar, =
Shoulder Flexion 0.400 4 1.00 3
Shoulder Extension ** 4 *$ 3
Shoulder Abduction 0.500 4 1.00 3
Shoulder Adduction ** 4 *$ 3
Shoulder Internal Rotation 0.400 4 0.500 3
Shoulder External Rotation 1.00 4 0.500 3
Elbow Flexion 1.0 4 0.00 3
Elbow Extension ** 4 0.500 3
Supination 0.632 4 0.500 3
Pronation 0272 4 1.0 3
Wrist Flexion 0316 4 -0.500 3
Wrist Extension 0.800 4 0.00 3
* small sample size prevented statistical analysis
** tied ranks prevented statistical analysis
Negative (-) represents inverse relationships between data sets
Bold represents statistically significant results (a  = O.OS)
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Table 8
Passive Ranee of Motion Measurements Test-retest Reliability 
Preliminary Study
Joint Motions C H r,=
n=
n= M A r,=
Shoulder Flexion 1.00 4 1.00 3
Shoulder Extension ** 4 ** 3
Shoulder Abduction 0.800 4 1.00 3
Shoulder Adduction ** 4 ** 3
Shoulder Internal Rotation 0.600 4 1.00 3
Shoulder External Rotation 0.775 4 1.00 3
Elbow Flexion 1.00 4 -0.866 3
Elbow Extension ** 4 0.500 3
Supination 0.632 4 1.00 3
Pronation ** 4 0.500 3
Wrist Flexion 0J33 4 -0.500 3
Wrist Extension 1.00 4 0.500 3
* small sample size prevented statistical analysis
** tied ranks prevented statistical analysis
Negative (-) represents inverse relationships between data sets
Bold represents statistically significant results
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TEST
Subject 1 
Trial 1 Trial 2
Subject 2 
Trial 1 Trial 2
Subject 3 Subject 4
Trial 1 Trial 2 Trial 1 Trial 2
M - Shldr. Flex 0 0 — — ---- ---- 0 0
M - Shldr. E x t 0 0 — — ---- ---- 1 1
M - Shldr. Abd. 0 0 0 0 ---- 0 0
M - Shldr. Add. 0 0 2 2 -------- -------- 1 1
M - Shldr. IR 0 0 2 2 --------- ---- 1 1
M - Shldr. ER 0 0 0 0 ---- —- 1 1
M - Elbow flex. 1 1 3 3 — ---- 1.5 1.5
M - Elbow e x t 0 0 3 3 ---- ---- 0 0
M - Supination. — — 1 1 — — ---- — —
M - Pronation 0 0 0 0 - - - - ---- 0 0
M - W rist flex 1 1 — — ---- ---- 0 0
M - W rist ext. 3 3 4 4 ---- ---- 0 0
Shoulder A 88 88 — ---- —— ---- 114 110
Flexion P 120 120 — ---- - - - - ---- 110 110
Shoulder A 0 0 — ---- ---- ---- 0 0
Extension P 0 0 — --------- --------- --------- 0 0
Shoulder A 72 76 — — — --------- -------- 74 75
Abduction P 89 88 — --------- --------- -------- 80 82
Shoulder A 0 0 — — --------- -------- 0 0
Adduction P 0 0 — — --------- --------- 0 0
Shoulder A 70 89 — — --------- —— — 70 70
Internal Rot. P 84 85 — -------- 70 70
Shoulder A 11 10 — --------- -------- 27 25
External Rot. P 20 28 — --------- --------- --------- -8 -8
Elbow A 114 116 — --------- --------- --------- 122 124
Flexion P 122 124 — _ _ _ _ --------- 135 145
Elbow A -32 -29 — --------- --------- -------- -35 -33
Extension P -17 -14 — --------- --------- -------- -15 -9
Supination A 0 0
P 2 5
M = Modified Ashworth Scale 
A = Active Range of Motion 
P = Passive Range of Motion 
—  = data not collected
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TEST
Subject 5 Subject 6 Subject 7 Subject 8
Trial 1 Trial 2 Trial 1 Trial 2 Trail I Trial 2 Trial 1 Trial 2
M- Shldr. Flex 0 0 0 0 0 0 0 0
M- Shldr. Ext. 0 0 0 0 1 1 1.5 1.5
M- Shldr. Abd. 1 1 0 0 0 0 1 1
M- Shldr. Add. 0 0 1 1 0 0 0 0
M- Shldr. IR 0 0 1 1 0 0 0 0
M- Shldr. ER 0 0 1 1 0 0 1 1
M- Elbow flex. 1.5 1.5 1.5 1.5 1.5 1.5 2 2
M- Elbow ext. 0 0 0 0 0 0 2 2
M- Siq>ination. 0 0 — — — — — 0 0
M- Pronation 0 0 — --------- — — 6 0
M- W rist flex 0 0 1 1 — — 2 2
M- W rist e x t 0 0 0 0 — — 0 0
Shoulder A 0 0 124 132 — --------- --------
Flexion P 150 93 143 143 118 125 --------- --------
Shoulder A 0 0 0 0 — — 171 173
Extension P 0 0 0 0 0 0 173 171
Shoulder A 79 78 120 120 — — 123 125
Abduction P 95 96 132 140 90 91 145 135
Shoulder A 0 0 0 0 — — — —
Adduction P 0 0 0 0 0 0 — —
Shoulder A 70 70 70 70 — — — —
Internal Rot. P 70 70 70 70 70 70 — —
Shoulder A 0 0 48 46 — — — —
External R o t P 19 24 44 41 38 39 — —
Elbow A 67 62 145 145 — — — —
Flexion P 145 145 145 145 140 140 — —
Elbow A -50 -45 0 0 — — — —
Extension P -15 -17 0 0 14 10 — —
Supination A 0 0
P 45 55
M = Modified Ashworth Scale 
A = Active Range of Motion 
P = Passive Range of Motion 
—  = data not collected
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Subject 1 Subject 2 Subject 3 Subject 4
Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2
A =  =  =  =  —  =  73 70“
P —  —  —  —  —  —  75 70
A 45 62 —  —  —  —  50 45
P 68 60 —  —  —  —  65 70
A 15 16 —  —  —  —  40 15
P 42 35 —  —  —  —  71 71
A —  —  —  —  —  —  0 0
P —  —  —  —  —  —  15 22
A —  —  —  —  —  —  0 5
P —  —  —  —  —  —  15 10
4 4 —  —  1 1 1 1
—  —  —  —  —  —  1 1
6 6 1 1 —  —  —  —
Pronation
W rist 
Flexion
W rist 
Extension 
Ulnar 
Deviation
Radial 
Deviation
FIM-bed
transfer
FIM -toilet
transfer
FIM-walking
FIM-stairs
M = Modified Ashworth Scale
A = Active Range o f Motion
P = Passive Range o f Motion
FIM = Functional Independence Measurement
—  = data not collected
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TEST
Subject 5 
Trial 1 Trial 2
Subject 6 
Trial 1 Trial 2
Subject 7 
Trial 1 Trial 2
Subject 8 
Trial 1 Trial 2
Pronation A 0 0
P 90 0
W rist A 0 0 50 50 — ----- ---- —
Flexion P 85 90 90 85 _ _ _ _ _ _ _ _ — —
W rist A 0 0 50 45 ----- ----- --------- --------
Extension P 35 33 75 80 --------- --------- ---------
Ulnar A 0 0
Deviation P 27 33
Radial A 0 0
Deviation P 30 35
FIM-bed 2 2 7 7 4 4 7 - - - -
transfer
FIM -toilet 7 7 6
transfer
FIM-walking _ _ _ _ --------- 7 7 _ _ _ _ _ _ _ _ 6 _ _ _ _
FIM-stairs --------- --------- 7 7 --------- --------- — --------
M = Modified Ashworth Scale
A = Active Range of Motion
P = Passive Range o f Motion
FIM = Functional Independence Measurement
—  = data not collected
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TEST
Subject 1 Subject 2 Subject 3
Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2
Subject 4 
Trial 1 Trial 2
M - Shldr. Flex 1 1 3 3 — — 0 0
M - Shldr. E x t 0 0 3 3 — — 0 0
M - Shldr. Abd. 1 1 0 0 — — 0 0
M - Shldr. Add. 0 0 4 4 — — 0 0
M - Shldr. IR 0 0 3 3 — — 0 0
M - Shldr. ER 0 0 0 0 — — 0 0
M - Elbow flex. 2 2 3 3 — — 1 1
M - Elbow e x t 1.5 1.5 3 3 — — 0 0
M - Supination. 0 0 0 0 — — 0 0
M - Pronation — — 0 0 — — 0 0
M - W rist flex 3 3 — — — — 0 0
M - W rist e x t 3 3 4 4 — — 0 0
Shoulder A 70 65 ———— — — — 145 145
Flexion P 83 82 — — — — 70 82
Shoulder A 0 0 — - - - - — — 0 0
Extension P 0 0 — — — ———— — 0 0
Shoulder A 68 67 — — — 75 80
Abduction P 80 79 — — — — 83 79
Shoulder A 0 0 — — — — 0 0
Adduction P 0 0 — ----------- — — 0 0
Shoulder A 70 70 — — — — 70 70
Internal Rot. P 89 88 __ ___ — — — 70 70
Shoulder A 31 32 — — — — -25 -28
External Rot. P 6 6 ■■■■ — — — -7 -13
Elbow  A 115 114 — — — — 145 145
Flexion P 153 153 — — — — - 145 145
Elbow  A -44 -50 — — — — -27 31
Extension P -25 -25 --------- — — — 0 0
Siq>ination A 20 30 --------- — — — 10 10
P 20 18 --------- — — — 20 22
M = Modified Ashworth Scale 
A = Active Range of Motion 
P = Passive Range of Motion 
—  = data not collected
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Subject 5 Subject 6 Subject 7 Subject 8
TEST Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2
M - Shldr. Flex — — 0 0 0 0 0 0
M - Shldr. E xt — —— 0 0 0 0 2 2
M - Shldr. Abd. — — 1.5 1.5 0 0 1 1
M - Shldr. Add. — — 0 0 2 2 1.5 1.5
M- Shldr. IR — — 0 0 0 0 — —
M - Shldr. ER — — 0 0 1 1 — —
M - Elbow flex. 1.5 1.5 1.5 1.5 12 2 1.5 1.5
M - Elbow ext. — — 0 0 1.5 1 1.5 1.5
M - Supination. 0 0
M - Pronation 6 6
M - W rist flex — — 1 1 0 0 1.5 1.5
M - W rist ext. — — 1.5 1.5 0 0 6 6
Shoulder A 0 0 119 125 — --------- ---------
Flexion P 90 91 132 140 105 115 -------- ---------
Shoulder A 0 0 0 0 — — -------- ---------
Extension P 0 0 0 0 0 0 — —
Shoulder A 0 0 119 107 — — --------- ---------
Abduction P 97 102 107 106 75 80 -------- ---------
Shoulder A --------- — 0 0 — — -------- ---------
Adduction P 0 0 0 0 0 0 — —
Shoulder A 70 70 70 70 — -------- ---------
Internal R o t P 70 70 70 70 70 70 -------- —
Shoulder A 0 0 90 90 — — -------- ---------
External Rot. P 25 28 90 90 40 45 -------- ---------
Elbow A 60 59 145 145 90 90 -------- ---------
Flexion P 145 145 145 145 145 145 -------- ——" —
Elbow A -25 -45 0 0 — — -------- —
Extension P -20 -21 0 0 -18 -20 -------- —
Supination A 0 0
P 45 37
M = Modified Ashworth Scale 
A = Active Range of Motion 
P = Passive Range o f Motion 
—  = data not collected
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Subject 1 
Trial I Trial 2
Subject 2 
Trial 1 Trial 2
Subject 3 
Trial 1 Trial 2
Subject 4 
Trial 1 Trial 2
Pronation A 71 81 ■■ — — — — 90 90
P 80 76 ---------- — — — 90 90
W rist A -20 -5 ---------- — — 37 37
Flexion P 21 17 ■ ■■I» ———— — — — 45 55
W rist A 52 52 ---------- — — — 43 35
Extension P 64 77 ---------- — — — 57 46
Ulnar A 17 15 — —— — — — 0 0
Deviation P 15 25 ---------- — — — 25 25
Radial A 22 23 — — — 0 0
Deviation P 31 26 — — — — 14 18
FIM -bed
transfer
4 4 — — — 1 1 — —
FIM -toilet
transfer
FIM -walking 6 6 1 1 — — — —
FIM -stairs
M = Modified Ashworth Scale
A = Active Range of Motion
P = Passive Range of Motion
FIM = Functional Indepedence Measurement
—  = data not collected
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TEST
Subject 5 
Trial 1 Trial 2
Subject 6 
Trial 1 Trial 2
Subject 7 
Trial 1 Trial 2
Subject 8 
Trial 1 Trial 2
Pronation A 0 0
P 90 90
W rist A 0 0 0 1 --------- ---- -----
Flexion P 45 60 20 15 _ _ _ _
W rist A 0 0 16 15 ---- ----- -------- ---------
Extension P 30 42 35 35 — -------- -----
Ulnar A 0 0
Deviation P 22 35
Radial A 0 0
Deviation P 24 17 —
FIM-bed
transfer
— — — — 4 4 7 7
FIM -toilet
transfer
6 6
FIM -walking — — — — 1 1 6 6
FIM -stairs
M = Modifîed Ashworth Scale
A = Active Range o f Motion
P = Passive Range of Motion
FIM = Functional Independence Measurement
—  = data not collected
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Subject 1 Subject 2 Subject 3 Subject 4
TEST Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2
M- Hip flex. — — —  — 0 0 —  —
M- Hip e x t — — —  — 0 0 —  —
M- Hip abd. — — —  _ 0 0 - —  —
M- Hip add. — — —  — -  1.5 1.5 —  —
M -H ipIR — — —  _ 0 0 —  — —
M- Hip ER — — —  _ 2 2 — —
M- Knee flex. — — —  _ 0 0 —  —
M- Knee e x t — — —  _ 0 0 —  —
M- Ankle PF — — —  _ 0 0 —  —
M- Ankle DF — — —  _ 0 0 ~ —  —
M- Ankle IV — — —  _ 0 0 - —  —
M- Ankle EV ______ _____ 0 0 __  —
Hip A
Flexion P
Hip A
Extension P
Hip A
Abduction P
Hip A
Adduction P 
Hip A
Internal R o t P 
Hip A
External Rot. P 
Knee A
Flexion P
Knee A
Extension P
M = Modified Ashworth Scale 
A = Active Range of Motion 
P = Passive Range o f Motion 
—  = no data collected
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Subject 5 Subject 6 Subject 7 Subject 8
TEST Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2
M- H ip flex. —  —  —  —  —  —  0 0
M- H ip e x t —  —  —  —  —  —  0 0
M- H ip abd. —    —  —  —  —  0 0
M- H ip add. —  —  —  —  —  —  0 0
M -H ip IR  —  —  —  —  —  —  1 1
M- H ip ER —  —  —  —  —  —  0 0
M- Knee flex. —  —  —  —  —  —  0 0
M- Knee ext. —  —  —  —  —  —  0 0
M- Ankle PF —  —  2 2 —  —  6 6
M -A nkle DF —  —  0 0 —  —  0 0
M- Ankle IV —  —  1 1 —  —  6 6
M- Ankle EV —  —  1 1 —  —  0 0
Hip A —  —  —  —  —  —  —  —
Flexion P —  —  —  —  95 95 —  —
Hip A —  —  —  —  —  — 175 173
Extension P —  —  —  —  0 0 175 176
Hip A —  —  —  —  —  —  65 82
Abduction P —  —  —  —  10 13 60 58
Hip A —  —  —  —  —  —  —  —
Adduction P —  —  —  —  10 10 —  —
Hip A —  —  —  _ _ _  —  —  —
Internal R o t P —  —  —  —  30 28 —  —
Hip A —  —  —  —  —  —  —  —
External Rot. P —    —  —  27 29 —  —
Knee A —  —  —  —  —  —  —  —
Flexion P —  —  —  —  80 85 —  —
Knee A —  —  —  —  —  —  —  —
Extension P —  —  —  —  0 0 —  —
M = Modified Ashworth Scale 
A = Active Range of Motion 
P = Passive Range o f Motion 
—  = no data collected
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Subject 1 
Trial 1 Trial 2
Subject 2 
Trial 1 Trial 2
Subject 3 
Trial 1 Trial 2
Subject 4 
Trial 1 Trial 2
Ankle A
Doisiflexion P
Ankle A
PlantarflexionP
Ankle A
Inversion P
Ankle A
Eversion P
FIM-bed 4 4 — — 1 I 1 1
transfer
FIM -toilet 1 I
transfer
FIM-walking 6 6 1 1 — __ _____ — —
FIM -stairs
TEST
Subject 5 
Trial 1 Trial 2
Subject 6 
Trial 1 Trial 2
Subject 7 
Trial 1 Trial 2
Subject 8 
Trial 1 Trial 2
Ankle A  — ----- 9 5 ----- ----- — —
Dorsiflexion P — — 9 9 — » . . . . —
Ankle A — ---- 30 45 ----- ----- — —
PlantarflexionP — ---- 33 35 ----- ----- — —
Ankle A  — ----- 14 18 ----- ----- — —
Inversion P — ---- 14 18 ----- — — ———
Ankle A  — ---- 15 15 ----- ---- — -----
Eversion P — ----- 34 29 ----- ———— — ----
FIM-bed 2 2 7 7 4 4 7 ----
transfer
FIM -toilet 7 7 6
transfer
FIM-walking 7 7 . . . . ___ 6
FIM-stairs ----- ---- 7 7 ----- — — ----
M = Modified Ashworth Scale
A = Active Range of Motion
P = Passive Range o f Motion
FIM = Functional Independence Measurement
—  = no data collected
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LOWER EXTREM ITY DATA COLLECTION
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TEST
Subject 1 
Trial 1 Trial 2
Subject 2 
Trial 1 Trial 2
Subject 3 
Trial 1 Trial 2
Subject 4 
Trial 1 Trial 2
M- Hip flex. —  — — ------ 0 0 — —
M- Hip ext. —  — — — 0 0 — —
M- Hip abd. —  — —- — 0 0 — —
M- Hip add. —  — — — 3 3 — —
M -H ipIR —  — — — 2 2 — —
M- H ipER —  — — — 1 1 — —
M- Knee flex. —  — — — 3 3 — —
M- Knee e x t —  — — — 0 0 — —
M- Ankle PF —  — — — 0 0 — —
M- Ankle DF —  — — — 0 0 — —
M -A nkle IV —  — — — 0 0 — —
M- Ankle EV —  ■ — — — 0 0 — —
Hip A
Flexion P
Hip A
Extension P
Hip A
Abduction P
Hip A
Adduction P 
Hip A
Internal R o t P 
Hip A
External R o t P 
Knee A
Flexion P
Knee A
Extension P
M = Modified Ashworth Scale 
A = Active Range of Motion 
P = Passive Range of Motion 
—  = no data collected
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Subject 5 Subject 6 Subject 7 Subject 8
TEST Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2
M -H ip flex. —  —  —  —  1.5 1.5 0 0
M- Hip e x t —  —  —  —  2 2 0 0
M- Hip abd. —  —  —  —  0 0 —  —
M- Hip add. —  —  —  —  0 0 0 0
M -H ip IR  —  —  —  —  0 0 0 0
M- Hip ER —  —  —  —  —  —  2 2
M- Knee flex. —  —  —  —  0 0 0 0
M- Knee e x t —  —  —  —  0 0 0 0
M -A nkle PF —  —  2 2 3 3  0 0
M -A nkle DF —  —  0 0 0 0  6 6
M -A nkle IV —  —  2 2 0 0  6 6
M -A nkle EV —  —  —  —  0 0 0 0
Hip A —  —  —  —  80 87 —  —
Flexion P —  —  —  —  125 125 —  —
Hip A —  —  —  —  —  —  —  —
Extension P _________________        0 0  —
Hip A —  —  —  —  15 15 —  —
Abduction P —  —  —  —  20 13 —  —
Hip A —  —  —  —  —  —  —  —
Adduction P —  —  —  —  10 10 —  —
Hip A —  —  —  —  —  —  —  —
Internal Rot. P —  —  —  —  20 15 —  —
Hip A —  —  —  — --------------- —  —  —
External R o t P _________    24 24 —    —  —
Knee A —  —  76 83 —  —  —— —
Flexion P —  —  74 76 —  —  —  —
Knee A —  —  -10 -3 —  —— —  —
Extension P —  —  -3 -10 —  —  —  —
M = Modified Ashworth Scale 
A = Active Range o f Motion 
P = Passive Range of Motion 
—  = no data collected
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TEST
Subject 1 
Trial 1 Trial 2
Subject 2 
Trial 1 Trial 2
Subject 3 
Trial 1 Trial 2
Subject 4 
Trial 1 Trial 2
Ankle A
Dorsiflexion P
Ankle A
PlantarflexionP
Ankle A
Inversion P
Ankle A
Eversion P
FIM-bed
transfer
FIM -toilet
transfer
FIM -walking
FIM -stairs
TEST
Subject 5 
Trial 1 Trial 2
Subject 6 
Trial 1 Trial 2
Subject 7 
Trial 1 Trial 2
Subject 8 
Trial 1 Trial 2
Ankle A — —  17 20 ---- — — — —
Dorsiflexion P — —  20 20 ---- — —
Ankle A — —  30 28 ---- — — ----
PlantarflexionP — —  35 36 ---- — — ——
Ankle A — —  34 39 ---- — — ----
Inversion P — —  15 20 — — — ----
Ankle A — —  35 24 ---- — — ----
Eversion P — —  24 24 ---- — — ----
FIM-bed
transfer
— - —  — -------- 4 4 7 7
FIM -toilet
transfer
FIM -walking -------- —  — — -------- 1 1 6 6
FIM -stairs
M = Modified Ashworth Scale
A = Active Range o f Motion
P = Passive Range of Motion
FIM = Functional Independence Measurement
—  = no data collected
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FOOTPRINT ANALYSIS AND NINE HOLE PEG TEST 
INTRA-TESTER RELIABILITY RESEARCHER CH 
PILOT STUDY UNINVOLVED SUBJECTS
TEST
Day 1 Day 1 Day 1
Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 Trial 6
Day 1 
Trial 7 Trial 8
Footprint-
velocity 129.15 135.77 131.66 135.77 13427 135.17 136.99 133.68
(cm/sec)
Cadence
(steps/min) 101.69 106.90 103.67 106.90 105.73 106.43 107.87 105.26
Stride length R 142.23 142.37 142.20 142.47 14223 142.40 142.33 142.40
(cm) L 141.25 141.15 141.25 141.20 141.15 141.30 141.25 141.10
Step length R 72.18 72.23 72.23 72.10 72.18 72.15 72.18 72.18
(cm) L 69.40 69.27 69.27 69.30 69.30 69.27 69.30 69.27
Nine Hole Peg 17.04 17.06 17.00 17.02 17.02 17.06 16.99 17.00
test (sec.)
TEST
Day 1 
Trial 9 Trial 10
Day 2 
Trial 1 Trial 2
Day 2 
Trial 3 Trial 4
Day 2 
Trial 5 Trial 6
Footprint-
velocity 133.98 134.87 131.95 133.10 133.68 132.81 131.66 134.27
(cm/sec)
Cadence
(steps/min) 105.49 106.19 103.90 104.80 10526 104.58 103.67 105.73
Stride length R 142.33 142.27 142.13 142.10 142.13 141.97 142.03 141.93
(cm) L 140.20 141.25 140.87 140.80 140.73 140.77 140.83 140.83
Step length R 72.15 72.18 72.23 72.33 72.23 72.30 72.28 72.25
(cm) L 69.30 69.33 69.20 69.07 69.27 69.13 69.13 69.10
Nine Hole Peg 17.03 17.02 17.22 17.31 17.31 17.28 17.30 17.26
test (sec.)
All data collection evaluated subject #5
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TEST
Day 2 
Trial 7 Trial 8
Day 2 
Trial 9 Trial 10
Footprint-
velocity 135.47 134.57 134.57 134.27
(cm/sec)
Cadence
(steps/min) 106.67 105.96 105.96 105.73
Stride length R 142.13 141.90 142.13 141.93
(cm) L 140.80 140.73 140.93 140.73
Step length R 72.30 72.25 72.28 72.35
(cm) L 69.33 69.17 69.17 69.23
N ine Hole Peg 17.21 17.39 17.28 17.36
test (sec.)
AU data coUection evaluated subject #5
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INTRA-TESTER RELIABILITY RESEARCHER MA
PILOT STUDY UNINVOLVED SUBJECTS
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FOOTPRINT ANALYSIS AND NINE HOLE PEG TEST
INTRA-TESTER RELIABILITY RESEARCHER MA
PILOT STUDY UNINVOLVED SUBJECTS
Day 1 Day 1 Day 1 Day 1
TEST Trial 1 T rial2 T ria l3 T ria l4  T ria ls  T ria l6 T ria l?  Trial 8
Footprint-
velocity 137.61 139.82 134.57 137.92 136.07 134.27 135.47 133.98
(cm/sec)
Cadence
(steps/min) 121.90 110.09 105.96 108.60 103.39 105.73 106.67 105.49
Stride length R 141.67 114.70 141.93 141.83 141.73 141.73 141.80 141.97
(cm) L 141.80 142.35 141.80 141.95 142.18 141.98 141.93 141.90
Step length R 72.20 72.40 72.40 72.53 72.40 72.50 72.45 72.38
(cm) L 69.35 69.83 69.63 69.65 69.58 69.55 69.80 69.87
Nine Hole Peg 17.46 17.31 17.28 17.29 17.29 17.22 1727 1729
test (sec.)
TEST
Day 1 
Trial 9 Trial 10
Day 2 
Trial 1 Trial 2
Day 2 
Trial 3 Trial 4
Day 2 
Trial 5 Trial 6
Footprint-
velocity 136.38 135.17 136.38 137.61 136.85 136.85 136.85 136.85
(cm/sec)
Cadence
(steps/min) 107.38 106.43 107.38 108.35 108.11 108.11 108.11 108.11
Stride length R 141.93 141.60 140.00 142.00 143.57 141.60 140.90 141.03
(cm) L 142.08 142.33 142.73 142.10 142.33 141.90 140.9 141.03
Step length R 72.58 72.38 72.38 71.48 72.25 71.08 71.68 72.95
(cm) L 69.65 69.70 69.90 69.58 69.70 69.70 69.73 69.58
Nine Hole Peg 17.19 17.13 17.19 17.20 17.00 17.26 17.29 17.40
test (sec.)
All data coUection evaluated subject #5
1 6 2
Day 2 Day 2
TEST T ria l?  Trial 8 Trial 9 Trial 10
Footprint-
velocity 134.87 137.61 136.07 136.99
(cm/sec)
Cadence
(steps/min) 106.19 108.35 107.14 107.87
Stride length R 141.07 141.87 142.77 141.90
(cm) L 142.13 141.58 141.50 142.03
Step length R 72.45 73.48 72.35 73.15
(cm) L 69.98 69.50 68.75 69.88
Nine Hole Peg 17.30 17.34 17.40 1129
test (sec.)
All data collection evaluated subject #5
APPENDIX Z
FOOTPRINT ANALYSIS AND NINE HOLE PEG TEST
INTER-TESTER RELIABILITY
PILOT STUDY UNINVOLVED SUBJECTS
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FOOTPRINT ANALYSIS AND NINE HOLE PEG TEST
INTER-TESTER RELIABILITY
PILOT STUDY UNINVOLVED SUBJECTS
TEST
Subject I Subject 2 Subject 3 Subject 4
Tester Tester Tester Tester Tester Tester Tester Tester
CH MA CH MA CH MA CH MA
Footprint-
velocity
(cm/sec)
Cadence
117.91 115.45 123.15 120.24 97.69 100.43 118.83 120.95
(steps/m in) 104.45 102.27 109.09 106.51 105.77 108.73 105.26 107.14
Stride length R 134.30 134.17 130.37 130.33 113.63 113.55 144.27 144.23
(cm) L 134.48 134.55 130.30 130.13 112.40 114.4 142.03 141.83
Step length R 67.10 67.15 64.63 64.50 55.50 55.56 71.28 71.15
(cm) L 67.30 67.10 65.45 6525 56.76 56.90 70.53 71.63
N ine Hole Peg 
test (sec.)
17.75 18.19 16.02 16.40 15.94 16.27 14.98 15.04
Subject 5 Subject 6 Subject 7 Subject 8
TEST Tester Tester Tester Tester Tester Tester Tester Tester
CH MA CH MA CH MA CH MA
Footprint-
velocity 130.54 137.61 136.99 137.61 125.69 129.98 125.95 119.76
(cm/sec)
Cadence
(steps/min) 102.78 105.73 107.87 102.35 111.34 106.09 111.57 114.16
Stride length R 142.13 141.67 150.87 149.07 133.45 133.40 134.27 134.27
(cm) L 140.87 141.80 149.20 151.00 136.57 136.77 133.78 133.45
Step length R 72.23 72.20 75.13 75.35 65.83 66.05 67.50 67.38
(cm) L 69.20 69.35 65.25 73.87 56.90 67.38 71.63 66.05
N ine Hole Peg 17.03 17.46 17.46 17.67 17.23 17.84 13.77 14.19
test (sec.)
165
Subject 9 Subject 10
TEST Tester Tester Tester Tester
CH MA CH MA
Footprint-
velocity 112.39 119.53 151.64 152.40
(cm/sec)
Cadence
(steps/min) 100.00 105.88 119.40 120.00
Stride length R 141.35 141.35 147.33 147.13
(cm) L. 143.13 143.13 147.70 147.13
Step length R 71.25 71.33 72.78 72.85
(cm) L• 70.13 69.80 74.27 73.80
Nine Hole Peg 15.59 16.02 17.49 17.65
test (sec.)
APPENDIX AA
UPPER EXTREMITY DATA COLLECTION
RESEARCHER CH -  PRELIM INARY STUDY
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UPPER EXTREMITY DATA COLLECTION
RESEARCHER CH -  PRELIMINARY STUDY
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Subject 1 
TEST Day 1 Day 2
Subject 2 
Day 1 Day 2
Subject 3 
Day 1 Day 2
Subject 4 
Day 1 Day 2
M- Shldr. Flex 0 0 2 2 0 0 0 0
M- Shldr. ExL 0 0 0 0 0 0 0 0
M- Shldr. Abd. 0 0 0 0 0 0 0 0
M- Shldr. Add. 0 0 0 0 0 0 0 0
M - Shldr. IR 0 0 0 0 1.5 1 0 0
M- Shldr. ER 0 0 1.5 1.5 0 0 0 0
M- Elbow  flex. 0 0 0 0 0 0 0 0
M- Elbow  e x t 0 0 0 0 1.5 1.5 0 0
M- SiQ>ination. 1.5 1 0 0 0 0 1.5 1.5
M- Pronation 0 0 0 0 0 0 0 0
M- W rist flex 0 0 0 0 0 0 0 0
M- W rist ext. 0 0 0 0 0 0 1 1.5
Shoulder A 160 152 157 168 148 160 162 179
Flexion P 155 163 163 167 168 173 176 180
Shoulder A 0 0 0 0 0 0 0 0
Extension P 0 0 0 0 0 0 0 0
Shoulder A 135 130 135 126 117 106 132 130
A bduction P 129 148 127 140 135 141 143 161
Shoulder A 0 0 0 0 0 0 0 0
A dduction P 0 0 0 0 0 0 0 0
Shoulder A 38 45 58 60 54 49 42 73
Internal R o t P 70 60 58 63 87 75 71 77
Shoulder A 90 90 81 86 71 66 63 64
External R o t P 90 90 81 90 85 90 76 82
Elbow A 145 145 145 145 145 145 133 134
Flexion P 145 145 145 145 145 145 132 137
Elbow A 0 0 0 0 0 0 0 0
Extension P 0 0 0 0 0 0 0 0
Supination A 80 85 55 70 66 70 65 61
P 90 90 63 76 100 105 90 65
Pronation A 63 65 90 90 90 90 62 90
P 90 90 90 90 90 90 60 90
168
Subject 1 Subject 2 Subject 3 Subject 4
TEST Day 1 Day 2 Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
W rist A 80 80 75 60 61 65 60 65
Flexion P 80 80 62 60 80 80 65 90
W rist A 81 83 47 55 76 72 83 80
Extension P 70 70 62 60 70 70 79 85
Nine Hole Peg 
Test (sec.)
33.66 29.24 32.16 27.65 1:03.60 68.70 65.90 87.84
M = Modified Ashworth Scale 
A = Active Range o f Motion 
P = Passive Range of Motion
APPENDIX BB
UPPER EXTREM ITY DATA COLLECTION
RESEARCHER M A -  PRELIMINARY STUDY
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UPPER EXTREMITY DATA COLLECTION
RESEARCHER M A -  PRELIMINARY STUDY
Subject 5 
TEST Day 1 Day 2
Subject 6 
Day 1 Day 2
Subject 7 
Day 1 Day 2
M - Shldr. Flex 0 0 0 0 0 1
M - Shldr. E x t 0 0 1 1 0 1
M - Shldr. Abd. 2 1.5 0 0 0 1
M - Shldr. Add. 0 0 0 0 0 0
M - Shldr. IR 0 0 0 0 1 0
M - Shldr. ER 1 1.5 0 0 0 1
M - Elbow flex. 2 2 1 0 0 0
M - Elbow e x t 2 1.5 0 0 1.5 1.5
M - Supination. 1 1 0 0 0 0
M - Pronation 0 0 0 0 0 0
M - W rist flex 0 0 1 1 1.5 1
M - W rist ext. 0 0 0 0 1 1
Shoulder A 94 129 149 150
Flexion P 139 132 180 163 150 142
Shoulder A 0 0 0 0 0 0
Extension P 0 0 0 0 0 0
Shoulder A 88 82 90 120 120 127
Abduction P 125 117 108 116 131 132
Shoulder A 0 0 0 0 0 0
Adduction P 0 0 0 0 0 0
Shoulder A 75 76 56 56 52 73
Internal R o t P 80 95 64 70 71 84
Shoulder A 45 53 60 75 67 60
External Rot. P 65 60 82 90 75 83
Elbow A 129 145 145 145 140 138
Flexion P 145 146 145 145 39 148
Elbow A -10 -7 0 5 -15 -19
Extension P -6 -1 0 -2 -14 -3
Supination A 34 25 70 16 80 71
P 51 43 20 40 80 100
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Subject 5 Subject 6 Subject 7
TEST Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
Pronation A 90 106 80 91 58 90
P 100 99 105 91 75 88
W rist A 80 58 76 55 60 115
Flexion P 100 95 79 80 74 106
W rist A 75 52 1 52 65 67
Extension P 75 85 53 66 85 73
Nine Hole Peg 
Test (sec.)
82.20 62.51 1:46.91 2:01.09 29.36 31.94
M = Modified Ashworth Scale score 
A = Active Range of Motion 
P = Passive Range of Motion
